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SUMMARY 
 
In the UK alone 28 000 sudden cardiac deaths a year are found to be unrelated to 
structural heart problems, likely having ion channel malfunction and arrhythmia as an 
underlying cause. With the discovery of human induced pluripotent stem cells (hiPSC), 
a new field has emerged, allowing the creation of personalised cellular models of 
disease that can be studied in vitro. In this study we aim to functionally characterize and 
validate an in vitro model of Catecholaminergic Polymorphic Ventricular Tachycardia 
type 1 (CPVT1), an adrenergically elicited arrhythmic condition caused by a mutation 
in the cardiac ryanodine receptor (S2246L). The cardiac ryanodine receptor (RyR2) is 
an intracellular ion channel that releases Ca
2+
 stores essential to cardiac contraction 
during EC-coupling. Inherited defects in the RyR2 can result in an intracellular calcium 
leak during diastole that may lead to arrhythmia. The most frequent arrhythmic events at 
a cellular level in CPVT cardiomyocytes (CM) are delayed afterdepolarizations (DADs) 
although early afterdepolarizations (EADs) and triggered activity (TA) may also occur. 
With the need of obtaining a human cell based disease model to establish in vitro valid 
assays for CPVT study and drug screening, a standardized quantitative approach is 
ideal. Nonetheless, because the quantitative definition of these arrhythmic endpoints is 
subjective by nature, most studies using hiPSC CPVT derived CM have assessed these 
cells only from a qualitative point of view. Using whole cell patch clamp in the ruptured 
membrane modality and Ca
2+
 fluorescence imaging, this study aimed to provide a 
quantitative characterization of arrhythmic endpoints in a CPVT hiPSC model. 
Pharmacological rescue was carried out using flecainide, propafenone, dantrolene 
(10µM for all drugs) and propranolol (1µM) in the presence of isoprenaline.  Our results 
show that the average response of hiPSC CPVT CM to recapitulate disease is 
heterogeneous and therefore not a consistent in vitro model of disease. 
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1.1 Sudden arrhythmic cardiac death – the unsolved mystery 
Among death causes in developed countries, sudden cardiac death (SCD) is still the 
leading cause of mortality. It is defined as an unexpected death that occurs in a short 
period of time, due to the onset of cardiac related symptoms (Kauferstein et al.,2013). In 
the UK alone, about 60 000 sudden cardiac deaths occur every year (Papadakis et 
al.,2009) and in USA circa 300 000 deaths occur (Kannel et al.,1987) reporting no 
structural cause for about 40% of these cases. 
 There are several potential causes for sudden cardiac death. Sudden death fatalities can 
be related to anatomical or structural disease, such as valvulopathies (mitral valve 
prolapse, aortic valve stenosis), inflammatory disease (myocarditis, amyloidosis, 
sarcoydosis), vascular disease (myocardial infarctation, coronary spasm or anomalies, 
aortic rupture), cardiomyopathy (dilated and hypertrophic cardiomyopathy, myotonic 
dystrophy, arrhythmogenic right ventricular cardiomyopathy), arrhythmic syndromes 
(long QT, short QT, Catecholaminergic Polymorphic Ventricular Tachycardia, Brugada 
syndrome, Wolf Parkinson‟s White Syndrome) or even trauma (commotio cordis). 
From the above mentioned causes, vascular related, namely ischaemic heart disease is 
responsible for the majority of events. Although most SCD causes can be identified on a 
post mortem exam, a proportion of cases do not present any structural, anatomical 
toxicological or pathological underlying findings that could justify a cardiac arrest. 
These cases are considered as sudden arrhythmic cardiac deaths (SACD) and most 
SACD happen in young people, children and young infants that die suddenly and 
unexpectedly sometimes during their sleep. The definition of SACD is sudden 
unexpected death from age 4 to 64 years, with no previous cardiac disease history, last 
seen alive within 12h of being found dead and without identifiable post mortem cause.  
The predominant aetiology for SACD involves inherited cardiac disease, namely 
genetic mutations that are translated into functional defects in ion channels and 
receptors (channelopathies) that affect the cardiac action potential and hence its 
electrical activity. Channelopathies are likely responsible for about half of SACD (Behr 
et al.,2008).  
Molecular autopsies should always be performed in SACD, but due to several factors it 
still isn‟t a routine practice in developed countries. One of the reasons why genetic 
screening (in living or dead subjects) for inherited cardiac is not always performed is 
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that the mutated genes have a highly variable degree of penetrance. This means that a 
known mutation doesn‟t always cause disease. Therefore, a set of factors, such as 
clinical history, family records and genotyping, have to be considered for a more 
accurate diagnosis. In some cases a functional test is needed, with a pharmacological 
challenge using ß-agonists, such as adrenaline, during monitored exercise to elicit a 
potential arrhythmic event. 
Due to the above mentioned factors, SACD is still difficult to diagnose and predict even 
if genotyping is available.  From all diagnosed patients with channelopathies, circa 30% 
are refractory to treatment. There is currently a huge need to find channelopathy models 
of disease that allow a more efficient study of mechanisms of disease and drug 
screening.  
1.2 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) 
 
This inherited arrhythmogenic channelopathy is an example of abnormal regulation of 
intracellular Ca
2+
.  A mutation in the gene coding for the cardiac Ryanodine Receptor 
(RyR2) in the sarcoplasmic reticulum (SR) can cause CPVT1. It can also be caused by a 
mutation in the gene coding for the SR intra-luminal protein, calsequestrin (CASQ2), 
causing CPVT2. Arrhythmia, syncope and death can be elicited by strong emotions or 
stress via ß-agonist (catecholaminergic) stimulation.  
Two other forms of CPVT have been described but without having RyR gene mutations 
as an underlying cause. CPVT3 is related with loss of function of Kir 2.1, a channel 
responsible for an inward potassium rectifying current (IK1) and was described by 
Postma et al.,(2002) and Tester et al.,(2006). The other form of disease, CPVT4 is 
associated with an abnormal ankyrin-B structural protein, in which impairment of INCX 
and IP3 receptors can lead to arrhythmia (Mohler et al.,2004).  
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1.2.1  Background and recent history 
 
The earliest reference to this clinical entity was made by Reid et al., 1975, describing a 
bi-directional tachycardia in the ECG trace upon physical effort or emotional stress 
(both related to ß-adrenergic stimulation). A few years later, Coumel et al.,1978 named 
this condition CPVT for the first time. The next major publication happened in 1995 
authored by Leenhardt et al. with a series of clinical cases presented. Later, a group 
from Finland (Swan et al.,1999) reported that a mutation in chromosome  lq42-q43 
occurring in 2 large Finnish families with a history of SACD was related to malignant 
polymorphic ventricular tachycardia. Only in 2001, advances in molecular genetics, 
allowed Priori et al. and Laitinen et al., to associate RyR2 autosomal dominant 
mutations with CPVT1. This type of CPVT accounts for 70% of all CPVT patients 
(Cerrone et al.,2004) with 155 different mutations already known 
(http://www.triad.fsm.it/cardmoc/). In the same year, Lahat et al. also correlated 
abnormalities in the calsequestrin protein (CASQ2) with CPVT2. In this case disease 
was caused by an autosomal recessive mutation, found in a family of a Bedouin tribe in 
chromosome 1p13-21.These findings show that lack of functional CASQ2 in autosomal 
recessive mutations is not lethal. 
 
Given the fact that there are still a significant number of CPVT patients that are 
negative for the known abnormal proteins mentioned above, the involvement of other 
genes was obvious, as we now know in the case of CPVT3 and CPVT4. 
 
Healthy paediatric patients, account for most CPVT cases and it has been described that 
by the age of 40, 80% of patients will have presented cardiac symptoms, with a 
mortality rate of 30-50% (Liu et al.,2008). In their first or second decade of life, most 
patients will present their first cardiac episode and clinical diagnosis is always 
challenging, as most patients present a normal echocardiogram and ECG (Electro 
cardiogram). In the absence of genetic diagnosis or family history, exercise stress tests 
may be performed to achieve a diagnosis. During the stress exercise diagnostic tests, 
when heart rate increases to 90-110 beats per minute, episodes of ventricular 
tachycardia (VT) are frequently recorded in the ECG with a typical bidirectional shape 
which is the hallmark of the disease. 
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The use of mice as animal models of disease has been extremely valuable to understand 
possible CPVT mechanisms of disease. Several knock-in models have been made for 
different CPVT1 mutations (Jiang et al.,2002; Cerrone et al.,2005; Liu et al.,2006; 
Kannankeril et al.,2006; Lehnart et al.,2008; Sedej et al.,2010; Kobayashi et al.,2010; 
Bai et al.,2013; Denegri et al.,2014) as well for CPVT2 (Knollmann et al.,2006; Song et 
al.,2007; Rizzi et al.,2008). Mice models are also used to study drug effect and potential 
new treatments, such as flecainide (Liu et al.,2010) a drug which already has clinical 
use, derived from translational research. 
 
1.2.2 The cardiac ryanodine receptor - RyR2 
 
The RyR channel was first identified in 1985 when isolated from the skeletal muscle by 
Fleischer et al., who reported that a plant alkaloid from Ryania speciosa usually used as 
an insecticide, could lead to irreversible muscle contractures. Another isoform named 
RyR2 was later isolated from the canine cardiac muscle by Meissner and Henderson in 
1987. The skeletal muscle predominant isoform, RyR1 is activated directly by Ca
2+
 via 
the LTCC (L-Type Calcium Channel), releasing SR Ca
2+
 stores during muscle 
contraction and a third isoform RyR3 is found in the brain and nervous tissue mainly. 
Although a conservative domain of 70% of the protein composition is shared between 
the three RyR isoforms, all three isoforms have been found in smooth muscle and the 
brain, with not completely elucidated physiological roles. Similar permeation 
properties, with large conductance for divalent and monovalent cations, and relatively 
low Ca
2+
 selectivity are shared by all three isoforms (Fill & Copello, 2002). 
RyR2 is the biggest membrane protein in the human body. The monomer contains 4967 
amino acids encoded by one of the largest genes in the human genome containing 105 
exons. This large protein is present in the sarcoplasmic reticulum of the cardiomyocyte 
and has a transmembrane and a cytosolic domain.  
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Figure 1.1– RyR2 protein structure – RyR2 satellite proteins are shown around the 
primary polypeptide chain. Junctin (JCN) and triadin (TDN) should bind to luminal 
interluminal region where they anchor CASQ. The three main divergent regions are 
indicated as DR1, DR2 and DR3. On the cytosolic region, FKBP 12.6, phosphatase 1, 
calmodulin and phosphatase 2A are shown to bind (Yano et al.,2008). 
 
 
 
Figure 1.2– Structure and cytoplasmic domain organization of the rabbit RyR1 – 
Cytoplasmic view of spatial arrangement of the cytoplasmic domains preceding the 
Central domain within one RyR1 protomer (Yan et al.,2015). 
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1.2.3 RyR2 pharmacology 
 
Several drugs can be used to study RyR2 function. However none have been used as 
potential therapeutical agents for CPVT. For purely classification purposes it is 
considered that agonists will trigger Ca
2+
 release from the SR and antagonists will block 
SR Ca
2+
 release. The mechanisms of action can range from altering channel gating to 
direct block of the RyR2 pore via physical obstruction. Finally a third possible 
mechanism of action may occur by enhancing RyR2 subunits interaction. Although 
these agents do not have current therapeutic use, they can be studied and profiled for 
new drug discovery based on their mechanisms of action. Known RyR2 agonists are: 
methylxanthines such as caffeine, digoxin, suramin, 4-CMC (4-Chloro-m-cresol), 
tacrolimus, halothane, isofluorane and imperatoxin A (IpTxa), a toxin from the scorpion 
Pandinus imperator. Pharmacological RyR2 antagonists are ryanodine (at 10µM and 
above), ruthenium red, dantrolene, tetracaine and procaine (West & Williams.,2007).  
 
1.2.4 RyR2 Mutations 
Most of the RyR2 mutations able to cause CPVT1 are missense mutations (in which one 
single base pair is abnormal) and occur in three hot-spot regions: the N-terminal region, 
the central domain and the C-terminal domain including the pore-forming region. These 
three regions are well conserved among the RyR gene family and are involved in the 
regulation of RyR channels. Recently Medeiros-Domingos et al.,2009 confirmed these 3 
hot-spots as key for CPVT mutations in a patient cohort study in which 105 exons were 
screened. Although missense mutations are more frequent in these mentioned hot-spots, 
some large deletions and rearrangements have been reported in domains I and II 
(Medeiros-Domingos et al.,2009; Marjamaa et al.,2011). It should be routine to screen 
for mutations outside the most frequent hot-spots and exons as these can occur as 
previously reported. 
As with other channelopathies, mutation penetrance is highly variable, from 25 to 
100%. In some cases, CPVT1 genotyped members of the same family, have suffered 
sudden death as a first symptom, despite not presenting any arrhythmia during stress 
exercise tests (Bauce et al.,2002). 
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1.3 Ca
2+
 handling and mechanisms of disease 
1.3.1 Cardiac EC-coupling 
Cardiac myocytes (CM) are unique cells that present complex functional molecular 
mechanisms essential to their function. The cardiac muscle and chambers need to 
expand and contract in order to propel oxygenated blood to all the tissues and cells in 
the body. Cardiac Excitation- Contraction coupling is the process that allows the heart 
to function and it starts by an electrical sequence of events terminating with the 
mechanical contraction of the cell. Excitation begins when a depolarisation of the 
cardiac cell membrane (with an average resting membrane potential – RMP of -80 mV) 
occurs leading to an action potential (AP). This depolarisation, starts via the I(Na), with 
an inward Na
+
 current reaching 30-50mV, activating I(to) and subsequent repolarization 
process. Activation of inward Ca
2+
 I(L-Ca) causes a plateau that is more prolonged in 
ventricular cells compared to atrial CM. Inactivation of  I(L-Ca) is then followed by 
repolarisation through the outward K
+
 current, I(Ks), I(Kr) and  inward rectifier K
+
 current 
I(K1). All of these events mark and represent the different phases of the cardiac AP (0-4). 
 
 
Figure 1.3 – The ventricular cardiac action potential - different phases and involved 
electrical currents (Morita et al.,2008). 
During the I(L-Ca) activity, Ca
2+
 concentration increases in the cytosol, activating RyR2 
channels to release more Ca
2+ 
from the SR. RyR2 are large ion channels located in the 
SR, one of the CM organelles responsible for storing intracellular Ca
2+
 (figure 1.4). 
Stimulated by Ca
2+
 influx via LTCC, RyR2 opens, creating a Ca
2+
transient, allowing 
these ions to bind to the CM contractile machinery, namely to troponin C present in the 
myofibers. This process, by which cytosolic Ca
2+
 influx from the extra-cellular space 
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triggers Ca
2+
 release from the SR via activation of RyR2, is referred to as Calcium-
Induced Calcium-Release or CICR, (Fabiato, 1983). After a systole, Ca
2+
 is then 
removed from the CM cytosol via four possible mechanisms: SR Ca
2+
ATPase 
(SERCA2A), NCX, sarcolemmal Ca
2+
ATPase, and mitochondrial Ca
2+
 transporter. 
NCX function is of particular relevance in triggering possible arrhythmogenic events in 
CPVT. 
 
Figure 1.4 – Ca2+ transport in ventricular myocytes - time course of an action 
potential, Ca
2+
 transient and contraction, measured in a rabbit ventricular myocyte at 
37ºC. Ca
2+ 
occurs via L-type Ca
2+
 channel, induces Ca
2+
 release from SR via RyR2 to 
allow myofilament contraction. Ca
2+
 is then released into cytosolic space to be extruded 
via Ca-ATPase, NCX and mitochondrial calcium pump (Bers, 2002). 
 
In ventricular CM the AP plateau is more prominent and hence the APD is longer than 
in atrial cells. This plateau also allows the contracted cell to relax before the next beat 
(and Ca
2+
 transient) preventing permanent contraction of the heart, that would clearly 
prevent the re-filling of the cardiac chambers and impair cardiac function. 
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1.3.2 ß-Adrenergic stimulation 
 
One of the most important cardiac control mechanisms, is clearly the chain of events 
triggered by sympathetic ß-adrenergic stimulation and the classical cardiac 
physiological response of inotropy, lusitropy and chronotropy. 
All sympathetic nerve endings in the heart have ß-adrenergic receptors and there are 
four main mechanisms underlying the cardiac inotropic, lusitropic and chronotropic 
properties: 1) decreased myofilament Ca
2+
 sensitivity due to troponin I phosphorylation, 
2) increased I(L-Ca), 3) enhanced SERCA2A (Sarcoplasmic Reticulum Ca-ATPase) rate 
via PLB (Phospholamban) phosphorylation and 4) altered RyR2 gating. 
Endogenous ß-adrenergic agonists or synthetic analogous such as isoprenaline  cause 
the above effects by stimulating adenylyl cyclase, activating binding protein Gs and 
elevating cAMP-dependent PKA (Protein Kinase A), which in its turn phosphorylates 
several other key proteins in the process. In the presence of ß-receptor agonists, more 
calcium enters the cell at each cycle, causing the SR to build bigger Ca
2+
 stores. 
Experiments made in mice ventricular CM demonstrated that PLB is a key protein in 
the inotropic and lusitropic ß-adrenergic mediated effects. Transgenic PLB KO (Knock 
Out) mice had CM with a significant decrease in both effects when compared to wild 
type mice CM (Li et al., 2000). The same authors also reported that, although 
significantly reduced, there was still an inotropic effect in PLB KO CM. This could be 
due to a large increase in I(L-Ca) which progressively increases Ca
2+ 
stores in the SR in 
the absence of PLB. 
Another important characteristic of most mammalian CM (excluding rat and mouse)  is 
the positive force-frequency relationship that describes the increase of calcium transient 
amplitude (and hence force in Newtons) with an increase in rate. Several authors have 
demonstrated this CM property in different species including human adult CM (Pieske 
et al.,1999). There are three factors suggested as possible underlying causes for this 
property: 1) increased I(L-Ca)  2) increase in cytosolic diastolic Ca
2+
 and 3) increased SR 
load available for release as a consequence of the previous two factors. In addition, due 
to an increased rate of depolarization a subsequent increase in intracellular Na
+
 
concentration reduces NCX (Sodium-Calcium Exchanger) Ca
2+
 extrusion and hence 
more calcium is available in the cytosol and SR (Boyett et al.,1987). 
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1.3.3 SOICR – Store Overload Induced Calcium Release 
 
In CPVT1 or CPVT2 a ventricular diastolic Ca
2+ 
leak is the basic event that can 
predispose to after-depolarisation and arrhythmia. This is the most widely accepted 
arrhythmic mechanism for the above mentioned channelopathies, resulting from either a 
dysfunctional RyR2 or CASQ2 protein, in which an abnormal action potential may 
follow an initial after-depolarization. Events of this type are described as triggered 
activity, as they can generate an extra systole in cardiac regions other than the 
pacemaker tissue. 
 
During systole, Ca
2+ 
concentration rises rapidly from approximately 100nM to 1µM, 
favouring binding to troponin C and leading to sarcomere contraction. The majority of 
this Ca
2+
 does not come from the extracellular space but from the SR, although it‟s a 
small influx of Ca
2+
 via the LTCC (ICa) that triggers RyR2 opening and a huge release 
of SR Ca
2+
 via CICR. During diastole, Ca
2+
 is removed from the CM cytosol via four 
possible mechanisms: SR Ca
2+
ATPase (SERCA2A) (70%), NCX (28%), sarcolemmal 
Ca
2+
ATPase (1%) and mitochondrial Ca
2+
 transporter (1%). These percentages can 
differ from species to species and while the above average values are from rabbit 
ventricle, in the rat heart SERCA2A can be responsible for up to 92% of Ca
2+
 re-uptake 
(Bers, 2000). These proteins and their regulatory pathways play a key role in one of the 
main suggested mechanisms of arrhythmogenesis related to the dramatic increase of 
cytosolic Ca
2+
. 
Diastolic SR Ca
2+
 release can occur in the absence of depolarization through a 
mechanism described as spontaneous Ca
2+
 release (Fabiato et al.,1992) and this event is 
facilitated by a SR Ca
2+
 overload (Lakatta et al.,1992). Diastolic spontaneous SR Ca
2+
 
release events have been described as SOICR (Store Overload Induced Calcium 
Release) (Jiang et al.,2004;2005) and can be triggered by digitalis intoxication, ß-
adrenergic stimulation,  elevated extracellular Ca
2+
 and fast pacing, such as in the case 
of CPVT (Lakatta et al.,1993).  
Stimulation of the ß-adrenergic receptor, leads to phosphorylation of several proteins, as 
a consequence of an increase of cAMP and subsequent PKA activation, contributing to 
SOICR. Proteins such as the LTCC and phospholamban (PLB) will favour SR Ca
2+ 
uptake when phosphorylated by increasing cytosolic Ca
2+
 influx and by reducing 
SERCA inhibition, respectively. 
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Cardioglycosides such as digoxin and digitoxin inhibit Na
+
/K
+ 
ATPase. This effect 
leads to cytosolic Na
+
 concentration increase and inhibition of NCX. By causing NCX 
inhibition, more cytosolic Ca
2+
 is available for SR Ca
2+
 uptake,  leading to SR Ca
2+ 
overload and consequently SOICR.  
 
Evidence suggests that spontaneous Ca
2+
 release will occur when SR Ca
2+ 
reaches an 
excessive critical load (Diaz et al.,1997) and hence that Ca
2+
 concentration from the 
inside of the SR (luminal side) is the main trigger for Ca
2+
 release during SOICR. 
Some authors suggest that luminal Ca
2+
 activates RyR2 by passing from the SR via the 
channel pore and activates Ca
2+
 release by from the cytosolic side. This mechanism, 
also known as the “feed-through“ hypothesis (Tripathy et al.,1996), is challenged by 
single channel experiments in which RyR2 Ca
2+
 release is activated by cytosolic Ca
2+
 in 
the absence of luminal Ca
2+
 (Ching & Williams & Sitsapesan, 2000) leading these 
authors to suggest that luminal Ca
2+
  activation has a different site than the cytosolic 
activation site. 
Moderate changes in RyR2 activity are regulated by the SR Ca
2+
 content, probably as 
the result of RyR2 regulation by SR luminal Ca
2+
  (Trafford et al.,2000), a mechanism 
known as “SR autoregulation”. 
 
1.3.4 Afterdepolarizations and Triggered Arrhythmia  
 
As a consequence of ß-stimulation, SOICR can occur leading to an increase of cytosolic 
Ca
2+
 that can alter the sarcolemmal membrane potential by activating NCX. The 
activation of this electrogenic exchanger will cause a transient inward current by 
increasing the cytosolic Na
+
 concentration, while removing Ca
2+
 to the extracelluar 
space at the ratio of 1 (Ca
2+
) : 3 (Na
+
). If the membrane depolarization occurs after an 
action potential has ended, this event is called a delayed after-depolarization (DAD) 
(Marban et al.,1986). If this DAD reaches an amplitude sufficient to activate the sodium 
channels it can initiate I(Na) and trigger a full arrhythmic action potential – triggered 
activity (TA). It has been estimated that the release of at least 50 to 70% of the SR Ca
2+
 
load is necessary to create a DAD with enough amplitude to generate TA (Schlotthauer 
& Bers, 2000). 
 
Another possible arrhythmic electrogenic event is an early after-depolarization (EAD). 
These depolarising events may take place before the action potential has terminated, 
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frequently during phase 2 and 3 of the AP. Both I(L-Ca) and I(Na) seem to be the main 
currents involved in EAD arrhythmogenic activity (Volders et al.,2000). Other authors 
have also suggested that I(NCX) can play a role in EAD genesis (Priori et al.,1990). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 – DAD and EAD - Cardiac AP arrhythmogenic events and respective 
differences in AP time and involved electrical currents. EAD events (A) occur before 
repolarization completion and are caused mainly by  I(L-Ca) , while DAD events (B) are 
mainly caused by I(NCX) and only occur after complete repolarization between two 
consecutive APs (Hoekstra et al.,2012). 
 
 
 
 
 
 
 
 
 
A 
B 
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1.4 Current clinical diagnosis and therapy 
 
1.4.1 Clinical diagnosis 
Most CPVT early symptoms happen in children, presenting syncope episodes, related to 
exercise or strong emotions. A polymorphic ventricular tachycardia observed on the 
ECG, is typically present in most cases. The heart is usually structurally normal and a 
lower resting heart rate has been reported, especially for boys with RyR2 mutations 
(Hayashi et al.,2009). A typical CPVT patient usually has a normal ECG but the 
arrhythmia is usually reproduced in an exercise stress test or with isoprenaline 
administration. Using a Holter monitor, ECG traces for 24h can be obtained and usually 
a polymorphic ventricular tachycardia is recorded when heart rate thresholds around 
120-130 beats per minute. 
 
 
 
Figure 1.6 – CPVT ECG trace -  Classical CPVT patient ECG trace, from a twelve-
lead machine during exercise stress test, showing typical bidirectional ventricular 
tachycardia characterised by 180º  alternating QRS axis on a beat to beat basis, 
presenting a right bundle branch block pattern suggesting a left ventricular origin 
(Leenhardt et al.,2011)  
 
The trace will initially present ventricular premature beats (VPBs) and progress to 
bidirectional ventricular tachycardia (VT). If exercise or isoprenaline stimulation 
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persists, VT increases in frequency and number and can lead to syncope that in some 
cases can progress to ventricular fibrillation and death. 
Although ventricular tachycardia is most prevalent in CPVT, atrial arrhythmia including 
atrial fibrillation can be observed in stress tests and has been described in adult patients 
(Kazemian et al., 2011). 
 
1.4.2 Current therapeutic approaches 
 
Understanding the pathophysiology of CPVT1 is a critical step to direct 
pharmacological treatment. Drugs that can target and help prevent SOICR caused by 
RyR2 modulation and prevention of SR Ca
2+
 overload, would be ideal choices but 
medicine still lacks specific molecules for this purpose. 
There are some drugs available with some clinical efficacy such as ß-blockers and 
LTCC inhibitors. Although ß-blockers can reduce heart rate and hence reduce 
phosphorylation favouring SERCA2A inhibition and LTCC blockers reduce Ca
2+
 
influx, RyR2 inhibition itself seems an obvious promising therapeutic target as mono or 
combined therapy. 
Flecainide and other Na
+
 channel blockers such as propafenone, are old drugs with a 
few good results and renewed clinical interest, when added to ß-blockers in refractory 
cases to first line pharmacological treatment (Watanabe et al.,2009). 
Preliminary pre-clinical reports, in mice and rabbit models as well as CPVT human 
induced pluripotent stem cells (hiPSC) derived CM, indicate that dantrolene is a 
possible candidate to undergo clinical trials in CPVT patients refractory to other drug 
classes. 
Other alternatives involve medical device implantation such as an implantable 
cardioverter defibrillator (ICD) to prevent VF. This device may be indicated in patients 
refractory to pharmacological treatment that may reach 20 to 30% of CPVT cases 
(Zipes et al.,2006). Surgical procedures such as left cardiac sympathetic denervation 
(LCSD) can also be indicated. A report recently presented by de Ferrari et al.,(2015)  
from an observational study from 1988 to 2014, in 63 CPVT patients, reveals that 
LCSD seems very promising. However the procedure still lacks quantitative clinical 
trial data. 
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1.5 Models of cardiac disease 
The study of cardiac disease and the great medical advances achieved in the past, would 
not have been possible if it wasn‟t for the use of cardiac models either at a full organ or 
cellular and molecular level. Cardiovascular disease is the leading cause of morbidity 
and mortality worldwide, with estimated 17 million deaths per year (Laslett et al.,2012). 
In drug discovery and development, cardiac toxicity is a huge burden. In the past 30 
years alone, about 20 different compounds have been commercialised and withdrawn 
from the market, due to unexpected cardiovascular events. Toxicity at the ion channel 
level is known to cause LQT, Torsade des Pointes, syncope and death. It is estimated 
that each of these discarded compounds has cost about 1.5 billion US dollars in research 
and development (Quigley et al.,2011). 
Regulatory authorities such as the FDA and EMA have set new rules for preclinical 
testing regarding cardiac toxicity and including animal and cell base models in which 
specific ion channels are overexpressed in order to try and predict adverse cardiac 
events. 
Despite an obvious need of human cardiac cell models, access to live human cardiac 
tissue is restricted. Lack of viable cardiac tissue from human donors is a problem due to 
ethical, legal and physiological reasons. Human CM are also difficult to isolate and 
maintain in culture, with only a few days of viability. In some institutions, foetal cardiac 
tissue can be obtained from pregnancy interruptions, more frequently than adult cardiac 
tissue.  
For these reasons different mammalian species have been used for research, from mice, 
rat, rabbits, guinea pig, even carnivores such as ferrets and dogs and occasionally non-
human primates. Although huge advances in cardiac physiology, and pathophysiology 
have been achieved by using other mammalian species, the inter-species differences are 
still a great limitation for a better understanding of human CM.  
Animal models can be used for whole organism research or to obtain primary single 
CM for cell level experiments.  
Heterologous mammalian cell models (transfected with ion channels) such as HEK293 
or CHO immortal lines are also frequently used due to their robustness minimal culture 
demands.  
17 
 
Immortalised cardiac cell lines such as H9c2, derived from an embryonic rat ventricle 
have also been used for more than three decades (Kimes & Brandt, 1976). Another 
immortalised cardiac cell line has been isolated from a mouse atrial tumor (HL-1). HL-1 
cells have been extensively studied for ion channel and calcium handling physiology 
research (Claycomb et al.,1998). 
1.6 Pluripotent stem cells 
More recently a new in vitro cardiac cell model has become available from the stem cell 
emergent field. Stem cell derived CM are now a reality and can be used for the same 
purposes as primary cells, with the advantage of being human cells and coming from a 
stable cell line. The main disadvantages are that these cells still have foetal features, 
culture requires intensive labour and are much more sensitive to cell culture routine 
procedures than other cell lines (HEK, CHO, etc.).  
Despite these disadvantages, the potential derived from this technique is immense and 
future research will likely improve and overcome these disadvantages. 
Stem cells are cells with the capacity of differentiation into any type of tissue in the 
body and can be classified regarding their potential of differentiation.  
Regarding their potential of differentiation stem cells can be: totipotent (differentiate 
into all tissues including trofoectoblast – placenta), pluripotent (differentiate into all 
tissues except trofoectoblast) and multipotent (can only differentiate into an organ cell 
lineage with different sub-types) (Tanabe et al.,2014). 
For mainly ethical reasons human totipotent stem cells are not used extensively in 
research since in theory they could give origin to a complete human being. Pluripotent 
stem cells are nowadays the focus of intense research since these can originate any cell 
or tissue except for the placenta embryonic precursor (trofoectoblast), offering 
additional advantages over multipotent stem cells.  
The first report of these cells was made regarding mouse embryonic stem cells (mESC) 
obtained from the inner part of a day 8 embryo or blastocyst (Evans et al.,1981). But if 
research with mouse ESC was not controversial, the same was not true when human 
embryonic stem cells (hESC) started being studied. Research with these cells met great 
public opinion resistance, mainly for religious and ethical reasons. 
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Still, significant advances were made regarding hESC differentiation in to different 
tissues and in 1994, Maltsev et al. reported for the first time a functional study using 
hESC derived CM characterising it‟s action potential and isolated currents. These 
authors confirmed the presence of I(Na), I(to) I(L-Ca), I(K) and I(K1) in hESC derived CM. 
Due to the inherent ethical problems in using human embryos to obtain hESC, some 
countries halted almost all research with these cells but kept work with multipotent stem 
cells such as cardioprogenitor cells, blood chord cells and mesenchymal stem cells. 
 The presence of cardioprogenitor cells (CPCs) in mammalian hearts challenge the view 
that the heart is terminally differentiated, as in vitro studies show that CPCs can 
differentiate in to different CM sub-types, endothelial and smooth muscle cells 
(Beltrami et al.,2003). These cells have been used in several trials for cardiac 
regeneration as they can be harvested from a patient atrial biopsy, expanded in vitro and 
then injected into the cardiac affected areas. Despite the regenerative potential, no major 
outcomes came from such trials (Messina et al., 2004). These multipotent stem cells 
have the advantage of being harvested from adult hearts and hence being more mature 
cells than hESC. 
Researching the genetic basis of pluripotentcy, a new type of pluripotent stem cells was 
created more recently by Yamanaka et al. in 2006 revolutionising the stem cell field and 
opening the door for new possible applications in stem cell technology. The creation of 
induced pluripotent stem cells (iPS) by reprogramming somatic cells back into a 
pluripotent stage resolved the ethical issues that hESC presented and heralded the 
beginning of personalised cell models. 
These iPS are equally immortal as hESC, as able to be maintained indefinitely in culture 
and hold the potential to differentiate into any type of tissue including CM. With the 
advantage of maintaining most of the original somatic cell genome, they allow the 
possibility of developing in vitro models of disease as well opening the field of 
individual drug screening. 
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1.6.1 Human induced pluripotent stem cells – hiPSC 
1.6.1.1 Historical background 
 
The idea that some cells hold totipotency goes back to 1895, when Hans Dreish 
succeeded for the first time in cloning an animal, namely a sea urchin (Gilbert, 2010). 
His experiment revealed that a single cell from an embryo had the potential to create an 
entire organism. Decades would pass with the field still quiescent. In 1952, the first 
nuclear transfer from a late stage embryo into a frog enucleated egg was made, growing 
to a full adult as a result (Briggs and King, 1952). Science would have to wait another 
decade until the first adult somatic cell nuclei from an adult frog enterocyte was 
transferred into an unfertilized frog egg, still creating tadpoles (Gurdon, 1962). This last 
experiment reported by John Gurdon was pivotal in showing that the adult cell nuclear 
material had all the genes to originate a tadpole. This event was dependant on external 
factors to unlock that potential. Finally, the culmination of embryonic transfer and 
cloning reached a peak when in 1997, Wilmut et al. successfully cloned a mammal from 
an adult epithelial cell, transferred into an unfertilized oocyte.  
These reports provided evidence that adult terminally differentiated somatic cells have 
the potential to re-differentiate into other cell-types and that oocytes hold the factors to 
unravel that potential. 
 
1.6.1.2 Induced Pluripotency 
 
With the discovery of mESC in 1981 (Evans et al.) pluripotency was confirmed as a 
cellular property without resorting to unfertilized oocytes. It was obvious that mESC 
contained in their genome, the active ‟factors‟ allowing them to produce different types 
of tissues.  
Although cell fate conversion by defined ectopic factors was a known fact to science, 
(Davis et al.,1987; Laiosa et al.,2006; Cobaleda et al.,2007) it was only in 2006 that 
Takahashi et al. working under Shynia Yamanaka‟s supervision, achieved success in 
identifying the factors able to make cells retrocess, in the Wadson differentiation scale. 
 
From among 24 identified factors that could maintain pluripotency of ESC, Yamanaka‟s 
team found that expression of four proteins was essential and sufficient to reprogram 
cells: Oct3/4, Sox2, Klf4 and c-Myc (OSKM). These reprogrammed cells via viral 
delivery of the OSKM factor genes, had similar features to ESC regarding expression 
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and epigenetic profiles. More importantly they were pluripotent and able to differentiate 
into teratomas and the three germinal layers. These cells were then denominated 
„induced pluripotent stem cells‟ (iPS). 
 
The creation of fully reprogrammed iPS cells was not completely achieved initially as 
iPS cells didn‟t manage to originate a viable chimeric mouse after being inserted into an 
oocyte. Researchers used other factors such as Nanog and Oct3/4 locus as a reporter 
system instead of Fbx15 (previously unsuccessful). The result was the first generation 
of iPS chimeric mice (Okita et al.,2007). One other factor, c-Myc (a known oncogene) 
was not used in this experiment, allowing oncogenesis reduction on F1. (Nakagawa et 
al.,2008). 
 
Less than a year from the first iPS report in mice, human iPS (hiPSC) were produced 
with the same success (Takahashi et al.,2007).  In the same year, Yu et al. published a 
new efficient pluripotent combination of defined factors to create hiPSC using Oct3/4, 
Nanog, Sox2 and LIN28. 
 
1.6.1.3 iPS cell generation and pathways 
 
Despite the important step achieved with the discovery of iPS, pluripotency induction 
was very low and typically less than 1% of reprogrammed cells that received OSKM 
combination, become iPS cells (Takahashi et al.,2006). However, a new report mentions 
significant improvement of pluripotency induction, achieving 20% success of 
pluripotency induction with the same OSKM factors (Tanabe et al.,2013). 
One of the best pluripotency surface markers is TRA-1-60. Within 7 days of 
transduction, more than 20% of transduced cells (normally fibroblasts) are TRA-1-60 
positive. Despite this, 15 days post-transduction, the majority of TRA-1-60 positive 
cells frequently become negative for this marker. This observation suggests that 
maturation rather than initiation is the biggest obstacle during the reprogramming 
process. Promotion of additional factors to be expressed, such as LIN28 (Tanabe et 
al.,2013) and LIN41 (Worringer et al.,2014) can also increase pluripotency efficiency. 
Histone modifications and DNA methylation play a very important role in the 
reprogramming process and have been targets of intense research. Histones regulate 
gene expression and therefore help to maintain stable cell lines. At a very early stage of 
the reprogramming process, up to 48h after transduction, Oct3/4, Sox2 and Klf4 bind to 
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close chromatin sites of promoters resistant to DNase digestion. After the binding, these 
heterochromatic regions are opened. This way Oct3/4, Sox2 and Klf4 function as 
initiators, opening the epigenetic barriers and increasing the reprogramming 
transcription factors accessibility (Soufi et al.,2012). Some histone deacetylase 
inhibitors have been reported to increase iPS generation, such as valproic acid, 
trichostatin A and sodium butyrate (Huangfu et al.,2008; Mali et al.,2010) 
Promoters of ESC responsible genes, such as Nanog and Oct3/4 are known to suffer 
demethylation during the reprograming process (Takahashi et al.,2007). The reduction 
of DNA methylation levels by a methyl-transferase inhibitor (Aza-C) promotes 
reprogramming efficiency (Mikkelsen et al., 2008). 
These findings show the complexity of the reprogramming process and iPS induction 
protocols will surely become much more efficient when most of the pathways are 
unravelled and used to create reliable and more stable iPS cell lines in the future. 
 
1.7 hiPSC derived CM 
 
Following cell reprogramming and creation of hiPSC, (Takahashi et al., 2007) 
differentiation of these cells into CM was an obvious sequential step (Zhang et al., 
2009). A new opportunity emerged to study human CM. Although our knowledge of 
cardiac physiology is vast and detailed as a result of decades of research, human CM are 
by far the most relevant and yet less studied CM from all mammalian models.  
When hiPSC technology was initially developed, the first expected clinical applications 
were, as in the case of human embryonic stem cells (hESC), to use them in regenerative 
medicine. Unlike hESC, the problem of immune response and rejection of allogenic cell 
therapy could be overcome. These cells (hiPSC) can be made from other postnatal 
somatic adult cells of a patient and hence allow autologous cytotherapy with minimum 
rejection probabilities. Another frequent problem with hESC cell therapy was the 
development of teratomas (Nussbaum et al., 2007) that in several clinical trials had to 
be surgically removed. Despite being embryonic benign tumors and having a low 
metastatic potential, their growth could reach life threatening proportions in a vital 
organ like the heart or brain. 
After some initial expectations, it was clear that, as is the case for hESC, hiPSC, could 
also be responsible for teratoma formation (Liu et al., 2013). 
Although several research groups still work in the cardiac regeneration field using 
hESC and hiPSC, a new field has emerged using the latter. Disease modelling allied to 
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the potential perspective of personalised medicine and individual pathophysiology study 
was a real possibility. By creating in vitro models of disease, using hiPSC became 
obvious and a new field was born. 
The problems that cardiac researchers faced for decades due to lack of human cardiac 
tissue, seemed to have a new hope with this technology. The main advantage was 
having a bigger translational potential and creating more bench to bedside knowledge.  
Inherited cardiac disease such as cardiac channelopathies, always have been a particular 
challenge to study, since animal models aren‟t ideal for several reasons. Faster 
repolarization rates, different body/heart size ratio, different expression levels of ion 
channels and individual specific evolutionary adaptations, are responsible for significant 
inter-species differences. 
New and more efficient hiPSC CM differentiation protocols have been reported, 
reaching in some cases near 100% beating cluster terminal differentiation (Burridge et 
al., 2012). After 5 years of their discovery, hiPSC derived CM started being researched 
intensively as these cells have several advantages over hESC and primary cells for 
ethical, physiological and economical reasons. 
 
1.7.1 Drug discovery and toxicology screening 
 
During the reprogramming process, target cells (usually fibroblasts) maintain their basic 
genome mostly unchanged, even when undergoing other tissue terminal differentiation 
such as becoming CM. As a result, these newly differentiated cells can be used as in 
vitro models of inherited disease. The main advantage that hiPSC present is the 
possibility of collecting information regarding a particular inherited disease in a specific 
patient, something that was impossible to achieve until this technology was discovered. 
Cardiac toxicology is a major problem in some patients undergoing chemotherapy for 
cancer treatment, namely with anthracycline derivative drugs such as doxorubicin 
(Bernstein et al.,2014). If a patient already presents a degree of cardiac disease such as 
HF, clinicians may decide to hold the use of anti-cancer drugs to prevent further cardiac 
damage. This could decrease life expectancy as the patient may not benefit for the anti-
cancer drug. By creating hiPSC derived CM from candidates for chemotherapy, 
personalised predictive toxicity screening could be performed. This information would 
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help in making a better clinical decision, by detecting abnormalities in the cardiac AP 
(Zhang et al.,2014). 
Besides personalised cardiac toxicity screening, hiPSC derived CM can also be a 
powerful tool to screen for drug efficacy in patients needing any cardiac treatment. By 
allowing drug selection with less adverse events and optimal response, significant 
advantages could be obtained for the patient. But this area is still an unexplored field, 
and research has been focused mostly in inherited cardiac disease (Liang et al.,2013).  
Specific hiPSC derived CM from patients with inherited cardiac disease, may have a 
major role in new drug discovery. Drug companies have now available different models 
of hiPSC derived CM that allow screening of new chemical entities that can result in 
potential new drugs. 
As is the case with hESC, the major drawback that hiPSC derived CM have is that they 
retain an immature CM phenotype. These pluripotent derived CM present immature 
sarcomeric architecture characterized by the absence of H zones, I bands and M lines. 
They also present spontaneous contraction due to the high presence of pace-maker 
currents; immature sarcoplasmic reticulum and more round/irregular shape than the 
classical rod shape (Yang et al., 2014). 
Several approaches have been developed in attempts to mature hiPSC derived CM. 
These can range from plating them in 3D platforms to enhance contractile function, 
promoting CM elongation, orientation, alignment and conduction velocity (Zhang et 
al.,2013). Plating hiPSC CM in continually electrically stimulated platforms has also 
been attempted (Mihic et al.,2014). However, a successful maturation process will 
likely have to involve multiple components such as the inclusion of hormonal and 
pharmacological factors to the protocols described above. 
Despite these cells immaturity, physiological characterization confirms that they 
possess several functional cardiac receptors. Response to ß-adrenergic and muscarinic 
agonists and antagonists, anti-arrhythmic drugs and ion channel modulators are reported 
(Fatima et al.,2011; Kujala et al.,2012; Novak et al.,2015). Cardiac chronotropic, 
lusitropic and inotropic responses have been documented for hiPSC CM (Matsa et 
al.,2012), demonstrating that these cells can be very useful in screening new potential 
cardiac drugs. 
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1.8 Recent work and context of this project 
The main objective of this project is to characterise and assess the validation of a 
CPVT1 in vitro model of disease using hiPSC derived CM. Several authors have 
published data regarding similar models of disease for the same channelopathy (Jung et 
al.,2012; Fatima et al.,2011; Itzhaki et al.,2012) as well  for CPVT2 (Novak et al.,2012).   
Most reports present a strong suggestion of disease recapitulation and good 
pharmacological response, but a systematic standardised functional study hasn‟t been 
reported yet. Each publication relates to a different mutation and possibly phenotype. 
Hence, it is difficult to assess those differences with such diverse experimental 
protocols. If we need to determine if this technology really has translational potential 
and can be used as a model of disease, different mutations should follow similar 
protocols to elicit arrhythmia and drug rescue.  
Most publications rely on spontaneous data, assuming that observed arrhythmic events 
are better seen without external pacing. Using spontaneous beating cells can be a 
problem since single cells can have their own pacing frequency. On the other hand, by 
controlling the pacing we may also bypass these cells nature and artificially correct 
possible arrhythmogenic behaviour.  
A common feature of the data presented in most of these publications, is that, although 
they present DADs percentages, there is no quantitative information regarding these 
arrhythmic traces, namely regarding frequency, amplitude and/or duration, making it 
more difficult to quantify DAD-based drug response. 
Ca
2+
 handling is also a major component of CM physiology. Basic pharmacological 
characterisation and protein detection was reported in most studies regarding hiPSC 
CPVT CM, but there is still a need to provide a deeper characterisation of these cells 
Ca
2+
 transients. Functional study of Ca
2+
 handling during pacing and ß-agonist 
stimulation is essential in order to mimic exercise and strong emotions. These are 
pivotal in CPVT pathophysiology. 
In 2011 the first report of a CPVT1 hiPSC derived CM was published by Fatima et al. 
This report characterised a mutation localized in the FKBP1.2 binding domain of the 
RyR2 protein (p.F2483I). Cells were differentiated in co-culture with a murine visceral 
endoderm-like cell line. Immunocytochemistry and protein expression (PCR) profiles 
were made, demonstrating a similar profile between control and CPVT cells with 
25 
 
immature characteristics. Functional data were only presented regarding spontaneous 
activity. Mutant cells presented negative chronotropy compared with control cells when 
perfused with isoprenaline and 34% presented DADs in the presence of a ß-agonist. No 
details on the DADs duration or these events presence in control cells, were provided. 
No quantitative data regarding the DAD were provided. 
Although DADs are the arrhythmic hallmark of CPVT, other events may occur. Kujala 
et al.,2012 demonstrated that EADs can also be present in hiPSC CPVT CM for the 
P2328S mutation. Patch-clamp recordings were only made in spontaneously beating 
cells and a quantitative definition for EADs and DADs was given (≥3% amplitude of 
the previous AP). A qualitative assessment of calcium transients was presented in terms 
of variations in amplitude and rhythm.  
Similar qualitative assessment of Ca
2+
 transients is also reported by Jung et al.,(2012). 
Amplitude and rhythm are presented, although paced at different frequencies. These 
authors demonstrated for the first time, hiPSC CPVT CM potential for new drug 
discovery, reporting that dantrolene could rescue arrhythmic DADs and restored normal 
Ca
2+
 spark properties. Electrophysiology data were obtained with partial pacing of 
hiPSC CM at 1Hz. This publication presented a more systematic approach for 
electrophysiology recordings than other authors. No definition of a DAD or quantitative 
data for DADs is provided.  
Itzhaki et al.,(2012) reported the use of flecainide (10µM) with apparently good 
response to abolish disease phenotype in hiPSC CPVT CM with RyR2 heterozygous 
point mutation M4109R. Patch-clamp recordings were obtained from both 
spontaneously beating and quiescent cells (paced at 1Hz). Percentage of cells presenting 
DADs, and quantification of DAD magnitude (amplitude) is presented: 13.0±8.2mV for 
mutant cells and circa 5.7±3.9mV for control CM. No data regarding DAD duration is 
mentioned and no quantitative definition of DADs is provided. 
Zhang et al.,(2013) reports a very detailed study on Ca
2+
 handling using CPVT derived 
hiPSC CM from a patient carrying the RyR2 F2483I mutation. These authors presented 
mainly voltage-clamp data, using the patch clamp technique to determine I(L-Ca) and 
I(NCX). No current clamp data or action potential characterisation is reported. Only 
spontaneous beating cells were used and this report is the only one to suggest that based 
on functional Ca
2+
 experiments, hiPSC CPVT cells present an adult CM phenotype. 
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Support for the drug screening and therapeutic strategy optimization of CPVT hiPSC 
derived CM comes from Di Pasquale et al.,(2013). These authors used CM with RyR2 
mutation p.Glu2311Asp and tested a novel anti-arrhythmic chemical entity, KN-93. 
This molecule acted as an inhibitor of CaMKII to reduce DADs in hiPSC CPVT CM. 
Evoked (0.5Hz) and spontaneous AP were recorded. Despite the authors suggestion of 
KN-93 efficacy, no quantitative data is presented regarding number of DADs, amplitude 
or duration, and no definition of DAD is given. Results are reported as significant 
relating to n=7 hiPSC CPVT CM cells. 
While Ca
2+
 handling and AP functional characterisation are given in these cited reports 
demonstrating the CM phenotype of these cells, the lack of systematic definition and 
quantitative data regarding DADs is obvious. Such definition should be a critical point 
to report validation of a CPVT in vitro model of disease. Despite this, all authors 
suggest very clearly that disease phenotype recapitulation is demonstrated in their 
experiments. 
1.9 Aims and hypothesis of this study 
 
The CPVT hiPSC derived CM used in this project were obtained from a patient that had 
undergone cardiac surgery for ICD implantation. This 5 year old patient presented a 
RyR2 genotyped mutation, c.6737C>T (Ser2246Leu) and the resultant ryanodine 
receptor malfunction is known to cause a classical bidirectional ventricular tachycardia, 
leading to arrhythmia.  
In channelopathies such as CPVT preclinical research plays a vital role in trying to 
discover new basic mechanisms of disease, drug toxicity testing and new drug 
discovery.  A potential for personalised treatment is also in sight if mutant hiPSC CM 
can be validated as a good model of disease. 
 
To my knowledge no reports have been published regarding the use of hiPSC derived 
CM with this mutation. A robust characterisation has been made by different groups 
regarding different mutations, mainly from a functional CM perspective. A consistent 
systematic approach to model CPVT in vitro using patch-clamp and Ca
2+
 imaging is a 
gap in this field of research. Such experiments will help to clarify how good the disease 
modelling potential of this technology is. 
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The main aim of this project is to assess if hiPSC CPVT derived CM can recapitulate 
the disease in vitro and if so, if the observed arrhythmic phenotype can be rescued or 
reduced with pharmacological treatment. For this objective it is necessary to proceed to 
a basic physiological characterisation of these mutant cells and their controls. 
 
The following hypotheses were formulated regarding functional characterisation: 
1 – hiPSC CPVT CM and hiPSC Control CM (BT-1) express basic cardiomyocyte 
markers (Troponin C) and Ca
2+
 handling proteins (RyR2, CASQ2, PLB, SERCA) 
 
2 - hiPSC CPVT CM and hiPSC Control CM (BT-1) present a typical CM AP and that 
the three CM sub-types are present in a cell population. 
 
3- hiPSC CPVT CM and hiPSC Control CM (BT-1) present basic cardiomyocyte 
physiological and pharmacological responses, namely increased pacing and ß- 
adrenergic response (to isoprenaline and propranolol) demonstrated by the expected 
inotropic, lusitropic and chronotropic properties. 
 
4 - hiPSC CPVT CM and hiPSC Control CM (BT-1) present basic cardiomyocyte Ca
2+
  
handling pharmacological responses, namely to caffeine, ryanodine and nifedipine. 
 
The following hypotheses were formulated regarding disease modelling: 
 
1 – hiPSC CPVT CM will present a higher arrhythmic response (having higher DADs 
incidence as a hallmark) than hiPSC Control CM (BT-1) from a qualitative and 
quantitative point of view when stimulated by increased pacing or ß-agonist stimulation. 
 
2 – hiPSC CPVT CM will present higher Ca2+  handling arrhythmic behaviour (having 
higher incidence of abnormal calcium transients) than  hiPSC Control CM (BT-1) from 
a qualitative and quantitative point of view when stimulated by increased pacing or ß-
agonist stimulation. 
 
3 - hiPSC CPVT CM arrhythmic behaviour (namely DADs frequency, amplitude and 
duration) can be rescued or improved when treated with anti-arrhythmic drugs in the 
presence of isoprenaline. 
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4 – hiPSC CPVT CM arrhythmic behaviour (abnormal Ca2+  transients and respective 
parameters) can be rescued or improved when treated with anti-arrhythmic drugs in the 
presence of isoprenaline. 
 
The previous hypotheses were tested using different techniques, namely western blot, 
immunocytochemistry, patch-clamp and Ca
2+
 imaging. 
 
Although spontaneous AP recordings were also obtained, one of the main objectives 
regarding patch-clamp experiments is to study these cells as a potential in vitro model 
of disease, using a systematic protocol of evoked action potentials for different 
conditions. Studies of this nature have not yet been reported in the literature. 
 
Another novel objective is to present a more objective and quantitative analysis of 
spontaneous and stimulated Ca
2+
 transients from hiPSC CPVT CM. By using a 
specialised software, SALVO, a more detailed analysis of Ca
2+
 handling properties of 
these cells may be obtained. 
1.10 Future applications and scientific impact 
Disease modelling plays a pivotal role in medical research to study new mechanisms of 
disease, find new treatments, drug testing and for the development of personalised 
treatment with optimal efficacy and safety. 
With all the challenges that each new technology faces, disease modelling with hiPSC 
derived CM has had a significant impact in the field. It has brought new information 
regarding mechanism of disease (Itzhaki et al., 2012; Ma et al., 2015), new possible 
drug treatments (Jung et al.,2012) and innovative therapeutic approaches (Matsa et 
al.,2014). In less than a decade, the cardiac pluripotent stem cell differentiation field has 
seen great advances, (Burridge et al.,2012; 2014). 
Already based on this technology, there is at least one report that demonstrates the 
bench to bedside translational potential of these cells. In this case, a clinical decision of 
increasing the pacing frequency of an ICD, in a LQT patient with a complex phenotype, 
was made based on data obtained from personalised hiPSC CM (Terrenoire et al.,2013). 
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Therefore despite a recognized immature phenotype of hiPSC derived CM, these cells 
are already providing valuable information that in some cases has already saved lives 
(Terrenoire et al.,2013). 
 Researchers are placing increased effort in creating a more mature phenotype of these 
cells. There is a need to establish an optimal maturation stage, ideal culture substrate 
and stimulation factors (Rao et al.,2013). 
The real potential of these cells may be better understood and unlocked when effective 
robust differentiation and maturation protocols to produce hiPSC CM are obtained. 
But if a true translational application of this technology is to have a significant impact in 
the clinical setting a specialized group initiative, such as a consortium, should be 
created. Testing different mutations with the same experimental protocols to 
characterise and recapitulate a disease in vitro, would help to achieve uniformity and 
consistency in the data obtained. In this way innovative diagnostic and therapeutic 
guidelines could possibly be achieved for CPVT. 
 
 
 
 
 
 
 
 
 
  
30 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
General materials and methods 
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2.1 Cell culture and differentiation of hiPSC CM 
The main objective of this current report is to characterise and validate a CPVT1 in 
vitro model of disease.  For this purpose, CM differentiated from both a control hiPSC 
BT1 cell line and a CPVT hiPSC cell line were used. 
All hiPSC were obtained from reprogrammed adult somatic fibroblasts, made at the 
University of Nottingham, by the Prof. Chris Denning group. For more details on 
fibroblast reprogramming and CPVT hiPSC characterisation please refer to Appendix I. 
For this project, the adopted CM differentiation protocol was the Burridge protocol 
(Burridge et al., 2011) chosen because it presents high efficiency in producing beating 
clusters of cells as EBs. 
In this project cell culture of both hiPSC CPVT and BT1 CM was carried out in Cardiff 
University to proceed with CM differentiation. However as this process was very 
challenging and due to low CM differentiation efficiency, most hiPSC CMs were 
generously provided by Notthingham University. 
2.1.1 Burridge Protocol 
2.1.1.1 Cell Maintenance 
The original Burridge protocol uses a conditioned media to feed hiPSC.  MEF (Mouse 
Embryoic Fibroblast) conditioned media was used to feed all hiPSC daily, adding 
2ng/ml FGF2 before changing the media. Conditioned media was obtained by feeding a 
layer of 4.5 x10 6  MEFs in a T75 gelatin 0.1% coated flask over 24h.  
The media obtained was frozen and could be kept for 6 months at -40
º
C. This media 
was then used to feed hiPSC. 
All pre-conditioned media was made of basal DMEM F12, 15% KSR (Knock-Out 
Serum Replacement), 1% NEAA (Non Essential Amino Acids), 1% P/S 
(Penicillin/Streptomycin) and 100µM β-Mercaptoethanol. 
However the use of MEF conditioned media presents some disadvantages, namely batch 
variability, irregular supply and more frequent infections. In this project it also 
presented lower efficiency in differentiating CMs from hiPSC.  
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In order to increase hiPSC quality and eliminate the use of undefined media from our 
cultures we add the mTeSR1 media from Stem Cell Technologies. mTeSR1 is a 
defined, feeder-free maintenance medium for hESCs and hiPSCs designed to maintain 
pluripotency of all cultured cells. 
Both hiPSC and control cells from a healthy subject (confirmed CPVT1 mutation free) 
were expanded and split every 3 days and plated at 1.25 x10 6  cells in Geltrex® 
(Invitrogen)  coated T25 flasks. Each T25 flask was coated with 5ml of the Geltrex®  
suspension (0.25ml Geltrex® in 49.5ml DMEM) and incubated at 37
º
C for 1h.  
 
 
 
Figure 2.1– Colony of hiPSC CPVT - Morphology of a confluent colony of hiPSC 
CPVT ready for splitting. Image obtained using inverted microscope (20x 
magnification). 
 
Splitting hiPSC was carried out at 80-100% confluence. Maintenance media was 
removed and PBS was used to wash culture flasks before adding 1ml TryplE enzyme 
(Invitrogen) and incubating for 1 minute at 37
º
C. PBS wash was important to avoid 
enzymatic inhibition from residual media. TryplE was blocked with addition of 5ml 
maintenance media. Cells were aspirated and spun in a 15ml falcon tube at 1000 RPM 
for 3 minutes, and counted. All media used were filtered to avoid pathogen 
contamination.  
100 µm 
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2.1.1.2 Differentiation protocol 
The basal media for all the Burridge protocol is RPMI 1640 and this protocol involves 
three main steps with different media composition. 
 
Figure 2.2 – Timeline diagram of hiPSC derived CM differentiation protocol 
(Burridge et al.,2011) 
CPVT hiPSC and BT1 hiPSC were split and re-suspended on day 0 media (RPMI-
PVA). The number of cells used for a V-bottom 96 well plate depended on the size of 
EBs desired, but it is recommended that 5x10
3
 cells per well are used as a minimum and 
not more than 10x10
3 
to prevent undernourishment of cells at the EB core. 
Day 0-2 media contains RPMI 1640, PVA (poly vinyl alcohol), lipids, ITS, BMP4, 
FGF2 and 1-Thioglycerol (Table 2.1). BMP4 and FGF2 factors should always be added 
fresh from frozen aliquots. Cells remain in a suspension in the media and using a multi-
channel pipette, 100µL are placed in each well of a V-bottom 96 well plate (figure 2.2).  
On day 2, 95µL of the old media is removed and replaced with 100 µL fresh RPMI – 
FBS, containing RPMI, FBS and 1-Thioglycerol. At this stage solid embryoid bodies 
(EBs) should be observed. 
On day 4 the media is changed and the EBs are transferred to a U-bottom 96 well plate. 
The old media is aspirated with multichannel pipette set to 90µL and 100µL fresh 
RPMI-ITS is added after to each well. This media contains ITS, lipids and 1-
Thioglycerol and can subsequently be used to feed differentiated beating clusters. 
To transfer EBs a multichannel pipette is set to 115µL and holding it at an oblique angle 
and in a continuous movement, 60µL are aspirated and flushed to detach the EB (figure 
2.3). The pipette is then positioned vertically and the full content of the aspirated well, 
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is dropped to a U bottom 96 well plate normally containing the detached EB. The EBs 
should be cohesive and solid enough at this stage to survive the turbulence produced. 
 
 
Figure 2.3 - Embryoid body transfer at day 4  - Burridge protocol pictogram. Passage 
from V-bottom 96 well plate to U-bottom 96 well plate. 
At day 8 some beating clusters should be seen,and spontaneous contractibility may be 
considered the main macroscopic differentiation endpoint. 
These beating clusters can then be plated on other plates or cover slips depending on the 
experiment to be done or if they are to be maintained as a beating cluster. 
Differentiated cells appear to maintain their contractile phenotype longer if in culture as 
EBs, and not so stable if disaggregated, but no accurate studies have been found in the 
literature regarding this issue. 
If EBs are maintained in the U-bottom 96 well, there is a tendency for fibroblast 
overgrowth to be observed whichcan cover the EB and hence reduce physical space for 
contractibility. 
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Figure 2.4 - Beating cluster hiPSC CPVT CM - EB from hiPSC CPVT CM in a 6cm 
plate after transplanted from 96 well plate. Abundancy of fibroblasts is seen growing 
around the EB.   Image obtained using an inverted microscope (10x magnification). 
However if transferred to a larger area plate (i.e. 6 well plate), although fibroblast 
growth is still a potential problem, to preserve contractility the EBs can more easily be 
physically detached  and transferred to another plate. 
Differentiated hiPSC CM were fed every 4-5 days with fresh RPMI-ITS media. 
 
 
Table 2.1 – Cardiac differentiation protocol for hPSC – Protocol used to induce hPSC 
differentiation into CM. (Burridge et al.,2011)   
 
100 µm 
µM 
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2.1.2 hiPSC cell lines  
The Burridge protocol has shown excellent results in differentiating several hiPSC cell 
lines (Burridge et al.,2011) withconsistent high percentages of beating clusters and 
although several publications and our collaborator‟s experience confirm this fact, this 
efficiency was not always seen in this project. In order to gain experience and acquire 
skills with this protocol, hESC H9 were also used, since these were readily available 
and produced good results. All subsequent experiments were made with cells provided 
from our collaborators from Nottingham University. 
2.1.3 EB disaggregation and plating  
In order to study the differentiated hiPSC derived CM, beating clusters had to be 
disaggregated enzymatically and plated on cover slips as single cells. 
For patch clamp experiments 13mm cover slips previously coated with 0.1% gelatine 
incubated at 37
 º
C for 30 minutes were used. The same coating and incubation times 
using glass bottom Mattek dishes, were used for all Ca
2+
 imaging experiments.. 
The disaggregation protocol of Maltsev et al., 1997 was used. This protocol uses a 
three-step gentle dissociation process using collagenase B as the active enzyme. This 
protocol uses three different buffers with specific composition (table 2.2). Each buffer is 
made and frozen in 0.5ml aliquots, being stored for 6 months at -40ºC. 
Before starting the disaggregation process 20μl/ml of 1M glucose were added to each 
thawed buffer aliquot (i.e. 20µL in 1 ml aliquots). 
 
For the first step, EBs were dissected from the original wells/flasks collected in a P200 
tip and transferred to 0.5ml of buffer 1. A maximum number of 6-8 EBs per eppendorf 
is recommended and these were incubated at room temp for 30 minutes in buffer 1. 
 
The second step involves collecting the EBs in a P200 tip and transfer to 0.5ml of buffer 
2. Incubate at 37°C for 30-45 minutes in buffer 2 (depends on size of beaters). 
For step 3, EBs were collected in a P200 tip and transferred to 0.5ml of buffer 3 
incubated at room temp for 60 minutes. 
 
As soon as the buffer 3 incubation period ends and clumps are collected in a P200 tip, 
these were transferred to a desired volume of RPMI-ITS media. 
37 
 
 
At this point the EBs need to be pressure dissociated and by pipetting up and down 5-6 
times with either a P1000 or P200 a single cell suspension should be obtained. 
Harsh pipetting may also damage the cells and experience needs to be gained with this 
step. 
 
Once dissociated, cells were plated in gelatine coated Mattek dishes, allowing 24h for 
the cells to attach undisturbed. 
A ratio of 1/2 beater per dish should be plated in 150μL RPMI-ITS, dropped carefully 
onto the centre of the slide, and carefully add 200μL RPMI-ITS after 24 hours. 
 
Table 2.2 – Disaggregation buffer composition - method used for hPSC derived EB 
(Maltsev et al., 1997) 
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2.1.4 Cardiac differentiation efficiency 
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Figure 2.5 – Cardiac differentiation efficiency in the current project – Average 
percentage EB per 96-well plate for both hESC and hiPSC (A). Total number of 
protocols in which at least one beating cluster was produced (B). 
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2.2 ICC and Protein detection 
2.2.1 Western Blot (WB) 
2.2.1.1 Protein analysis by SDS-PAGE  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is used for 
the separation of proteins according to their Molecular Weight (MW). This method is 
used for several different purposes such as to identify a protein, determine protein size 
and abundance, find the number of proteins present and find the purity of a sample.  
 
The proteins in a sample will have a number of variables including length, shape, 
weight and charge. For SDS-PAGE to work correctly the proteins must be put in their 
native state, i.e. primary structure. SDS is an anionic detergent that disrupts the 
hydrogen bonds and Van der Waal‟s interactions in proteins and breaks down cell 
membranes. This destroys the proteins secondary, tertiary and quaternary structures 
causing them to become linear. SDS also gives the protein a uniform negative charge 
making the protein travel to the positive pole in an electrical field. 
After protein separation, specific protein identification can be obtained using antibodies 
with the WB technique. Primary antibodies will bind to the target protein, a secondary 
antibody will then bind to the primary based on species similarity. This secondary 
antibody carries a molecule capable of light emission (HRP) and when stimulated, 
detection can be achieved as a photographic record. 
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2.2.1.2 SDS-PAGE Running Gel Preparation 
The running gel preparation includes several steps and several aspects must be taken in 
consideration: 
 Prepare running buffer  
 After assembling the gel case, add running buffer inside and wash wells with 
pipette. 
 On first well use a control or a ladder, (20-40 µL for Biorad) 
 Deposit protein sample in sequential wells 
 Run gel at 90V first half hour and then when reached half way, increase voltage 
to 130V. Stop when bromophenol blue line hits the bottom. 
 After running the gel, wash glass support and membrane in distilled water 
 Cut and detach membrane 
Required solutions: 
 10 x electrophoresis running buffer (SDS) 1L : 30.3g Tris base + 144g Glycine + 
10g SDS in distilled water. 
 
 5x sample buffer : 1.19ml 1M Tris-HCl pH 6.8 + 1g SDS + 1ml B-
mercaptoethanol + 3.96g glycerol + 1ml 0.2% bromophenol blue (filtered) + water to 
make 10 ml 
 
 10 x TBS-Tween: (1L) 60.57 g Tris base + 87.66 g NaCl  (pH 7.4 HCl ) + 10ml 
Tween 20 
 
 
Gel parts: 
Bottom gel: 4x Tris-HCl 1.5M pH 8.8 (100 ml) 18.2g Tris base; pH 8.8 with HCl. 
Top gel (Stacking): 4x Tris-HCl 0.5M pH 6.8 (100 ml) 6.05g Tris base; pH 6.8 with 
HCl. 
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 15% 10% 5% 3.5% (stacking) 
Acrylamide 7.5 ml 5 ml 2.5 ml 583 µl 
Tris (1.5M) 5 ml  5 ml 5 ml 1.25 ml (0.5M) 
SDS (5g-50ml) 160 µl 160 µl 160 µl 50 µl 
APS (10%) 160 µl 160 µl 160 µl 50 µl 
TEMED 20 µl 20 µl 20 µl 8.3 µl 
Water 7.16 ml 9.66 ml 12.16 ml 4.73 ml 
 
Table 2.3 – SDS – PAGE Running gel composition. Acrylamide percentage according 
to target protein molecular weight.  
 
Acrylamide concentration will depend on the molecular size of the protein to be 
detected. In this study 15% acrylamide concentration was used for small proteins such 
as CASQ and PLB and 5% acrylamide concentration was used for SERCA2A, ATPase 
and RyR2 detection. 
2.2.1.3 Cell lysis 
Protein extraction from cell pellets (minimum 1x10
6
 cells per pellet) was achieved by 
solubilisation for 30 minutes at 4ºC using RIPA modified buffer (150 mM NaCl, 1% 
Triton, 50 mM TRIS; pH 7.4 (HCl)) with protease inhibition cocktail (1:100) (Sigma P-
8340). Cells used in these experiments were hiPSC CPVT, hiPSC CPVT CM and 
primary guinea pig CM.  The pellet was centrifuged for 5 minutes at 7000 rpm 
(MiniSpin® Eppendorf), separating the supernatant which was used for WB. BCA 
Protein Assay kit (Thermo Scientific, ref.: 23227) was used to assess protein 
supernatant concentration. Samples containing at least 100µg of protein were stored at -
80 ºC and used when necessary. 
2.2.1.4 Sample Preparation 
Each sample, adjusted to contain approximately 35µg of protein, was mixed with SDS 
sample buffer and bromophenol blue in order to achieve a volume no greater than 60µL. 
Individual samples were inserted into individual wells of prepared running SDS gel. A 
guinea pig (Cavia porcellus) heart lysate was used as control in the first well and a 
Biorad control ladder (20-40 µL) inserted in the second well.  
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2.2.1.5 Protein Transferring 
When electrophoresis was completed, the gel was washed in distilled water, and iBlot ® 
Dry Blotting System (Life Technologies) was used to transfer proteins to a 
nitrocellulose membrane, following the manufacturer‟s instructions as shown in figure 
2.6. A P3 program was used and the transfer process took 13 minutes at 20V. Proteins 
transfer to the cathode direction. When the transfer was complete the sample part of the 
nitrocellulose membrane was cut out as necessary for the protein detection process. 
 
 
 
Figure 2.6 – iBlot ® Electroblotting layout – layout used to transfer SDS-PAGE 
separated proteins into nitrocellulose membrane. Proteins are transferred in the 
cathode direction. 
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Fig 2.7 – SDS-PAGE and WB – Electrophoresis machine and gasket used in SDS – 
PAGE experiments (A), sample insertion in SDS-PAGE gel wells (B), iBlot machine 
used for protein transfer from SDS-PAGE gel to nitrocellulose membrane (C) and 
nitrocellulose membrane with transferred proteins (D). 
 
2.2.1.6 Antibody detection 
After the protein transfer step to a nitrocellulose membrane, protein identification using 
antibodies was performed. A blocking protein step was carried out to reduce unspecific 
protein binding using a TBS-Tween solution with 50mg/ml of powdered milk for 60 
minutes at room temperature on an automatic shaking platform . The sample membrane 
was then washed in TBS-Tween for 5 minutes in constant movement. Primary antibody 
incubation was carried out for 2h at room temperature or overnight (16h) at 4ºC in TBS-
Tween with powdered milk at 50mg/ml. After primary antibody incubation, the sample 
membrane was washed 3 times for 5 minutes in TBS-Tween using a shaking platform. 
Secondary antibody (HRP-conjugated) was incubated at room temperature for 45 
minutes and the sample membrane was once again washed 3 times for 5 minutes in 
TBS-Tween. 
A 
 
C 
B 
D 
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For radiographic protein detection, a chemiluminescence kit from GE (Amersham ECL 
Prime Western Blotting Detection Reagent) was used according to the manufacturer‟s 
instructions. The membrane was placed on a plastic surface with the protein side up and 
the mixed detection solution was added to the membrane with incubation for 1 minute. 
Excess solution was removed and the membrane was covered with transparent plastic. 
In a dark room, the membrane was placed in an X-ray film cassette with the protein side 
up and a sheet of X-ray autoradiography film was placed on the top of the membrane. 
Reaction times depended on result ranging from 15 seconds to 1 minute. The film was 
then removed for development in an automatic developing system (X-Radiograph 
Imaging system, Compact X4). 
2.2.1.6.1 Antibodies 
Primary antibodies included: Anti-RyR2 ARP106/1 „in house‟ rabbit polyclonal (used 
at 1:1000) (West et al.,2002), Anti-SERCA2A mouse monoclonal (Affinity 
BioReagents - used at 1:1000 dilution), Anti-PLB mouse polyclonal (Badrilla - used at 
1:5000 dilution), Anti-CASQ rabbit polyclonal (Affinity BioReagents - used at 1:5000 
dilution) 
Secondary antibodies included: Anti-mouse secondary, HRP conjugate (Invitrogen), 
used at 1:5000 and Anti-rabbit secondary, HRP conjugate (Sigma), used at 1:10000 
dilution. 
Used antibodiy dilutions were provided by personal communication from Dr. Mark 
Bannister and Dr. Lowri Thomas. 
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2.2.2 ICC – Immunocytochemistry 
2.2.2.1 Fixation and permeabilization 
Cells used in patch clamp experiments were also used for ICC. After patch clamp 
experiment termination hiPSC CM were fixed with PFA (paraformaldehyde 4%) for 15 
minutes at room temperature. Cover-slips were rinsed three times with PBS and then 
permeabilized with Triton X-100 (0.2%) for 1 hour at room temperature.  
2.2.2.2 Primary antibody incubation 
Samples were blocked with 5% non-fat dry milk in 0.2% Triton X-100 solution for 2 
hours at room temperature on a rotator. Cover slips were rinsed with PBS twice and 
primary antibody was added to 0.1% Triton + 1% BSA (bovine serum albumin) and 
incubated overnight at 4ºC. Cover-slips were washed twice in PBS with 0.2% Tween 
20.          
2.2.2.3 Secondary antibody incubation 
A secondary antibody was added in the same solution as the first antibody. Cells were 
incubated at room temperature in a dark room for 1.5 hours. Cover slips were washed 
with PBS twice and nuclei were stained using Hoescht for 5 minutes at room 
temperature. Finally one drop of antifade agent (ProLong® Gold – Life Technologies) 
was added to each slide. 
2.2.2.4 Imaging 
All preparations were imaged with a confocal fluorescence microscope (SP5; Leica 
Microsystems, Wetzlar Germany). An oil immersion lens with magnification of 63x 
was used. Light source was argon laser at fluorescent wavelength of 488nm. 
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2.2.2.5 Antibodies 
Primary antibodies included: Anti-RyR2 ARP106/1 „in house‟ rabbit polyclonal (used 
at 1:1000) (West et al.,2002), Anti-Troponin I mouse polyclonal (Sigma - used at 
1:1000 dilution), 
Secondary antibodies included: Anti-rabbit secondary, Alexa 488 conjugate 
(Invitrogen), used at 1:5000 and Anti-mouse secondary, Alexa 488 conjugate (Sigma), 
used at 1:5000 dilution. 
Antibody dilutions were provided by personal communication from Dr. Mark Bannister 
and Dr. Lowri Thomas. 
2.3 Electrophysiology - Patch clamp technique 
In order to study the electrophysiological properties of hiPSC derived CM, the whole 
cell patch clamp technique, was used.  
This technique is a powerful tool to assess the hiPSC derived CM AP. The main 
objective was to obtain action potential recordings under specific experimental 
conditions using pharmacological intervention and electrical stimulation to record not 
only spontaneous action potentials but also evoked activity. 
2.3.1 Stage set-up 
 
Cover slips with plated cells, were transferred manually to 35mm glass bottomed 
culture dishes containing a superfusion insert (Automate PCP-1; Digitimer Ltd.,Welwyn 
Garden City, UK) (figure 2.8 ) 
 
 
Figure 2.8 – Superfusion insert for patch 
clamp – superfusion insert used in drug 
perfusion trial attached to 35mm petri dishes 
(Falcon 351008 easy grip petri dishes 
35x10mm). This insert was attached to the petri 
dishes with Lubricant Grease (Dow Corning 
valve lubricant & sealant). 
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The prepared glass bottomed culture dishes were mounted on the stage of an inverted 
microscope (CKX-41; Olympus, Tokyo, Japan) (figure 2.9) 
Patch pipettes were made from “Kwik-Fill” borosilicate glass capillaries (World 
Precision Instruments (1B150F – 4). Pipettes were pulled in a Micropipette Puller           
(Sutter instruments Co. Model P-97). 
 
 
2.3.2 Solutions and drugs 
The HEPES based extracellular perfusate (modified Tyrode‟s) for current-clamp 
recordings consisted of (in mmol/L): 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 10 
glucose, 10 HEPES and pH was adjusted to 7.4 with NaOH. All reagents used from 
(Sigma) 
 
The intracellular solution consisted of (in mmol/L): 130 KCl, 1 MgCl2, 10 HEPES, 5 
EGTA and KOH was used to set pH to 7.2. All reagents used were obtained from 
Sigma. Intracellular pipette solution was frozen in aliquots and stored at -20 ºC for up to 
6 months. 
 
Drugs and working concentrations used in patch clamp experiments were respectively: 
isoprenaline (1µM), flecainide (10 µM), dantrolene (10 µM), propranolol (1µM), 
propafenone (10 µM). All drugs used were obtained from Sigma. 
 
Stock aliquots for all drugs were made and frozen at -20 ºC for up to 6 months. 
 
Figure 2.9 – Patch clamp stage set up – 
patch clamp rig and inverted microscope 
used in electrophysiology experiments for 
this project.  
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Isoprenaline aliquots were made with ascorbic acid (Sigma) prepared in the ratio of 10:1 
of ascorbic acid to isoprenaline to  reduce oxidation of isoprenaline (Clements et 
al.,1980). 
 
2.3.3 Patch clamp recordings 
Recordings were made using a CV-7 headstage and MultiClamp 700B amplifier (Axon 
Instruments, Sunnyvale, CA, USA) controlled by Multiclamp software (Molecular 
Devices, Sunnyvale, CA). 
 
Current clamp (IC) recordings were digitized and acquired using a Digidata 1322a card 
and pClamp 10.3 software (Copyright © 2012 Molecular Devices, LLC). AP were 
sampled at 10 kHz and filtered at 5 kHz using the low pass (eight pole Bessel) filter. 
Data analysis obtained from patch clamp experiments was extracted using Clampfit 
10.3 (Copyright © 2012 Molecular Devices, LLC). 
 
2.3.3.1 Recording conditions 
Recordings were obtained at 25ºC from both hiPSC CPVT CM and hiPSC BT1 CM.  
Pipette bath resistance was between 2 and 5 MΩ. Pipette access resistance to cells was 
between 4 and 10 MΩ. 
Spontaneously beating cells were defined as cells presenting spontaneous activity in a 
Gap free protocol (no current or voltage clamp injected) that records native cell resting 
membrane potential. 
Quiescent cells were defined as cells not presenting spontaneous activity in a Gap free 
protocol. They did present evoked APs which were obtained in Current Clamp mode by 
injecting a single pulse of 500pA with 3ms duration.  Cells RMP was clamped at           
-80mV to standardise evoked AP.  
Evoked APs were obtained from both spontaneous and quiescent cells. 
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2.3.3.2 Protocol sequence 
In order to try and reproduce disease in vitro, a sequence of recording protocols were 
designed using evoked action potentials.  
The sequence for patch-clamp experiments involved 4 protocols. The purpose of this 
experimental sequence was to try and trigger any arrhythmic activity with isoprenaline 
perfusion and then observe if anti-arrhythmic drugs could rescue any presented pro-
arrhythmic events such as DADs. 
The first recording was a Gap-free protocol perfused with Tyrode‟s to record 
spontaneous activity or the cell RMP (if quiescent) with 60 seconds duration. The first 
Gap-free protocol was followed by 3 current-clamp protocols in which a minimum of 
50 evoked AP were recorded per cell.  Experiments with paced cells were made at 
0.5Hz and 1Hz. 
The first protocol for evoked activity was done with cells perfused with Tyrode‟s 
solution only, the second with isoprenaline (1µM) in Tyrode‟s and the third with one of 
the used antiarrythmic drugs in the presence of isoprenaline (1µM). 
2.3.3.3 Data extraction 
All the data used in Chapter 4 and Chapter 5 was obtained from the same experiments 
following the previous mentioned perfusion sequence. In Chapter 4, isoprenaline 
perfusion data is a sum from isoprenaline prefusion of the different drug trial. This was 
done in order to assess the effect of isoprenaline on more cells, as it was difficult to 
obtain a high number of cells that endured the full duration of the protocol when 
patched. 
Figure 2.10 – Image of hiPSC CPVT CM-
hiPSC CPVT CM being patch clamped.  
Triangular shade on the right side 
corresponds to glass micropipette. 
5µm
µm 
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DAD measurement was done manually using Clampfit 10.3 since no specific software 
was available to adequately measure these events.  
2.4 Ca
2+ 
fluorescence imaging 
2.4.1 Confocal microscopy 
A confocal microscope (SP5; Leica Microsystems) was used for all Ca
2+
 imaging 
experiments. Confocal microscopes allow tri-dimensional (x,y,t) visualization of the 
analysed cell upon light stimulation (usually a laser). A Ca
2+
 sensitive fluorophore 
indicator can then allow indirect visualisation of intracellular Ca
2+
 distribution. 
2.4.2 hiPSC CM loading and plating 
The microscope stage allows the use of Mattek dishes with a bottom glass cover slip, 
(Mattek dishes - uncoated 35mm glass diameter 14mm, P35G-1.5-14-C) which were 
used in all experiments.  
EB disaggregation (please see protocol in chapter 3) allowed plating hiPSC CM in 
dishes previously coated with gelatin 0.1%. Gelatin 0.1% (500µl per dish) was 
incubated 30 minutes at 37ºC and excess removed before plating cells.  
Fluo-4 AM (Life Technologies) was used to load cells in every Mattek dish. The 
working concentration of Fluo-4 AM was 5µM. Pluronic® F-127 (20% Solution in 
DMSO- Invitrogen  P-3000MP) was used to dissolve one frozen vial  of Fluo-4 (50 µg). 
Before loading the cells, 5µL of stock mixture of Fluo-4 and Pluronic was added to 1ml 
of Tyrode‟s. RPMI-ITS was removed from the Mattek dish and 1ml of Tyrode‟s 
containing Fluo-4 was used to incubate cells at room temperature in the dark for 20 
minutes. 
After loading, loading solution was removed and cells were washed with Tyrode‟s three 
times. Cells were then left with 1ml Tyrode‟s in the Mattek dish to rest for 20 minutes 
at room temperature for de-esterification of the Fluo-4 AM. 
Mattek dishes with loaded cells were then used for confocal imaging experiments.  
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Figure 2.11 – FLUO-4 loaded hiPSC CPVT CM and regions of interest (ROIs) – Cell 
pleomorphism observed (63x magnification oil immersion lens). Image extracted with 
Leica LAS software. 
 
2.4.3 Perfusion chamber and external stimulator 
The use of a perfusion insert chamber with platinum electrodes (model RC-37FS – 
Warner instruments – figure 2.12) allowed not only continuous perfusion of solutions 
but also field electrical stimulation to elicit CM contraction at different pacing 
frequencies. 
 
Figure 2.12 – Perfusion and stimulation chamber used in Ca2+ imaging experiments - 
Perfusion insert with electric field stimulation for cell culture dishes. Suitable for 
Mattek 35mm dishes. This commercial insert, model RC-37FS is designed for 
applications requiring field stimulation and incorporates a pair of platinum electrodes. 
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In order to stimulate cells, a specific tailor, made electrical stimulator was used (built by 
R.A.P. Montgomery). hiPSC CM were stimulated with bipolar pulses of 10-30Volts for 
5ms. Pacing frequencies were 0.5, 1, 1.5 and 2Hz. 
2.4.4 Perfusion drugs and solutions 
The HEPES based extracellular perfusate (modified Tyrode‟s) used as perfusion media 
in all recordings, consisted of (in mmol/L): 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 10 
glucose, 10 HEPES and pH was adjusted to 7.4 with NaOH. All reagents used, were 
obtained from Sigma. 
Perfusion was always carried out with drugs dissolved in modified Tyrode‟s (as 
previously described). Drugs used were isoprenaline (1µM) propranolol (1µM), 
nifedipine (1µM), flecainide (10µM), dantrolene (10µM), ryanodine (10µM) and 
caffeine (10mM). 
All drugs were acquired from Sigma. 
Stock concentration aliquots were made for isoprenaline, propranolol, dantrolene 
flecainide and ryanodine and frozen at -80ºC until used. 
10 mM caffeine was made fresh from solid every time required. 
2.4.4.1 Perfusion protocol 
The perfusion protocol for hiPSC CPVT CM and BT1 CM characterisation (Chapter 4) 
consisted of two recordings of 90 seconds. One in Tyrode‟s perfusion and another with 
Tyrode‟s in the presence of isoprenaline 1µM. Isoprenaline perfusion started 30 seconds 
after initiating recording (figure 2.13)  
 
Figure 2.13 - Ca
2+
 imaging drug perfusion diagram – Drug perfusion was initiated 30 
seconds after start recordings. Maximum length recording was 90 seconds. 
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In pacing experiments, stimulation would also be initiated 30 seconds after the start of 
recording. 
For drug rescue experiments (Chapter 5) three different recording files were made in 
sequence, with a 2 minute Tyrode‟s washout period in between different perfusates: 
1 – Tyrode‟s only, 2 – Tyrode‟s in the presence of isoprenline, 3 – Tyrode‟s with drug 
in the presence of isoprenaline. 
Caffeine (10mM) was always added at the end of experiments. No other experiments 
were made after caffeine perfusion. 
2.4.5 Recordings 
For experimental purposes spontaneous cells were considered as cells beating with no 
external pacing. Stimulated cells could be both quiescent and spontaneously active cells 
that responded to external pacing. 
Data used in Chapter 4 is a sum from all isoprenaline perfusion experiments, including 
data from Chapter 5. 
2.4.5.1 hiPSC culture 
Experiments were performed in hiPSC CM 5 days after disaggregation and plating 
down on Mattek dishes. Experiments were made with hiPSC CM between 5-30 days  in 
culture after disaggregation. Studied hiPSC single cells never had more than 2 months 
post differentiation (as EBs or single cells). Feeding media while cells were on  Mattek 
dishes was RPMI-ITS as per the protocol. 
2.4.5.2 Data acquisition 
Fluo-4 Ca
2+
-dependent signals were visualized as 100-µm
2
 ROIs. Only one ROI per 
hiPSC CM was analysed, selected so as to be away from the area of the nucleus to avoid 
excessive fluorescence.  A 63× oil immersion objective using argon laser excitation 
(488 nm) at 20% strength was used.  
Cells were maintained at 37 °C throughout experiments. Images were recorded every 
100ms at a 512 × 512–pixel resolution.  
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External pacing stimulation experiments were recorded as 90 second files.  External 
stimulation was initiated 30 seconds after the start of recording. Frequencies of 0.5Hz, 
1Hz, 1.5Hz and 2Hz were studied in the presence or absence of isoprenaline.  
For spontaneous activity recordings, similar conditions were used but without external 
stimulation. Drug perfusion was started at 30 seconds after the start of recording. A 2 
minute Tyrode‟s wash out period was given in between recordings. 
2.4.6 Data analysis - SALVO 
Data analysis was done using SALVO (Synchronization, Amplitude, Length and 
Variability of Oscillation) software. This program allows decoding the spatiotemporal 
patterning of Ca
2+
 oscillations within individual cells and across multicellular 
populations (Lewis et al.,2014). This specialized software outputs thirty parameters that 
describe Ca
2+
 signal organization.  
 
Figure 2.14 – Ca2+ transient parameters - Schematic showing some of the Ca2+ 
transient kinetic parameters monitored in this project. 
For Ca
2+
 transient characterisation (Chapter 4) the following parameters were analysed: 
peak regularity, inter transient noise (ITN), height (amplitude), length (duration), 
standardised area, rate (Hz), rate up, length up, rate decay and length decay. 
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For Ca
2+
 transient study and validation of in vitro disease modelling (Chapter 5) the 
following parameters were analysed: peak regularity, ITN (total), height (amplitude), 
standardised area, rate (Hz) and rate decay.  
Peaks and valleys used to analyse data in SALVO were taken from full length (90 
seconds) traces. 
 
SALVO output parameters definition, used in this study: 
Peak regularity Standard deviation of the distance between the transient 
peaks. If the ROI is perfectly regular, with each transient 
peak occurring exactly the same space apart, this will return 
zero.   
ITN (total) Intertransient noise. Sum of the absolute point to point 
difference in intensity of the sections of the trace between 
transients.  In non-oscillating ROIs, this covers the entire 
trace.  Calculated between start and stop. 
Height (Amplitude) Average height of the ROI’s transients. Averaged across all 
transients in the ROI. Height of a single transient is 
calculated as the difference between the maximum peak 
point and the valley at the start of the transient, divided by 
the start valley (all using intensity values. 
Length (Duration) Average length of the ROI’s transients. Averaged across all 
transients in the ROI.  Length of a transient is calculated as 
the difference between the ending valley and the starting 
valley (time in seconds). 
Standardised Area Average standardised area of the ROI’s transients. Averaged 
across all transients in the ROI.  Standardised area of a 
transient is calculated using the trapezoid method to find the 
area under the curve and bounded by the start and finish 
valleys and the maximum peak point, divided by the intensity 
of the starting valley. 
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Rate (Hz) Rate of oscillation of ROI in Hz. Transients per second.  
Calculated by the number of transients in the ROI divided by 
the length of the ROI.  
 
Rate up Average rate of increase to peak of transient. Averaged 
across all transients in the ROI.  Rate up for a transient is 
calculated by the difference between the intensity of the first 
peak point and the first valley point of a transient, divided by 
the time between the two points.   
Length up Average time to increase to peak of transient. Averaged 
across all transients in the ROI.  Length up for a transient is 
calculated by the difference between the time of the first 
peak point and the first valley point of a transient. 
Rate decay Average rate of decrease back to baseline of transient. 
Averaged across all transients in the ROI.  Rate decay for a 
transient is calculated by the difference between the intensity 
of the ending valley point and the first peak point of a 
transient, divided by the time between the two points. 
Length decay Average time to decrease back to baseline of transient. 
Averaged across all transients in the ROI.  Length decay for 
a transient is calculated by the difference between the time of 
the ending valley point and the first peak point of a transient.   
 
 
 
2.4.6.1 Data analysis and presentation 
 
Data obtained from SALVO were organised in tables using Microsoft Excel. Graphs 
produced from data obtained from SALVO analysis were made using Graphpad Prism 
version 5.00 for Windows, GraphPad Software, La Jolla, CA, USA.  
When no units are mentioned in presented graphs arbitrary units (AU) were used. 
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2.5 Statistical analysis 
 
Analysis of data obtained from patch clamp experiments was performed in Microsoft 
Excel and GraphPad Prism version 5.00 (GraphPad Software, La Jolla, CA, USA).  
Normal distribution of data sets was obtained with the D‟Agostino-Pearson algorithm, 
and normally distributed data columns were analysed with two-tailed Student‟s paired 
or unpaired t-test if data sets were paired or unpaired respectively. Mann-Whitney tests 
were used for data sets that were not normally distributed.  
When comparing multiple columns a repeated measures ANOVA with a Bonferroni 
Post test was used. If the data sets were not normally distributed, a Friedman statistical 
test was used, with a Dunn‟s Post Test. 
Data is presented as mean ± standard error (SE) with 95% confidence interval. 
Statistical significance was considered for p value ≤ 0.05 (*, p ≤ 0.05, **,p  ≤ 0.01, 
***, p ≤  0.001).  
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Chapter 3 
hiPSC derived CM Ca
2+
 handling protein 
detection and imaging 
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3.1 Introduction 
3.1.1 Cardiac Ca
2+
 handling proteins 
The mammalian CM is a cell with unique features and a protein expression profile 
necessary to facilitate the normal function of the heart. EC-coupling is the mechanism 
that allows the CM to contract. It starts as an electrical phenomenon leading to 
mechanical contraction. The rapid depolarization of the cell due to a Na
+
 influx 
activates LTCC and subsequent Ca
2+
 influx, triggering Ca
2+
 release from the SR via 
RyR2. Troponin T is then stimulated by Ca
2+
 and myofibres contract, leading to CM 
contraction. 
In addition to LTCC and RyR2, other proteins play pivotal roles in maintaining Ca
2+ 
homeostasis, including SERCA2A (by re-uptaking cytosolic Ca
2+
) and PLB (by 
stopping SERCA2A inhibition when phosphorylated). Other proteins, such as CASQ2 
bind to Ca
2+
, storing this ion inside the SR, while TDN and JCN have an accessory role 
close to RyR2 in the SR. 
Protein expression and detection techniques were used in this project in order to 
determine a preliminary Ca
2+
 handling profile for control and mutant hiPSC CM. WB 
and ICC were used in both cell types. 
Other methods can measure indirect protein expression but were not used in this project. 
Collection of mRNA from beating clusters could determine if these cells had the 
capacity to express these proteins but would fail to determine if they had been expressed 
and if they were located in the appropriate sub-cellular space.  
3.1.2 hPSC - Human pluripotent stem cells 
Several publications report protein detection in hPSC, (for both hESC and hiPSC) using 
WB and ICC. One of the first publications to present detection of cardiac marker 
proteins using ICC was by He et al., 2003. Detection of hERG, HCN4 (responsible for 
the “funny” current) and LTCC was reported in hESC derived CM. 
Absence of CASQ2 and PLB in hESC was reported by Binah et al., 2007. These authors 
found that although NCX, SERCA2A and α-actinin were detected by WB, neither 
CASQ2 nor PLB was found to be expressed in hESC CM. 
In 2010, Asp et al., used ICC to report, not only cardiac markers but some ion channel 
expression and location such as hERG, HCN4 and LTCC. 
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Similar findings to those reported for hESC derived CM were found in the literature 
regarding hiPSC CM. Zhang et al., 2009 used ICC to detect sarcomeric organisation in 
hiPSC, namely α-actinin, myosin light chain (MLC) and troponin C. Gupta et al., 2010 
used ICC and detected both troponin C and α-actinin as CM differentiation markers in a 
study comparing hESC and hiPSC protein expression profiles. 
Although some authors report protein detection of CM markers, no publications were 
found with detailed and extensive results for protein expression using specifically WB. 
Gupta et al., 2010 present an extensive study regarding hiPSC and hESC CM mRNA 
expression but not confirmation that coded proteins are present in the cells.  
3.1.3 hiPSC CPVT CM 
Protein detection and profiling has been reported by other authors in hiPSC CPVT CM. 
Ca
2+
 handling protein detection with WB was not a technique of choice for the majority 
of CPVT CM reports. ICC was presented by most authors to characterise not only 
hiPSC derived CM but especially to characterise hiPSC for pluripotency markers. 
Kujala et al., 2012 report the use of ICC in CPVT CM, detecting troponin T and α-
actinin (as CM markers). Detection of connexin 43 as a functional syncytial marker was 
also reported. Pluripotency profile with ICC for Nanog, Oct 4, TRA1-60 and SSEA4, 
was reported in hiPSC characterisation. 
Two other authors, Itzhaki et al., 2012 and Fatima et al., 2011 detected the same 
pluripotency markers in hiPSC (namely Nanog, Oct4, TRA1-60 and SSEA4) with ICC, 
as well as CM markers, such as α-actinin and RyR2. 
In the current project, SDS-PAGE followed by WB was used to detect CASQ2, 
SERCA2A, RyR2 and PLB. These were considered the most relevant proteins in CM 
Ca
2+
 handling and samples were obtained from CPVT patient fibroblasts, CPVT hiPSC 
and CPVT EBs at day 4 (d4) and EBs post differentiation day 15. 
A small study of ICC was also used to detect the presence of Troponin I and RyR2 in 
hiPSC CPVT CM in order to evaluate if these cells presented a classical differentiation 
CM marker and to detect RyR2 presence and distribution. 
3.2 Methods 
For methods details, please refer to Chapter 2, section 2.2 (ICC and protein detection). 
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3.3 Results 
The detection of Ca
2+
 handling proteins within hiPSC CM is important to understand 
their Ca
2+
 handling capacity. Establishing when these proteins are expressed during the 
cardiac developmental process is also essential to the characterisation of both BT1 and 
CPVT derived CM as these are pivotal to physiological cardiac responses such as 
positive inotropy and lusitropy. Due to the foetal nature of hiPSC derived CM, a protein 
detection and localisation study was undertaken.  
Immunocytochemistry (ICC) was used to observe RyR2 and Tropononin I distribution 
and location using specific primary antibodies that bind to target protein. Primary 
antibodies can then be targeted by a secondary labelled antibody enabling visualization 
of sub-cellular proteins distribution. This technique was applied in both CPVT and BT1 
hiPSC CM previously used in patch clamp experiments (figure 3.1). Control CM 
stained positive for Troponin I and presented some binucleated cells. ICC was not 
repeated in mutant cells due to time constraints. For the same reason ICC for CASQ, 
PLB and SERCA2A were not performed. RyR2 positive staining was observed in both 
hiPSC BT1 and CPVT CM with similar distribution in the cytosol and perinuclear 
region.  
The Western Blot (WB) technique was used for SERCA2A (figure 3.3), RyR2 (figure 
3.2), CASQ (figure 3.5) and PLB (figure 3.4) detection as it‟s suitable to separate and 
detect minimal presence of proteins, given that the amount of available tissue was 
limited. The absence of CASQ, SERCA2A and PLB detection in WB experiments for 
lysates of different cells and differentiation stages, suggests that these cells could still be 
immature. RyR2 could not be detected by WB in EBs day 15 post differentiation due to 
small sample of available EBs. These results suggest that these cells did not present the 
expected Ca
2+
 handling protein profile of adult CMs.  
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3.3.1 Immunocytochemistry 
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3.3.2 Western blot protein detection 
 
 
Figure 3.2 – Western Blot, SDS-PAGE for RyR2 – Representative blot from RyR2 
detection with SDS – PAGE and HRP chemiluminescence. Samples obtained from 
fibroblasts from a CPVT patient, hiPSC CPVT and EBs d4. Control well was dubious 
for RyR2 detection as blot was not close to expected MW. Possibly only RyR2 
proteolysis products containing the epitope were present, explaining the less than 
expected MW of the proteins detected. No RyR2 (or proteolysis products) were detected 
in any of the samples, as expected. The quantity of material was not enough to proceed 
with detection of EBs d15. 
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Figure 3.3 – Western Blot, SDS-PAGE for SERCA2A ATPase – Representative blots 
from SERCA2A ATPase detection with SDS – PAGE and HRP chemiluminescence. 
Samples obtained from fibroblasts from a CPVT patient, hiPSC CPVT and EBs d4. This 
blot does not present a positive detection of SERCA2A in CPVT patient fibroblasts, 
CPVT hiPSC and EBs d4. It may however present positive SERCA2A proteolysis 
products close to the 6kDa range. The quantity of material was not enough to proceed 
with detection of EBs d15. Guinea pig control lysate also presented positive detection of 
SERCA2A ATPase. 
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Figure 3.4 – Western Blot, SDS-PAGE for PLB – Representative blots from PLB 
detection with SDS – PAGE and HRP chemiluminescence in two different experiments 
(A and B). Samples obtained from fibroblasts from a CPVT patient, hiPSC CPVT CM 
and EB d4 (A) and CPVT CM, EBs d4 and EBs d15 (B). Control well was positive for 
PLB detection (monomer and pentamer) in both experiments, but no PLB was detected 
in CPVT patient fibroblasts or CPVT hiPSC. Lysates from d4 EBs and d15 EBs were 
also negative for PLB detection. 
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Figure 3.5 – Western Blot, SDS-PAGE for CASQ – Representative blots from CASQ 
detection with SDS – PAGE and HRP chemiluminescence in two different experiments 
(A and B). Samples from fibroblasts from a CPVT patient, hiPSC CPVT CM and EBs d4 
(A) and CPVT CM, EBs d4 and EBs d15 (B). Control well seems to be positive for 
CASQ detection although more marked in (B). No CASQ was detected in CPVT patient 
fibroblasts or CPVT hiPSC. Lysates from d4 EBs and d15 EBs were also negative for 
CASQ detection. 
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3.4 Discussion 
By using ICC and WB techniques, a preliminary Ca
2+
 handling protein profile was 
established for hiPSC CPVT CM with the mutation studied in the current project. 
Repeating WB similar experiments in more mature hiPSC CPVT CM (3-4 months EB 
maturation) could help to determine if the absence of SERCA2A, CASQ, PLB and 
RyR2 was related to CM immaturity or to a trafficking defect. This last possibility 
would not be expected in this CPVT mutation. WB repetition was limited due to lack of 
abundant sample protein due to the difficulty in obtaining hiPSC CM from both control 
and mutant cells. 
Jung et al., 2012 report that in CPVT CM matured by 2 months no CASQ2 or PLB were 
detected by WB, but in more mature cells with 3-4 months post terminal cardiac 
differentiation these authors found expression and detection of RyR2, CASQ2, PLB, 
TDN and JCN. In the same report, ICC revealed RyR2 with similar distribution on 
cytosol and perinuclear region, co-localised with myofilaments in CPVT CM. Using 
this last technique Jung et al., revealed that cluster density for RyR2 was similar in both 
mutant and control CM, suggesting that the particular mutation of CPVT CM was not a 
trafficking defect. 
Other authors, Di Pasquale et at., 2013 detected RyR2 expression by WB in both control 
and CPVT CM (1-3 months post differentiation) beating clusters using human foetal 
CM as controls which supports the suggestion that older, more mature, EBs may 
express RyR2 that seems to be absent in hiPSC CM with less than 1 month post-
differentiation. 
In this project, both control and CPVT hiPSC CM, used in ICC experiments were more 
mature (1-2 months post differentiation) than the ones used in WB (1 month 
differentiation). This fact could explain why staining was positive for RyR2 in both 
CPVT and BT1 CM. Troponin I was also present in striations in control hiPSC CM (1-2 
months post differentiation), indicating that cardiogenesis maturity is marked in this 
batch of cells.  A mature cardiac feature is also evident in this image (figure 3.1C), in 
which a cell presents two nuclei, a typical characteristic of adult CM. 
Detection of SERCA2A ATPase was negative for all the screened cell types. However, 
this protein detection was expected in early embryonic stages in most cell types. It is 
possible than some SERCA2A proteolytic fragments of the protein full length were 
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present and separated with SDS-PAGE (figure 3.3). Additional experiments could 
determine the presence of this protein in d15 EBs, but due to time constraints and lack 
of lysate sample this experiment could not be repeated.  
According to published results for the detection of Ca
2+
 handling proteins by WB and in 
accordance with results obtained in this project, a study with more mature hiPSC CM 
could confirm if cardiogenesis and Ca
2+
 handling associated protein expression 
increases with maturation.  
Ideally, ICC should be done to detect the presence and distribution of other proteins 
screened with WB (CASQ, SERCA2A and PLB). Due to time constraints such 
experiments could not be done. 
3.5 Conclusion 
The Ca
2+
 handling protein profile of hiPSC CM used in the reported experiments is 
more suggestive of a foetal CM for these cells. Essential Ca
2+
 handling proteins, namely 
CASQ, SERCA2A and PLB seem to be absent from early stage maturation hiPSC 
CPVT EBs. PLB and CASQ2 absence is characteristic of immature CM as these 
proteins are pivotal in classical cardiac response, such as positive inotropy and 
lusitropy. RyR2 detection could not be assessed in differentiated cells (EB day 15), due 
to the low number of cells available. Sensitivity of the protocol used for WB can also be 
related with the negative results in the selected proteins detection. New experiments 
with higher protein concentration present in the lysates, could determine if this was the 
case. However, small amounts of available material limited the sample size used for this 
set of experiments. Although RyR2 was not obviously detected with WB, ICC indicated 
expression of RyR2. A maturation time point study for detection of post differentiated 
hiPSC CM would aid in the understanding of differentiation and maturation of hiPSC 
CM. If hiPSC are to be used to recapitulate disease in vitro, they should ideally have a 
completely functional CICR and EC-coupling.   
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Chapter 4 
hiPSC derived CM  
functional characterisation 
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4.1 Introduction 
The cardiac muscle cell is unique from a physiological point of view, regarding its AP 
and Ca
2+
 handling properties. Excitation-Contraction (EC) - coupling is the process that 
starts with the electrical event of depolarization of the CM and that culminates in 
mechanical activity with the contraction of the cell. The initial electrical depolarization 
via INa will sequentially activate IL-Ca creating a Ca
2+
 ion influx into the cell sarcoplasm. 
In CM this influx will trigger CICR (Calcium Induced Calcium Release) by opening the 
ryanodine type 2 receptor (RyR2). This receptor is imbedded in the sarcoplasmic 
reticulum (SR), allowing Ca
2+
 stores in the SR to be released into the sarcoplasm, 
triggering contraction of myofibers by troponin C.. During the relaxation phase, SR 
Ca
2+
 release is terminated, and the released Ca
2+
 is recycled into the SR by the SR Ca
2+
-
ATPase (SERCA) or extruded from the cell by the Na
+
/Ca
2+
exchanger (NCX). These 
events will effectively lower the cytosolic Ca
2+
 concentration and allow Ca
2+
 
dissociation from the myofilaments and muscle relaxation. 
 
The advent of hiPSC technology, coupled with advances in cardiac differentiation 
protocols, has provided a potential, more accessible model of the human cardiac muscle 
cell. Some published studies (Itzhaki et al., 2010; Matsa et al., 2011; Malan et al., 2011; 
Jung et al., 2012; Fatima et al., 2012) suggest a very promising use for these cells as in 
vitro models of disease. In these publications, functional assessment and experimental 
methodological heterogeneity raise some questions regarding these cell‟s physiology. 
Hence these cells need to be properly characterised before rigorous and accurate 
translational applications can be made. 
All mutant cells in this project were hiPSC derived CM from a CPVT1 patient. This 
patient carried the RyR2 mutation S2246L in the central domain of the receptor. CM 
were made from a healthy subject and used as control (BT1 CM). AP characterisation 
for both control and CPVT hiPSC derived CM was performed using the patch clamp 
technique. 
The study of CM Ca
2+
 handling physiology is also pivotal to do a functional 
characterisation of these cells. Three of the main defining properties of adult CM 
(positive inotropy, chronotropy and lusitropy in the presence of ß-agonists) should be 
present if hiPSC CM are to be compared to adult human CM. Current existing reports 
for both beating clusters (Dolnikov et al., 2005; Binah et al., 2007) or single cells 
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(Mummery et al., 2003; Liu et al., 2009; Fu et al., 2010) present inconsistent 
methodology and divergent results.  
In this project Ca
2+
 imaging of single CM, was used to characterise functional Ca
2+
 
handling in both mutant and control CM. 
E-C coupling has been well documented in several adult mammalian species, including 
in human CM. However, there are still diverging reports regarding some of the proteins 
involved and the physiological characterisation of hiPSC CM. Therefore, before testing 
CPVT hiPSC derived CM as an in vitro model of disease, it was essential to 
characterise the cells used in this study. This characterisation should allow a better 
understanding of the physiology and maturity stage of these cells, playing a pivotal role 
in their use, by determining their functional profile. 
4.2 Electrophysiology characterisation 
The first functional characterisation of spontaneously contracting hiPSC derived CM 
was reported in 2009 by Zhang et al. Since then hiPSC derived CM, similar to hESC 
derived CM, have been demonstrated (Gupta et al., 2010). Basic parameters of the CM 
AP such as RMP, amplitude, time to peak, APD50 and APD90, have been recorded 
from several hiPSC derived CM cell lines, with very similar results (table 4.1). This 
similarity was also verified for individual currents such as I(Na), I(K), I(to), I(Ca,L) that have 
been well characterised by several authors for both hESC (Jian Qiang-He et al., 2003; 
Kehat et al., 2001) and hiPSC derived CM (Honda et al., 2011; Ma et al.,2011). 
The cardiac AP is the basic electrophysiological signature of the cardiac muscle cell. It 
is the resulting sum of the coordinated ion channel currents, namely I(Na), I(Ca,L), I(K) and 
I(to). It is also the primary event in the E-C coupling process that starts with an electrical 
event and ends in a mechanical contraction of the cardiac cell. The RMP of an adult 
human CM is approximately -80mV in ventricular and atrial cells, while pace-maker 
cells tend to have a resting membrane potential of about -50 mV. Several authors 
(Zhang et al., 2009; Ma et al., 2011; Lahti et al., 2012) report that most hiPSC derived 
CM have a less negative RMP than the adult cells, suggesting a more foetal-like 
phenotype. 
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The AP characterisation and shape, allows the classification of these cells in to three 
different main sub-types: nodal-like, atrial-like and ventricular-like. 
 
 
Table 4.1 - AP parameter characteristics in hiPSC and human ventricular 
cardiomyocytes (Hoekstra et al., 2012. 
 
Figure 4.1 –Human ventricular cardiac AP - Example trace of a cardiac ventricular 
AP from and adult human CM with electrophysiology parameters diagram and involved 
electrical currents. 
 
The ß-adrenergic response of these cells is essential to functionally characterise CM 
physiology. Pace-maker cardiac cells should have a positive chronotropic response to 
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isoprenaline. This effect in pace-maker cells will then control atrial and ventricular CM. 
These last two CM sub-types are quiescent in the adult heart and contraction is 
controlled by the pace-maker CM.  
In contrast to what is seen in adult CM, positive chronotropy can also be observed in 
both atrial and ventricular-like hiPSC derived CM (Zhang et al., 2009). This observation 
is possibly due to the foetal nature of these cells. Positive chronotropy is nonetheless a 
marker of ß-adrenergic response and is relevant to functional characterisation in hiPSC 
derived CM.  
 
Chen et al.,(1979); report that the ß-adrenergic chronotropic response of the foetal 
mammalian heart increases in the third gestational period due to 3 possible factors: 1) 
receptor density increase, 2) receptor affinity increase and 3) maturation of other 
molecules and coupling mechanisms. This can explain why in different studies with 
different maturation times and cell lines, different chronotropic responses have been 
observed.  
 
In the present study, a detailed characterisation of individual currents was not 
performed.  Functional properties of INa, Ito, ICa,L and IK have been well established in 
the literature for hESC (Maltsev et al.,1994) and hiPSC derived CM (Honda et al., 
2011; Ma et al., 2011). The focus of this project was the AP due to the fact that the 
arrhythmic hallmark of CPVT (DAD) is obtained from the full AP trace. 
4.2.1 Methods 
 
For more detailed methods used for electrophysiology, please refer to section 2.3 from 
Chapter 2. 
 
For this project, both control BT-1 hiPSC and hiPSC CPVT derived CM were patch 
clamped in the whole-cell mode. Perforated patch was not performed because despite 
several attempts and recordings, whole cell access wasn‟t obtained consistently.  
 
Spontaneous activity recordings were obtained using a Gap Free mode protocol. In this 
protocol no current or voltage is injected into the cell. The reading is recorded as 
presented by the CM and the RMP is not clamped. 
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Induced AP were obtained from both quiescent and spontaneous CM, by pacing hiPSC 
at 0.5Hz and 1Hz, using a 3ms step protocol in Current Clamp mode injecting a single 
pulse of 500pA. Before obtaining any recordings, RMP was clamped at circa -80mV.  
By lowering the resting membrane potential of these cells close to -80mV, a more 
physiological and standardised RMP was obtained. Inhibition of the funny current I(f) 
was achieved, preventing spontaneous activity driven by this current.  
An average of five consecutive AP within the second half of a minimum of a one 
minute recording was used for AP analysis. Isoprenaline perfusion (1µM) was made one 
minute after normal Tyrode‟s perfusion as a washout procedure.  
4.2.2 Results 
The objective of the work presented in this chapter, was to characterise hiPSC derived 
CM AP electrophysiology for both spontaneous and evoked activity models. This was 
achieved by using the patch clamp technique in both CM cell lines (CPVT and BT-1) in 
order to define AP parameters and ß-agonist response. Using AP electrophysiology data 
the predominant CM sub-type can also be suggested. This last classification is relevant, 
since CPVT is based in ventricular tachycardia episodes. Several parameters were 
obtained from AP recordings, but particular relevance was given to RMP, APD50, 
APD90, peak and amplitude. A study of force-frequency relation is also presented since 
in adult human CM a positive force-frequency relation is observed. 
4.2.2.1 Spontaneous APs 
The majority of current hiPSC derived CM differentiation protocols are based on the 
embryoid body technique. This technique has spontaneous contractile activity of the 
beating cluster as a terminal differentiation endpoint. This is both the benefit and the 
curse of hiPSC derived CM as ideally, only pace-maker cells should have spontaneous 
contractility. Atrial and ventricular cells should be quiescent. Because spontaneous 
beating CMs are visually contracting, they can be easily selected for analysis. Ideally 
analysed CM should be quiescent with a ventricular phenotype as spontaneously active 
cells may give false positives for certain pro-arrhythmic events. An ideal differentiation 
protocol would produce different subtypes of CM according to required needs but such 
a protocol is still not currently available. 
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Comparison of the responses of hiPSC CPVT CM and control BT1 cells to isoprenaline 
perfusion did not reveal any significant changes (figure 4.2A, C) for RMP and AP peak. 
A significantly lower RMP in Tyrode‟s was observed in CPVT CM, when compared to 
BT1 CM (figure 4.2A). BT1 CM have a RMP of approximately -60 mV, still far from 
the physiological -80mV of adult human CM. A significantly higher (10%) AP peak 
was observed in CPVT CM comparing to BT1 CM in Tyrode‟s (figure 4.2C). 
A significant lower RMP was observed in spontaneous BT1 CM compared with 
spontaneous CPVT CM (figure 4.3A).  Spontaneous beating CPVT CM and BT1 CM 
also presented a significantly lower RMP compared with the same cells if quiescent 
(figure 4.3A).  
It was found that BT1 CM had a significantly higher beating rate, when perfused in 
Tyrode‟s only, compared with CPVT CM (figure 4.4C). A positive chronotropic effect 
(figure 4.4D) was observed only in CPVT CM with 23% BPM average increase.  
Regarding APD, the main finding was that in Tyrode‟s, both APD50 (figure 4.5A) and 
APD90 (figure 4.5C) were longer for hiPSC CPVT CM compared with control CM. 
Our results show that isoprenaline has a positive chronotropic effect in the studied 
CPVT CM, contrary to what other authors have found for in CPVT CM with different 
mutations. 
 The number of cells with spontaneous contractile activity was higher than the 
percentage of quiescent cells, in CPVT CM compared to control BT1 CM (figure 4.7). 
A similar comparison was not found in published literature. 
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Figure 4.2 - Spontaneous beating, AP parameter comparison, RMP and AP peak - 
hiPSC CPVT CM (n=21 from 5 batches) and hiPSC control BT1 CM (n=10 from 3 
batches) in Tyrode’s and in the presence of isoprenaline (1µM). AP peak (A) and RMP 
(C), with respective percentage mean difference for isoprenaline effect on RMP (B) and 
AP Peak (D).  
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Figure 4.3 – Average RMP from Gap Free protocols in hiPSC CM - figure showing 
average RMP obtained using Gap Free protocol in quiescent (Q-BT1 and Q-CPVT) and 
spontaneous (S-BT1 and S-CPVT) hiPSC CM. Example trace of RMP in a quiescent 
hiPSC BT1 CM (B). In this study quiescent cells were defined as not presenting any AP 
during Gap Free recordings but when evoked, presented an AP. 
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Figure 4.4 - Spontaneous AP rate and amplitude - comparison between hiPSC CPVT 
CM (n=21) and hiPSC control BT1 CM (n=10) in Tyrode’s and in the presence of 
isoprenaline (1µM) for AP Amplitude (A) and Beating rate in bpm-beats per minute (C), 
presenting respective percentage mean difference for isoprenaline effect on AP 
amplitude (B) and beating rate (D).  
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Figure 4.5 - Spontaneous AP parameter  - APD50 and APD90 - comparison between 
hiPSC CPVT CM (n=21) and hiPSC control BT1 CM (n=10) in Tyrode’s and in the 
presence of isoprenaline (1µM) for APD50 (A) and APD90 (C), presenting respective 
percentage mean difference for isoprenaline perfusion on APD50 (B) and APD90 (D).  
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Figure 4.6 – Spontaneous AP traces with isoprenaline perfusion- representative 
traces of both BT1 CM (A) and CPVT CM (C) for spontaneous recorded activity in 
Tyrode’s solution and with isoprenaline 1µM perfusion (B and D respectively for BT1 
CM and CPVT CM). Red arrows indicate spontaneous inter AP events. These events 
were considered as DADs. In CPVT CM, isoprenaline perfusion increased DADs 
frequency (figure 4.6D). This response is expected for disease phenotype recapitulation. 
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4.2.2.2 Evoked AP 
Not all hiPSC derived CM showed spontaneous activity after disaggregation. This work 
found that the vast majority become quiescent after 5 days in culture (figure 4.7). In 
order to better characterise these cells and study their AP signature when paced, an 
induced activity study was performed, since this allows a better control of experimental 
conditions. Beating rate can vary depending on temperature, time in culture and other 
idiosyncratic factors, hence the need to pace these cells. 
In this study, APs were evoked in both CPVT and control BT1 CM at 0.5Hz and 1Hz. 
The objective was to observe the cell‟s response to different pacing rates in the presence 
and absence of isoprenaline. The patch clamp seal would not last long in frequencies 
higher than 1Hz. 
Both quiescent and spontaneously beating cells were used in the pacing experiments. 
Spontaneously beating cells, displayed spontaneous AP, but responded to pacing when 
clamped had RMP and evoked AP. 
A study of the electrophysiological profile of hiPSC derived CM evoked AP was 
undertaken. This included the response to ß-adrenergic stimulation with 1 µM 
isoprenaline perfusion, similar to the one presented for spontaneously beating cells. A 
frequency- response study was also made to better understand the physiological profile 
of these cells and determine if they present a CM expected response. For this last study 
both cells lines were paced at 0.5, 1, 1.5, 2 and 3 Hz. 
For cells paced at 0.5Hz in Tyrode‟s, similar average AP peak values were observed 
while AP peak presented a significant decrease under the effect of isoprenaline in BT1 
CM. In CPVT CM the AP peak difference was higher, with a significant 15% decrease 
from baseline value in Tyrode‟s (figure 4.9C). However despite this decrease, AP 
amplitude shows only 4% average decrease for both cell lines in response to ß-agonist 
stimulation (figure 4.9E). 
When compared, APD50 and APD90 in CPVT CM present significantly longer APD 
than BT1 CM cells. The isoprenaline effect on APD is statistically significant in both 
cell types, presenting an average percentage decrease of 10% for both parameters in 
BT1 CM and 20% in CPVT CM (figure 4.10). 
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In 1Hz paced experiments, the main relevant finding is that perfusion with isoprenaline 
produced a 10% reduction in AP amplitude (figure 4.11F) for CPVT CM. None of the 
differences for APD50 and APD 90 were found to be statistically significant.  
A new description is for the first time presented regarding hiPSC CM morphology, 
grouping them in 3 main types: lemon/fibroblast type, irregular and round shape (figure 
4.14 and 4.15). 
According to the selected criteria, the vast majority of studied hiPSC CM had VM 
features (figure 4.16). This finding was different that what has been reported in previous 
publications, what is probably related to the chosen criteria to group CM sub-types. 
No significant observations could be made regarding the force-frequency study 
presented (figure 4.18). 
More recordings were obtained at 0.5Hz suggesting that this can be an optimal pacing 
frequency in evoked AP experiments. More objective and less variable measurements 
were obtained with evoked AP when compared to spontaneous AP. This study was 
essential to characterise hiPSC CPVT as a potential model of disease with obvious 
advantages and less biases of evoked versus spontaneous AP. 
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Figure 4.7 – Percentages of spontaneous contracting and quiescent CM - data from 
GAP free mode, protocol recordings. Cells disaggregated from beating clusters plated 
as single cells for more than 5 days. Graphs (A) and (B) obtained from traces of hiPSC 
CPVT CM (n=61) and hiPSC BT1 CM (n=27) respectively. 
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Figure 4.8 -Induced AP sequence at 0.5Hz and 1Hz – AP example traces of hiPSC 
derived CPVT CM and hiPSC BT1 CM in Tyrode’s paced at 0.5Hz (A, B) and 1Hz (C, 
D) respectively. 
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Figure 4.9 – Evoked AP parameters at 0.5Hz – RMP, Amplitude and Peak - data 
obtained from parameters and mean percentage difference of isoprenaline effect (1µM) 
for RMP (A and B), AP Peak (C and D) and AP Amplitude (E and F) respectively. 
hiPSC BT1 CM (n=31)  and hiPSC CPVT CM (n=48).  
85 
 
 
Figure 4.10 – Evoked AP parameters at 0.5Hz – APD50 and APD90 - data obtained 
from parameters and mean percentage difference of isoprenaline effect (1µM) for 
APD50 (A and B) and APD90 (C and D) respectively. hiPSC BT1 CM (n=31) and 
hiPSC CPVT CM (n=48).  
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Figure 4.11 – Evoked AP parameters at 1Hz – RMP, Amplitude and Peak -  aata 
obtained from parameters and mean percentage difference of isoprenaline effect (1µM) 
for RMP (A and B), AP Peak (C and D) and AP Amplitude (E and F) respectively. 
hiPSC BT1 CM (n=8)  and hiPSC CPVT CM (n=14).  
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Figure 4.12 – Evoked AP Parameters at 1Hz – APD50 and APD90 -. Graphs obtained 
from parameters and mean percentage difference of isoprenaline effect (1µM) for 
APD50 (A and B) and APD90 (C and D) respectively. hiPSC BT1 CM (n=8) and hiPSC 
CPVT CM (n=14).  
 
4.2.2.3 Cell morphology and behaviour 
In addition to electrophysiological characterisation, cell morphology, size and 
contractile behaviour are also important criteria on which to evaluate hiPSC as CM 
models. Spontaneous contractility is an innate characteristic of hPSC derived CM made 
by the embryoid body method. However, cell behaviour changes over time, especially 
after disaggregation of beating clusters into single cells. Lack of contractility in a cluster 
is considered as indicative of poor CM viability. In agreement with this, when non-
beating clusters were disaggregated, no evoked APs were obtained from patched cells 
and no individual AP currents were isolated (data not shown). 
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A known feature of hPSC derived CM morphology is their lack of normal mammalian 
rod shape. These cells present a variety of sizes and shapes independent of their 
spontaneous activity or AP signature. In this study we found that their shape can be 
round, “lemon like” or irregular with three or more angles. In order to compare these 
cells with primary CM we need to determine a cell size indicator. Cell membrane area 
was a good candidate to assess morphological similarities between hPSC CM and adult 
human CM. A good way to determine cell membrane area is via determination of cell 
capacitance. Capacitance value was obtained after achieving whole cell access and 
displayed by pClamp10.3 software. Capacitance (C) is a measure of the ability of a cell 
to store a charge (Q-Coulombs) when a voltage change (ΔV) occurs across the two ends 
of the cell: 
Q = C ΔV 
Capacitance is proportional to the area and inversely proportional to the distance 
separating the two ends of the cell. Membrane capacitance is usually expressed in 
PicoFarads (pF). 
In this study it was observed that the average capacitance of CM for both cell lines is 
between 15 and 20pF (figure 4.13).  
 
    
 
Figure 4.13 – hiPSC CM capacitance – Average capacitance of hiPSC CPVT CM 
(n=61) and hiPSC control BT1 CM (n=27) shown as bar graphs (A) and vertical 
scatter plots (B). 
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  1a              1b  
  2a             2b                                                                                                                                     
  3a               3b     
 
Figure 4.14 – hiPSC CM morphology - Different morphology and shape of hiPSC CM 
during patch clamp experiments). These cell shapes can be grouped into 3 main 
categories: lemon/fibroblast type, due to their fusiform shape similar to fibroblast shape 
(1a, 1b), irregular (2a, 2b) or round shape (3a, 3b). Presented morphology categories 
were seen in both BT1 CM and CPVT CM.  
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Figure 4.15 – hiPSC CM category morphology percentage – Comparative percentages 
of the three different morphologies for control BT1 CM (n=22) and CPVT CM (n=25). 
No studies have been found in the literature reporting percentage of different 
morphology categories for hiPSC CPVT CM. No relationship was found between cell 
shape and AP sub-type.  
4.2.2.4 Cardiomyocyte sub-types  
A major challenge to the study of hiPSC derived CM is undoubtedly the 
characterisation of the different sub-types of these cells. In the case of primary cells it is 
relatively easy to separate these cells anatomically and then classify them according to 
their AP. There is a consensus concerning the basic electrophysiological characteristics 
of ventricular (VM), atrial (AM) or pace-maker (PM) primary cardiomyocytes. 
However, these criteria are difficult to apply to the AP analysis of hiPSC derived CM. 
In a mixed population of hPSC CM, it is not easy to determine which cells are from a 
particular sub-type especially due to the intrinsic heterogeneity of these cells regarding 
shape and size. Some authors suggest visual selection using anti-ventricular myosin 
heavy chain antibodies marked with a fluorescent tag (Jung et al., 2012). Other authors 
suggest selection by cell size (i.e. above 45 pF) when patched, assuming that bigger 
cells are more likely to be ventricular myocytes (Honda et al., 2001).  
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A more recent publication suggests that hiPSC derived CM have a sui generis AP and it 
depends on cell maturation confluence not displaying classical chamber specificity AP 
signature (Du et al.,2015). This view has however been challenged by other authors. 
Since an ideal classification system wasn‟t found to separate the three different CM sub-
types, in this study, the APD90/50 ratio was chosen for sub-type classification (i.e. 
Matsa et al., 2011). If the APD90/50 ratio is ≤ 1.4 a cell was considered to have a 
ventricular myocyte AP. If the ratio was between 1.4 and 1.7 the AP was classified as 
pace-maker and if the result was ≥1.7 the AP signature was considered as an atrial 
cardiomyocyte. 
In this project, sub-types of two different data sets from experimental patch-clamp 
protocols are presented. One from spontaneous beating cells obtained from gap-free 
protocols and the other data set obtained from APs obtained from evoked recordings at 
0.5Hz pacing frequency.  
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Figure 4.16 – AP sub-types for spontaneous activity -  Data in percentage for hiPSC 
CPVT CM  (A, n=21) and Control hiPSC BT1 CM (B, n=10). VM=Ventricular CM, 
AM=Atrial AM and PM=Pace-maker CM.  
Ratio APD50/90 analysis was also made for evoked AP and in this case the percentage 
of AP sub-types is quite different. As previously mentioned, all spontaneous AP 
analysis involves a higher degree of subjectivity, as it‟s difficult to define precisely 
when the AP starts and ends. In evoked AP analysis it is easier to determine the 
depolarization start point and the end point of repolarization. 
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Figure 4.17 –AP sub-types from evoked activity – Evoked AP sub-type for hiPSC 
CPVT CM (n=51) (A) and hiPSC Control BT1 CM (n=27) (B) from evoked AP at 
0.5Hz. Data obtained from cells perfused with Tyrode’s solution only. VM=Ventricular 
CM, AM=Atrial AM and PM=Pace-maker CM. Representative traces of ventricular like 
(C), pace-maker like (D) and atrial like (E) hiPSC derived CM. In control BT1 CM cell 
line, a higher percentage of atrial like CM was observed (figure 4.17B). In CPVT CM 
cells, a higher percentage of ventricular like CM is present (figure 4.17A). 
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4.2.2.5 AP rate of adaptation  
A fundamental property of cardiac myocytes is the ability to adapt to an increase in 
heart rate with a decrease in APD (He et al., 2003; Blazeski et al., 2012). Rate 
adaptation is present in atrial and ventricular cardiomyocytes, and it can be impaired in 
certain disease states. Shortening of APD with rate has also been observed in embryonic 
human ventricular muscle (7 to 12 weeks) (Jezek et al.,1982). Therefore, it remained 
important to determine if embryonic-like APs exhibited appropriate rates of adaptation. 
Single cells were studied with the patch clamp technique in the whole cell mode and 
membrane rupture modality with RMP clamped at -80 mV. Paced cells were both from 
spontaneously beating and quiescent populations with different AP sub-types. Cells 
were paced at five different rates, and steady state APs were then recorded and 
analysed.  
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Figure 4.18 –hiPSC CM rate-response  - Rate response for APD50 (A) and APD90 (B) 
of hiPSC BT1 CM (n=6) and hiPSC CPVT CM (n=10) in Tyrode’s for different pacing 
frequencies from 0.5Hz to 3Hz. A trend for APD50 and APD90 reduction is observed 
when pacing rate increases from 0.5Hz to 3Hz. 
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4.2.2.6 Discussion for electrophysiology based characterisation 
The electrophysiological characterisation of CPVT hiPSC derived CM, and control CM 
was essential to help understand the developmental stage of these cells before using 
them as in vitro models of disease. The spontaneous beating nature of these cells can 
help us to better understand the developmental processes of the human CM. This 
finding is however a challenge to overcome if these cells are to be used as a model of 
adult cardiac cells. Human adult cardiac atrial and ventricular cells do not present 
spontaneous activity. For this reason both spontaneous and evoked APs were analysed 
in this project for both mutant and control cell lines. 
Data variability was observed between CM with spontaneous activity and quiescent 
cells. APs of spontaneously contracting cells will present less accurate and objective 
measurements as they will be more prone to subjective assessment of where an AP 
starts and ends. Spontaneous beating CM can present highly variable basal beating 
rates. This can influence some parameters such as AP duration (APD) as reported by He 
et al., 2003 and Zhang et al., 2009. 
For these reasons it was decided to study spontaneous and evoked AP.  
Spontaneous activity 
A higher percentage in number of cells with spontaneous contractile activity compared 
with quiescent cells, was observed in CPVT CM compared to control BT1 CM (45% 
versus 30%) (figure 4.7). This observation suggests that CPVT CM may have 
mechanisms that predispose to higher contractibility, possibly related to the RyR2 
mutation. Publications regarding the proportion of spontaneous individual beating cells 
used to model CPVT CM were not found in the literature. This may be due to the fact 
that previous publications focused mainly on cells with spontaneous activity and did not 
analyse quiescent cells.  
As for isoprenaline stimulation, a significant positive chronotropic effect was observed 
in CPVT CM (figure 4.2), unlike the negative chronotropic response that some authors 
report for mutant cells. Two authors that studied hiPSC CPVT CM (Fatima et al., 2011; 
Novak et al., 2012) have presented data indicating a very marked chronotropic response 
to ß-adrenergic stimulation in control hiPSC CM and a negative chronotropic effect in 
CPVT hiPSC CM. 
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 In one of the studies, Novak et al., reported similar frequency (in bpm), for control and 
CPVT CM in Tyrode‟s. Contrasting with those results, cells studied in this project show 
that BT1 CM present a significantly higher beating rate compared with CPVT CM 
(figure 4.2), when perfused in Tyrode‟s only. This difference could be explained by the 
fact that different CPVT mutations can display a different phenotype, not excluding 
other potential simultaneous mutations in other ion channel and receptors. Control cell 
lines can also present variability that could underlie different responses. 
Measurement of RMP is also very important as this parameter can be a criteria for 
phenotypical maturity. Ideally this parameter should only be obtained from quiescent 
cells in a GAP free protocol before stimulation; since there is significant variability if 
the cells are contracting, as demonstrated in this project. Several authors reported RMP 
values when analysing spontaneously contracting CM (Kujala et al., 2012; Jung et al., 
2012; Novak et al., 2011).  
Author Disease hiPSC Control CM hiPSC CPVT CM 
Novak et al.,2011 CPVT-2 -55mV -56mV 
Jung et al., 2012 CPVT-1 -73mV -73mV 
Kujala et al., 2012 CPVT-1 -68 mV -67 mV 
Current project 
-contracting- 
CPVT-1 -61 ± 4 mV  -46 ± 2 mV  
Current project 
-quiescent- 
CPVT-1 -25 ± 4 mV  -28 ± 2 mV  
 
Table 4.2 – Summary of RMP comparative values - data reported in the literature 
(approximate values taken from graphs) and in this project for hiPSC CPVT CM and 
respective controls. 
Observed RMP values from quiescent control and mutant CM, presented in this report, 
have a similar trend (figure. 4.3). These values correspond to less negative average 
RMP than the ones obtained from contracting cells. Values reported by some authors 
(table 4.2) in which values range from -60 to -75mV, are not obtained from quiescent 
cells.  
A less negative RMP is more characteristic of a fetal like CM, since adult CM have 
RMP close to -80 mV. Measuring RMP from contracting CM can therefore bias the fact 
that these cells are indeed foetal and not even close to mature CM as seen in table 4.2.  
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The fact that average APD50 and 90 in spontaneous contracting CPVT cells in Tyrode‟s 
are significantly longer compared to BT1 CM in the same perfusion media (figure 4.5) 
suggests that mutant cells may have an abnormal repolarization mechanism. This 
abnormal mechanism can be potentially related to an increased Ca
2+ 
in the cytosol due 
to RyR2 calcium leak in CPVT CM. Novak et al., (2012) also report significantly longer 
APD50 in mutant cells compared to control, although in a model of CPVT2, suggesting 
similar mechanisms of disease may be involved in both CPVT1 and CPVT2. 
A trend for APD50 and APD90 shortening was observed in both CPVT CM and control 
spontaneously contracting cells, when perfused with isoprenaline (figure 4.5).  
Evoked activity 
No examples of evoked AP parameters paced at 0.5Hz from hiPSC CPVT cells were 
found in the literature and hence this may be the first report of such data. 
AP peak values for control and CPVT CM paced at 0.5Hz were similar, although the 
percentage decrease upon isoprenaline addition was more marked in mutant cells (figure 
4.9). AP amplitude decrease was minimal in both cell types for ß-agonist perfusion. This 
difference could be due to the fact that AP amplitude values are more consistent with 
fewer extreme values when averaging data. 
Repolarization duration measured in APD50 and APD90 for cells paced at 0.5Hz, 
confirmed that CPVT CM present a significant longer value for these parameters (figure 
4.10). Mutant cells present a higher number of ventricular like CM and this could also 
contribute to APD50 increase since this CM sub-type has the biggest value for this 
parameter. Isoprenaline stimulation caused a significant APD shortening in both cell 
lines as expected in a mammalian CM (figure 4.10). Mutant cells presented twice the 
average percentage decrease in both parameters. This could be possibly due to a 
compensatory mechanism of CPVT CM due to a likely Ca
2+
 leak. 
To compare AP parameters with a higher and more physiological frequency these same 
experiments were repeated pacing cells at 1Hz. Most results were not significant, but 
total number of analysed cells at this rate was small and this may have contributed to 
the absence of an effect. 
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Cell morphology and size 
Previously published data for capacitance of primary CM from rabbit, rat or ferret is in 
the range of 130 to 300 pF (Satoh et al. 1996; Barth et al. 1992). These are very 
different values from those observed in CM for the current report (figure 4.13). It seems 
to be a trend for hiPSC derived CM to have a much smaller average area than that of 
mammalian ventricular CM. This fact could be suggestive of embryonic immaturity that 
these cells can present. A smaller surface can also reduce the number of ion channels 
present in the cell membrane, which in turn can influence the AP maturity. 
Since Maltsev et al., 1994 first investigated hESC CM electrophysiology, no 
publications were found in the literature reporting different morphology and shape for 
hPSC CM. The same is the case for hiPSC CPVT CM. In this project, hiPSC derived 
CM have for the first time been grouped into three main morphological categories: 
lemon/fibroblast (1) (due to their fusiform shape similar to fibroblast shape) irregular 
(2) or round (3). CPVT CM presented a larger percentage of lemon/fibroblast cells, 
followed by round shape and lastly irregular cells demonstrating the morphological 
heterogeneity of these cells (figure 4.14). 
CM sub-types 
This topic is clearly one of the most diverse and controversial found in the literature as 
there is no consensus on which criteria are better to classify CM into their sub-types. 
Several authors including Maltsev et al., 1993; He et al., 2003; Ma et al., 2011 and 
Matsa et al., 2012; have mentioned three different sub-types in hESC and hiPSC, but Di 
Pasquale et al., 2013 and Zhu et al., 2010 classified hPSC CM in two subtypes, nodal 
(i.e. cells from the AV node) and working like (i.e. atrial and ventricular chamber). Di 
Pasquale et al., 2013 classified nodal-like cells which were distinguishable because of 
their pronounced phase 4 depolarization preceding the onset of the AP, and working 
myocardial cells, which presented the typical plateau phase, and therefore had the 
longest AP duration.  
 
Zhu et al., 2010 mentions that working-type hESC CM express high-conductance gap 
junction proteins (connexins-40 and 43), and they exhibit greater proliferative activity 
and more rapid electrical propagation than their nodal counterparts as observed in 
primary mice CM (Christoffels et al., 2004).  
 
99 
 
In this project, the difference seen between spontaneous and evoked AP sub-types can 
be due to the fact that evoked AP were clamped at -80mV. This procedure was adopted 
to allow depolarization from a more physiological RMP. Clamping the RMP will 
change APD times, which in turn is the main parameter used for AP sub-type 
classification in this study. In spontaneous cell experiments, the number of cells or 
sample size is small, and this may also reduce the probability of finding cells from other 
subtypes. Interestingly the percentage of PM CM in evoked AP experiments was very 
similar in both cell lines for this set of experiments. 
Some authors even suggest that each beating cluster differentiates only into one specific 
sub-type (Zhang et al., 2009) while others mention a mixed cell population with a 
tendency for VM-like predominance over the other two types (Ma et al., 2011; Jung et 
al., 2012). What seems clear is that some cells may fall outside the criteria chosen to 
categorize them and a different classification approach may be necessary to determine 
sub-types for hiPSC derived CMs to generate more consensus within cardiac research 
groups. 
 
AP rate response 
AP duration decrease is a functional response to increased beating frequency in CM 
(Jezek et al.,1982). He et al., (2003) reported APD rate adaptation of hESC derived CM 
for the first time. No reports of rate of adaptation have been found in the literature for 
hiPSC CPVT CM and respective controls as part of their physiological characterisation. 
In this project a trend was observed in APD50 and APD90 to be consistently shorter 
with an increased pacing frequency (figure 4.18). Statistical significance of the observed 
trend was only present at some CPVT CM pacing rates. 
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4.3 Ca
2+
 imaging based characterisation 
4.3.1 Ca
2+
 handling physiology 
In order to contract the cardiac cell depends not only on ion channel electrical activity 
but also on the orchestrated Ca
2+ 
movement into the cell from the extracellular media 
via L-type calcium channels imbedded in the sarcolemma. Ca
2+
 in turn initiates CICR 
by opening RyR2 channels located in the SR membrane. The subsequent rise in 
intracellular Ca
2+
 facilitates myofibre contraction. The cardiac cell relaxes when 
intracellular Ca
2+
 is returned to resting levels. 
If Ca
2+
 was not removed from the sarcoplasm it would cause permanent contraction of 
the myofibers preventing diastole and re-filling of the heart. Different mechanisms are 
in place to remove cytosolic Ca
2+ 
and initiate relaxation of the cell. Cytosolic calcium 
can either be re-sequestered into the SR, via the SERCA2A (Ca-ATPase) pump or be 
removed from the CM via the NCX that extrudes Ca
2+
 into the extra-cellular media in 
exchange for Na
+
 or via the sarcolemmal Ca-ATPase pump that actively removes 
intracellular Ca
2+
 from the cell. 
SERCA2A (Ca
2+
-ATPase) pump activity is regulated by PLB; that when 
phosphorylated, is unable to inhibit SERCA pump activity. Once in the SR, Ca
2+
 is 
usually bound and buffered by calsequestrin (CASQ). This protein binds approximately 
35 to 40 Ca
2+
 ions (Mitchell et al., 1988). Two other small proteins, triadin (TDN) and 
junctin (JCN) also interact with RyR2 and CASQ. These are usually attached to the 
junctional face membrane in the terminal cisternae of the SR (Zhang et al., 1997). The 
functions of junctin, triadin and CSQ in SR signalling have been extensively explored in 
transgenic animals. TDN, JCN and CSQ-null animals survive, but their longevity and 
ability to tolerate cardiac stress is compromised (Altschafl et al., 2011). 
 
Ca
2+
 imaging studies of ß-adrenergic response are particularly relevant in validating 
functional properties of hiPSC derived CM. It is essential to study the inotropic, 
chronotropic and lusitropic intrinsic response of these cells. The visualisation of 
calcium transients using calcium-sensitive fluorescent dyes offers a unique insight into 
fundamental intracellular Ca
2+
 handling mechanisms. This study is especially relevant 
to the characterisation and study of new CM models such as hiPSC derived CM. 
101 
 
The mutant cells used in this project are derived from a patient with CPVT. Since 
CPVT is caused by a diastolic Ca
2+
 leak it is essential to use calcium imaging to 
establish spacio-temporal dynamics and the basal Ca
2+
profile of these cells.  
4.3.2 Previous publications 
Most publications regarding hPSC derived CM present Ca
2+ 
handling data from hESC 
derived CM spontaneous activity of beating clusters (Dolnikov et al., 2006) or single 
cells (Liu et al., 2007; Satin et al., 2008).  
Since their discovery in 2006, hiPSC derived CM have also been the focus of Ca
2+
 
handling research. 
 Itzhaki et al., (2011) confirm that, as in the case of hESC CM, hiPSC CM present a 
functional, but foetal Ca
2+ 
handling phenotype. These cells presented functional 
SERCA-sequestering and RyR2 mediated Ca
2+
 stores, while CICR was dependent on L-
type Ca
2+
 channels. In response to caffeine stimulation these cells demonstrate SR Ca
2+ 
release and Ca
2+ 
transient amplitude was reduced with ryanodine perfusion. The 
SERCA Ca
2+ 
-ATPase was blocked with thapsigargin, producing a complete abolition 
of Ca
2+ 
transients. As reported for hESC CM, functional IP3 receptors were also 
detected in these hiPSC CM. 
In the same year (Lee et al., 2011) published a comparison of Ca
2+ 
handling in hESC 
and hiPSC CM using 20 day old post differentiated CM. These authors reported smaller 
Ca
2+ 
transients and a better caffeine response in hiPSC than hESC CM. Ryanodine 
perfusion only reduced Ca
2+ 
transients in hESC CM and no effect was seen in hiPSC 
CM. In this study a more immature SR and Ca
2+ 
handling phenotype was observed in 
hiPSC CM. Consistent with this, hiPSC CM presented lower levels of expression of 
SERCA, JCN, TDN and RyR2 compared with hESC CM. 
The potential of hPSC derived CM as models to understand mechanisms of disease and 
cardiac physiology were also recently highlighted by Chen et al., 2015. In a published 
report, transgenic-induced upregulation of PLB restored an inotropic response to ß-
adrenergic stimulation in both hESC and hiPSC derived CM. These cells initially had a 
positive chronotropic response but no inotropy was seen when perfused with 
isoprenaline. PLB gene transfer, via adenoviral vector, restored Ca
2+
handling in these 
immature cells, proving that the embryonic phenotype can be upgraded and matured. 
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Despite an abundance of data regarding hiPSC derived CM Ca
2+
 handling in the 
literature, there is still a need for more in depth studies regarding hiPSC CPVT CM. The 
spontaneous beating nature of hiPSC derived CM makes obvious the need of studying 
both spontaneous and stimulated activity in order to standardise experiments and allow 
a potential translational use of these cells in tachycardia related disease and to simulate 
cardiac arrhythmic behaviour.  
4.3.3 CPVT1 derived CM 
One of the main potential uses of hiPSC CM is as in vitro models of disease. 
Publications using CM made from hiPSC from patients carrying inherited cardiac 
channelopathies are now available. Several publications have studied Ca
2+
 handling 
properties of hiPSC CPVT1 CM in order to try and validate these cells as models of 
disease. 
One of the first CPVT hiPSC CM models was reported by Fatima et al., 2011 and a 
brief characterisation of Ca
2+
 handling was made. Higher amplitude and longer duration 
Ca
2+
 transients were seen in mutant cells compared with control CM. Control cells were 
a mixed population of hESC and hiPSC derived CM but a 100% positive chronotropic 
effect was observed upon ß-adrenergic stimulation in these cells, while 57% of CPVT1 
hiPSC had a negative chronotropic response. 
In a model of CPVT2 caused by a genetically inherited abnormal CASQ2, Novak et al., 
2012 demonstrated that control cells presented both positive inotropic and lusitropic 
effects when exposed to the ß-agonist isoprenaline (1µM), while mutant cells did not. In 
this study 100% of control cells had a positive chronotropic response compared with 
only approximately 50% of the CPVT2 cells. 
Zhang et al., 2013 reported an extensive study using CPVT1 hiPSC CM concluding that 
both control and mutant CM had an adult CICR phenotype. It was found that CPVT1 
hiPSC CM had smaller Ca
2+
 stores (due to Ca
2+
 leak) than control cells. Mutant cells 
also had lower levels of NCX expression and were caffeine responsive. 
In 2013, Di Pasquale et al., also reported an adult-like regulation of Ca
2+
 handling in 
CPVT1 derived CM. 
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4.4 Methods 
For more detailed information on Ca
2+
 imaging methods, please refer to section 2.4 of 
Chapter 2. 
In these experiments, FLUO-4 AM® (fluo-4 acetoxymethyl) from Invitrogen was used 
as a Ca
2+ 
sensitive fluorescent indicator at 5µM. Local and global Ca
2+
 signals were 
recorded from hiPSC derived CM, using laser scanning confocal microscopy (SP5; 
Leica Microsystems). 
Disaggregated single cells, were incubated for 20 minutes at room temperature in 
modified Tyrode‟s and FLUO-4 5µM. Ca2+ dependent signals, were visualized with a 
63x oil immersion objective, using argon laser excitation at 488nm. Experiments were 
carried out at 37 ºC A perfusion chamber with two electrodes was used to pace cells 
externally at 10-30V. 
For experimental purposes spontaneous cells were considered as cells beating with no 
external pacing. Stimulated cells were considered to be both quiescent and 
spontaneously active cells that responded to external pacing. 
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4.5 Results - hiPSC derived CM Ca
2+
 transient characterisation 
In this study, single cell fluorescent Ca
2+
 imaging was used to characterise ß-adrenergic 
responses and functional Ca
2+
 handling in both mutant and control CM. A more detailed 
Ca
2+
 transient profile analysis for hiPSC derived CM was undertaken for the first time, 
using SALVO software. 
Inotropic, chronotropic and lusitropic positive responses are classical characteristics of 
adult CM and therefore studied cells should display these features if meant to be used as 
in vitro models of disease.Ca
2+
 transients from spontaneous and paced hiPSC CM were 
studied.  
 
Spontaneous activity 
In spontaneous beating cells, a significant amplitude decrease was observed in BT1 and 
CPVT cells in response to isoprenaline (figure 4.19C, D). Only BT1 CM presented a 
positive chronotropic effect, while CPVT CM did not presented an expected positive 
response (figure 4.21). The lusitropic effect can be assessed by determining the rate 
decay of a transient. No significant response was seen in basal rate decay or with 
isoprenaline perfusion for both mutant or control cells (figure 4.22). 
 
Stimulation 0.5Hz 
BT1 CM presented a negative inotropic response following an amplitude transient 
decrease when perfused with isoprenaline. No effect was observed in CPVT CM (figure 
4.24C and D). BT1 CM rate, significantly increased with isoprenaline perfusion, 
superseding the imposed rate of stimulation. A positive chronotropic effect was 
therefore observed in control CM. No significant change in rate was seen on 
isoprenaline perfusion of CPVT CM (figure 4.26A). No lusitropic effect was observed 
in both BT1 CM or mutant cells, as no significant changes were observed in rate decay 
(figure 4.27C). 
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Stimulation 1Hz 
When paced at 1Hz, no inotropic effect was observed in either cell type (figure 
4.29C).A small positive chronotropic effect was observed in CPVT CM while an 
opposite response was observed in control CM (figure 4.31A). 
No significant change in the rate of response decay was seen during isoprenaline 
perfusion for either mutant or control cells (figure 4.32C). 
In summary, a lack of consistency in the responses to isoprenaline perfusion was 
observed in either spontaneously beating or paced cells at 0.5Hz and 1Hz. These results 
suggested a lack of mature or adult CM Ca
2+ 
handling profile. 
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4.5.1 Spontaneous Ca
2+
 transients 
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Figure 4.19 – Spontaneous Ca2+ transient parameters, ITN (A) and Amplitude (C) 
with respective isoprenaline (1µM) effect (B and D) in mean percentage change, for 
hiPSC BT1 CM (n=32) and hiPSC CPVT CM (n=20). From figure 4.19A it is clear that 
both mutant and control cells have similar values of ITN in Tyrode’s. However, there is 
a significant difference in amplitude between BT1 and CPVT cells and a significant 
decrease in amplitude in response to isoprenaline in both types of cell (figure 4.19C, 
D).  
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Figure 4.20 – Spontaneous Ca2+ transient parameters, Length (A) and Standardised 
area (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage 
change, for hiPSC BT1 CM (n=32) and hiPSC CPVT CM (n=20). A significant 
statistical difference was found between BT1 CM compared with CPVT CM in Tyrode’s 
for both parameters. CPVT CM present a much smaller value compared with BT1 CM 
(figure 4.20A and 4.20C). 
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Figure 4.21 – Spontaneous Ca2+ transient parameters, Rate (Hz) (A) and Peak 
regularity (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage 
change, for hiPSC BT1 CM (n=32) and hiPSC CPVT CM (n=20). Basal beating rate is 
significantly higher in CPVT CM compared with control CM (figure 4.21A). Although a 
positive chronotropic response would be expected with ß-agonist perfusion, this was 
only observed in BT1 CM.  A significant decrease in beating rate was observed in 
CPVT CM, demonstrating a negative chronotropic response of these cells (figure 
4.21B). Peak regularity is a rhythmicity parameter in which a near zero value 
corresponds to a perfectly rhythmic sequence of transients. Data presented in figure 
4.21C shows that BT1 CM have significantly higher peak regularity than CPVT CM. 
Isoprenaline perfusion reduces this parameter significantly by almost 50%, improving 
the rhythmicity of the control cells. No significant response is seen in mutant cells. 
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Figure 4.22 – Spontaneous Ca2+ transient parameters, Length decay (A) and Rate 
decay (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage 
change, for hiPSC BT1 CM (n=32) and hiPSC CPVT CM (n=20). A statistical 
significant difference was present in length decay, comparing BT1 CM with CPVT CM 
in Tyrode’s. CPVT CM presented a smaller length decay value (figure 4.22A).  
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Figure 4.23 – Spontaneous Ca2+ transient parameters, Length up (A) and Rate up (C) 
with respective isoprenaline (1µM) effect (B and D) in mean percentage change, for 
hiPSC BT1 CM (n=32) and hiPSC CPVT CM (n=20). A statistical significant difference 
was present in length up and rate up, comparing BT1 CM with CPVT CM in Tyrode’s. 
CPVT CM presented a smaller length up and rate up value than BT1 CM (figure 4.23A 
and 4.23C). 
 
 
 
 
 
 
 
 
111 
 
4.5.2 Stimulated Ca
2+
 transients 
4.5.2.1 Stimulation 0.5 Hz 
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Figure 4.24 – Stimulated Ca2+ transient parameters (0.5Hz), ITN (A) and Amplitude 
(C) with respective isoprenaline (1µM) effect (B and D) in mean percentage change, for 
hiPSC BT1 CM (n=18) and hiPSC CPVT CM (n=48). Isoprenaline perfusion caused a 
significant increase in ITN in BT1 CM while no significant effect was observed in CPVT 
CM (figure 4.24A).Amplitude of the average Ca
2+
 transients in Tyrode’s was 
significantly higher in CPVT CM when compared with BT1 CM (figure 4.24C). A 
significant percentage decrease was observed in BT1 CM amplitude when perfused with 
isoprenaline that could be translated in to a negative inotropic effect. No effect of 
isoprenaline was observed in CPVT CM (figure 4.24C and D). 
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Figure 4.25 – Stimulated Ca2+ transient parameters (0.5Hz), Length (A) and 
Standardised area (C) with respective isoprenaline (1µM) effect (B and D) in mean 
percentage change, for hiPSC BT1 CM (n=18) and hiPSC CPVT CM (n=48). A 
significant decrease in Ca
2+
 transient length in BT1 CM cells upon isoprenaline 
perfusion was observed (figure 4.25A). CPVT CM present a significant higher value for 
standardised area compared with BT1 CM in Tyrode’s (figure 4.25C) 
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Figure 4.26 – Stimulated Ca2+ transient parameters (0.5Hz), Rate (Hz) (A) and Peak 
regularity (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage 
change, for hiPSC BT1 CM (n=18) and hiPSC CPVT CM (n=48). Rate response to 
0.5Hz stimulation should be the same as the applied stimulation even when perfused 
with isoprenaline. CPVT CM and BT1 CM presented an expected 0.5Hz stimulation 
rate in Tyrode’s. However, BT1 CM rate, significantly increased by 15% with 
isoprenaline perfusion. No significant change in rate was seen on isoprenaline 
perfusion of CPVT CM (figure 4.26A). Peak regularity value was significantly smaller 
in CPVT CM compared with BT1 CM in Tyrode’s (figure 4.26C). 
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Figure 4.27 – Stimulated Ca2+ transient parameters (0.5Hz), Length decay (A) and 
Rate decay (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage 
change, for hiPSC BT1 CM (n=18) and hiPSC CPVT CM (n=48). A significant 
decrease in length decay is seen in BT1 CM cells upon isoprenaline perfusion. Length 
decay basal value is significantly higherin CPVT CM compared with BT1 CM (figure 
4.27A). Rate decay is significantly smaller in BT1 CM compared with mutant cells in 
Tyrode’s (figure 4.27C). 
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Figure 4.28 – Stimulated Ca2+ transient parameters (0.5Hz), Length up (A) and Rate 
up (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage change, 
for hiPSC BT1 CM (n=18) and hiPSC CPVT CM (n=48).  A significant smaller value 
was observed for length up in CPVT CM compared with control CM in Tyrode’s (figure 
4.28A). Rate up presents a significantly higher value compared with BT1 CM in 
Tyrode’s (figure 4.28C). 
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4.5.2.2 - Stimulation 1Hz  
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Figure 4.29 - Stimulated Ca
2+
 transient parameters (1Hz), ITN (A) and Amplitude (C) 
with respective isoprenaline (1µM) effect (B and D) in mean percentage change, for 
hiPSC BT1 CM (n=18) and hiPSC CPVT  CM (n=40). A significant smaller value was 
observed for ITN in CPVT CM compared with BT1 CM in Tyrode’s (figure 4.29A). BT1 
CM presented a significant smaller amplitude average value compared with CPVT CM 
in Tyrode’s (figure 4.29C) 
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Figure 4.30 – Stimulated Ca2+ transient parameters (1Hz), Length (A) and 
Standardised area (C) with respective isoprenaline (1µM) effect (B and D) in mean 
percentage change, for hiPSC BT1 CM (n=18) and hiPSC CPVT CM (n=40). A 
significant decrease in average transient length in CPVT CM cells upon isoprenaline 
perfusion was observed. Basal length value is significantly smaller in CPVT CM 
comparing with BT1 CM (figure 4.30A). BT1 CM standardised area value is 
significantly smaller in BT1 CM compared with mutant cells in Tyrode’s (figure 4.30C). 
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Figure 4.31 – Stimulated Ca2+ transient parameters (1Hz), Rate (Hz) (A) and Peak 
regularity (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage 
change, for hiPSC BT1 CM (n=18) and hiPSC CPVT  CM (n=40). Beating rate should 
be 1Hz exactly, since external stimulation was used. CPVT CM presented a very 
accurate 1Hz stimulation value with a very small significant increase upon isoprenaline 
perfusion. However the observed rate for BT1 CM is significantly lower than the 
expected 1Hz. BT1 CM present a significantly lower rate compared with mutant cells in 
Tyrode’s (figure 4.31A). After isoprenaline perfusion, BT1 CM presented a significant 
increase in peak regularity value, while no effect is seen in CPVT CM. Peak regularity 
was significantly smaller in CPVT CM comparing with BT1 Cm in basal conditions 
(figure 4.31C). 
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Figure 4.32 – Stimulated Ca2+ transient parameters (1Hz), Length decay (A) and Rate 
decay (C) with respective isoprenaline (1µM) effect (B and D) in mean percentage 
change, for hiPSC BT1 CM (n=18) and hiPSC CPVT  CM (n=40). A decrease in length 
decay was observed in CPVT CM cells upon isoprenaline perfusion. BT1 CM presented 
a significantly smaller legth decay value compared with CPVT CM in basal conditions 
(figure 4.32A). BT1 CM presents a significantly smaller value of rate decay compared 
with CPVT CM in Tyrode’s (figure 4.32C). 
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Figure 4.33 – Stimulated Ca2+ transient parameters (1Hz), Length up (A) and Rate up 
(C) with respective isoprenaline (1µM) effect (B and D) in mean percentage change, for 
hiPSC BT1 CM (n=18) and hiPSC CPVT  CM (n=40). An increase in length up in BT1 
CM cells upon isoprenaline perfusion found. CPVT CM presents a significant smaller 
length up value compared with BT1 CM in Tyrode’s (figure 4.33A). BT1 CM presented 
a very significant smaller rate up value compared with CPVT CM in basal conditions 
(figure 4.33C). 
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4.6 Force-frequency study 
A positive force-frequency relationship, evaluated by amplitude response to an increase 
in frequency of stimulation is an adult human cardiac characteristic (Pieske et al.,1999), 
but is not seen in rat and mice, in which a negative staircase response is present (Maier 
et al.,2000). 
 
Figure 4.34 – Field stimulated example traces of Ca2+ transients - traces from initially 
quiescent hiPSC CPVT CM at different stimulated frequencies (0.5Hz) (A), (1Hz) (B) 
and (1.5Hz) (C) in Tyrode’s. Data for force-frequency study was obtained from similar 
traces for different pacing stimulation rates. 
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Force of contraction is directly associated with a positive inotropic effect. Ca
2+
 transient 
amplitude increases with CM force of contraction in Newtons. A force-frequency study 
was performed in order to demonstrate if hiPSC CM have a positive force-frequency 
relationship. This positive response is a hallmark feature of mature human CM. 
 
 
 
 
Figure 4.35 – Force-frequency relationship study in hiPSC CM - data from paced 
(spontaneous and quiescent) BT1 CM (BT1 CM : 0.5Hz, n=18; 1Hz, n=18; 1.5Hz, 
n=18; 2Hz, n=16) and CPVT CM (CPVT CM : 0.5Hz, n=48; 1Hz, n=40; 1.5Hz, n=32; 
2Hz, n=28), with and without isoprenaline (1µM) perfusion. No statistically significant 
positive force-frequency response is observed in figure 4.35, for any of the cell types 
either in the absence or presence of isoprenaline.  
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4.7 CICR - Ca
2+
 Induced Ca
2+
 Release 
In order to study Ca
2+
 handling in CM the response of cells to the application to specific 
drugs, with agonist or inhibition properties towards Ca
2+
 handling proteins, is needed. 
Nifedipine is a specific L-type calcium channel (LTCC) blocker and as a consequence 
Ca
2+
 transients should have an amplitude reduction as less Ca
2+
 enters the cell during 
the AP. Ca
2+
 that enters the sarcoplasm via these ion channels opens RyR2 releasing 
more Ca
2+
 via CICR, so ryanodine that at 10µM inhibits the ability of RyR2 to open 
should also produce effective reduction or abolishment of calcium transients by 
affecting the amplitude or area under the curve by reducing available cytosolic Ca
2+
.  
The RyR2 is also sensitive to caffeine, and perfusion with this drug in the millimolar 
range should increase the probability of the channel opening and create a large Ca
2+
 
transient due to Ca
2+
 release into the sarcoplasm. Using these drugs it‟s possible to 
determine if hiPSC derived CM have a functional CICR mechanism that is an intrinsic 
property of mammalian CM. 
Evaluation of SERCA2A function using thapsigargin (a known SERCA inhibitor) was 
also planned, but due to time constraints these experiments could not be carried out. 
4.7.1 Results 
Nifedipine perfusion produced a Ca
2+
 transient amplitude significant decrease with both 
BT1 CM and CPVT CM. Washing out nifedipine with Tyrode‟s, did not reversed the 
nifedipine effect in CPVT CM (figure 4.36A). No effect was observed in Ca
2+
 transient 
amplitude upon ryanodine perfusion (figure 4.37). Caffeine perfusion did not presented 
a consistent and significant effect in either cell type (figure 4.39A). 
In summary, no robust CICR profile was found for either cell type in these experiments. 
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4.7.2 L-type Ca
2+
 channels – Nifedipine 
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Figure 4.36 –Nifedipine (1µM) effect in stimulated (0.5Hz) Ca2+ transient average, 
amplitude and standardised area for hiPSC BT1 CM (n=13) and hiPSC CPVT CM 
(n=23). Average Ca
2+
 transient amplitude presented a significant decrease with 
nifedipine (1µM) perfusion in both BT1 CM and CPVT CM (figure 4.36A).  Washing 
out nifedipine with Tyrode’s, caused a significant amplitude increase in control CM but 
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not in CPVT CM. A significant decrease in standardised area after nifedipine perfusion, 
was observed in both cell types (figure 4.44 B). Nifedipine washout caused a significant 
increase in stardardised area for both cell types (figure 4.36 E). A significant higher 
amplitude value was observed in CPVT CM compared with BT1 CM in Tyrode’s (figure 
4.36A). BT1 CM presented a higher standardised area value compared with CPVT CM 
at basal conditions (figure 4.36B). 
Perfusion with nifedipine at 1µM was used as reported by some authors as an optimal 
inhibitory concentration to LTCC (Harris et al.,2013; Dan et al.,2014). Initially it was 
planned to study the effect of nifedipine in both stimulated and spontaneous cells, but 
due to cell batch variability and time constraints, data are presented only from 
stimulated cells. Because the inhibition of LTCC by nifedipine is reversible, it was 
decided to washout this drug. This protocol established that its effect was reversible in 
these cells. 
4.7.3 Ryanodine receptor RyR2– Ryanodine 
 
Figure 4.37 – Ryanodine perfusion in average transient amplitude – data from 
spontaneous beating hiPSC CPVT CM (n=3) in Tyrode’s and in Ryanodine (10µM). 
The presented differences did not show statistical significance.  
In order to evaluate if CPVT CM possessed functional RyR2, spontaneously beating 
cells were perfused with 10µM ryanodine (Meissner G.,1986; Satin et al.,2008)  in 
Tyrode‟s for 5 minutes (figure 4.37A). The experiment could not be repeated in control 
CM due to time constraints and reduced cell availability. 
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4.7.4 Ryanodine receptor RyR2 - Caffeine  
 
 
Figure 4.38 –Caffeine response and traces – percentage of cells tested that produce a 
transient in response to 10mM caffeine stimulation. A Ca
2+
 wave response to caffeine 
was considered as being any transient resulting from caffeine perfusion in the absence 
of spontaneous transients. Spontaneous hiPSC BT1 CM (population of n=68) and 
hiPSC CPVT CM (population of n=63) (A). Example traces from a single cell caffeine 
response in hiPSC BT1 CM (B) and a hiPSC CPVT CM (C). 
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Caffeine at 10mM (Kong et al.,2008; Satin et al.,2008) was perfused on single CM that 
presented initial spontaneous activity. Perfusion was only made at the end of each 
experiment. Example traces do not demonstrate spontaneous activity, as towards the end 
of the experiments there was a trend for lack of spontaneous activity. This way a 
confirmation of  initial contractile activity was obtained.  
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Figure 4.39 –Caffeine response - Mean average amplitude (A) and length (B) of Ca2+ 
transient release in response to 10mM caffeine stimulation for spontaneous hiPSC BT1 
CM (n=16) and hiPSC CPVT CM (n=37). A significantly longer length value was 
observed in BT1 CM when compared with CPVT CM (figure. 4.39B). 
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4.8 Discussion of Ca
2+
 imaging characterisation 
In this study an innovative and more detailed Ca
2+
 transient characterisation is presented 
for the first time in hiPSC derived CM. However, hiPSC BT1 and CPVT CM did not 
consistently demonstrated classical cardiac properties such as positive inotropy, 
lusitropy and chronotropy. A force-frequency relationship was also not confirmed by 
the obtained data. It was also not possible to establish a cardiac typical CICR protein 
handling profile. Both hiPSC CPVT and BT1 CM did not respond robustly to 
pharmacological study. A maturation study with hiPSC CM older than 3 months post-
differentiation would be necessary to evaluate hiPSC CM cardiac characterisation. 
4.9 Conclusion 
Based on the data presented in this chapter it is clear that both CPVT and BT1 CM 
possess some basic cardiac physiological characteristics. However, when challenged, 
hiPSC CM do not always respond consistently. This will undoubtedly be a problem to 
overcome if hiPSC are to be used as in vitro models of disease. My data suggest that the 
electrophysiological features presented by these cells are not those of an adult CM.  
Lack of consistent positive inotropy and lusitropy are also features of foetal CM. 
Because for in vitro CPVT modelling, adult-like ventricular CM would be ideal, further 
efforts must be made to mature and select hiPSC CM sub-types. By increasing culture 
time, using selective factors or even transgenic technology, hiPSC CM should present a 
consistent, adult-like, ventricular profile to model CPVT in the near future. 
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Chapter 5 
hiPSC derived CM  in vitro  
CPVT1 model of disease 
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5.1 Introduction 
The main objective of this project is to test the hypothesis that it is possible to 
recapitulate CPVT1 in vitro, using patient specific hiPSC derived CM. It is 
hypothesised that either pharmacological challenge with catecholamines, or increased 
pacing should elicit arrhythmic events (DADs, EADs).  The use of anti-arrhythmic 
drugs (flecainide, propranolol, dantrolene, proprafenone), in the presence of such ß-
agonist, should rescue or reduce any pro-arrhythmic presented behaviour.  
The patch clamping technique was used to study spontaneous and evoked AP as well as 
CPVT hallmark arrhythmogenic events (DADs). AP parameter characterisation, under 
the effect of the drug in the presence of ß-agonist, was also made, (AP peak, amplitude, 
APD50 and APD90). Ca
2+
 fluorescent imaging was used to study Ca
2+
 handling and 
pro-arrhythmic Ca
2+
 transient behaviour.  
To date, no similar studies have been published regarding hiPSC CPVT1 derived CM, 
containing the S2246L RyR2 mutation. Additionally, only a few publications (Jung et 
al.,2011; Fatima et al.,2011; Itzhaki et al.,2012; Kujala et al.,2012; Di Pasquale et 
al.,2013) have demonstrated the cardiac disease modelling potential of hiPSC CPVT 
CM with different mutations. If confirmed, CPVT1 in vitro recapitulation, could not 
only allow disease specific drug screening and discovery, but also open a new field in 
personalised therapy for this malignant inherited channelopathy.  
There have been a number of publications describing different in vitro models of 
cardiac disease since 2011 (i.e.: Matsa et al., 2011; Novak et al., 2012; Terrenoire et al., 
2013). However, due to the practical issues and cell culture complexity that creating and 
optimizing hiPSC culture bring, these publications focus mainly on CM production and 
the differentiation process. Although present in every publication, functional 
characterisation of patient specific hiPSC CM has been neglected over developmental 
studies. Reported functional studies frequently present a low number of studied cells or 
EBs (Novak et al.,2001; Itzhaki et al.,2012; E Di Pasquale et al.,2013).  
Regarding electrophysiology studies to replicate disease in vitro, using the patch clamp 
technique, different approaches have been published. However arrhythmic endpoints 
and selected criteria are not well defined in the majority of publications and are often 
qualitative (Itzhaki et al.,2011; Kujala et al.,2012; E Di Pasquale et al.,2013). Despite 
the fact that most of these reports lack quantitative analysis of arrhythmic endpoints, the 
majority conclude that patient specific hiPSC CM are good in vitro models of disease.   
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5.2 Validation by patch-clamping 
Functional electrophysiological characterisation and pharmacological challenge of 
CPVT hiPSC CM is essential to address the postulated hypothesis of recapitulating 
disease in vitro. Use of the patch-clamp technique in single cells is required to assess 
disease modelling potential. The classical arrhythmic hallmark of CPVT are DAD 
events which can only be detected by analysing the cell AP. However EADs events can 
also occur in CPVT, despite being more typical in LQT syndromes (Kujala et al., 2012). 
DADs can progress to full-triggered activity events (TA) which can be translated into 
extra-systoles. 
One of the conventional explanations for DAD formation in CPVT1 is related to an 
intracellular Ca
2+
 overload, known as SOICR (Storage Overload Induced Calcium 
Release). SOICR can activate the Na-Ca exchanger (NCX). This membrane protein 
facilitates the exchange of these two ions (3 Na
+
 for 1 Ca
2+
) so that when Ca
2+
 is in 
excess in the cytosol it can be extruded from the cell, creating at the same time an 
inward Na
+
 current, generating an inappropriate cell depolarization.  This depolarization 
can then trigger a DAD or TA. A number of conditions can contribute to SOICR such as 
ß-adrenergic stimulation, digitalis toxicity, elevated extracellular Ca
2+
 concentration and 
fast pacing. 
5.2.1 Electrophysiology and CPVT1 in vitro disease recapitulation  
In the first publication regarding CPVT1 hiPSC derived CM, Fatima et al. (2011) 
observed that all analysed control derived CM (both hESC and hiPSC) presented 
positive chronotropy and no arrhythmic endpoints when perfused with isoprenaline, a ß-
agonist. In contrast approximately 58% of CPVT hiPSC derived CM presented negative 
chronotropy and 34% presented after depolarization events. All of the electrophysiology 
experiments were conducted in cells with spontaneous activity and no evoked activity 
experiments were mentioned. 
In 2012, Kujala et al. also published data on hiPSC CPVT1 CM with the RyR2 mutation 
P2328S. This group reported that these cells not only present DADs but also EADs as a 
pro-arrhythmic hallmark in the presence of ß-agonists. In this study the authors also 
defined DADs and EADs as events >3% of the previous AP, but no quantitative data 
were presented. For this endpoint the cells were all spontaneously beating and 
experiments conducted at 37ºC. Although the authors mention criteria to define EADs 
and DADs, it seems difficult to measure these events objectively based on the 
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percentage of the previous AP. This is particularly difficult in the case of EADs which 
occur during repolarization. DADs were observed in 42% of spontaneous contracting 
mutant cells while only 19% of control cells presented similar arrhythmogenic 
abnormalities. For this mutation of CPVT1 CM paced cells didn‟t present an increase in 
DADs compared with spontaneous activity. 
5.2.1.2 Electrophysiology for drug screening  
One of the potential uses of CPVT hiPSC derived CMs is personalised and disease 
specific drug screening.   
Jung et al.,2012 took advantage of this use to study the effect of dantrolene in hiPSC 
CPVT derived CM carrying the N-terminal RyR2 single point mutation S406L. CM 
used in this study were matured for 3-4 months and the authors report a similar 
percentage of ventricular CM sub-type (70-80%) using not only the AP signature from 
patch clamp experiments, but also ICC labelling for ventricular myosin light chain 
(MLC2v). This time, only quiescent cells were selected for dantrolene patch clamp 
experiments, and no difference in resting membrane potential was observed in mutant 
and control cells.   The authors mention that 56% of control cells didn‟t present after 
depolarizations after stopping 1Hz pacing (compared to 88% of CPVT cells). This 
means that presumably 44% of control ventricular cells did present arrhythmogenic 
behaviour, such as DADs and TA. Interestingly, dantrolene at 10µM apparently 
abolished arrhythmogenic activity in all CPVT investigated cells but the efficacy of this 
drug in control cells was unreported. The authors also reported that CPVT CM 
exhibited not only more DADs, but also a higher incidence of spontaneous activity after 
the end of pacing stimulation.  The percentage or number of cells that responded to 
dantrolene perfusion is not reported and it is not clear whether in these experiments a ß-
agonist was used to induce the CPVT phenotype. However, for the first time, some 
efficacy using dantrolene as an anti-arrhythmic agent is reported using hiPSC CPVT 
CM. 
Another emergent drug used to treat some patients with CPVT is flecainide, an anti-
arrhythmic class 1c that is also a I(Na) blocker. This drug apparently confirmed treatment 
potential using hiPSC derived CM, as demonstrated by Itzhaki et al.,2012. In this study 
approximately 69% of hiPSC CPVT CM presented DADs compared with 11% of 
control cell when perfused with 1µM isoprenaline.  
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The current literature concerning CPVT hiPSC CM, lacks consistent protocols for 
quantitative analysis of arrhythmic endpoints, namely DADs. Arrhythmic or abnormal 
Ca
2+
 handling reports using fluorescent Ca
2+
 imaging techniques also frequently lack 
report of quantitative endpoints (Jung et al.,2012;Itzhaki et al.,2012; Kujala et al.,2012).  
When reported, Ca
2+
 imaging endpoint quantification was confined to localised Ca
2+
 
release events termed calcium “sparks” (Fatima et al.,2011; Jung et al.,2012).  
Quantification of arrhythmic endpoints in hiPSC CPVT CM clearly needs to be 
addressed in order to validate any hiPSC CPVT CM model of disease.  In this chapter, 
using patch clamp and Ca
2+
 fluorescent imaging techniques, a quantitative and 
qualitative approach is reported for hiPSC CPVT CM in the studied mutation. 
Qualitative analysis was also performed to compare global validation of hiPSC CPVT 
CM with quantitative analysis of arrhythmic endpoints. The main objective is to 
determine if hiPSC CPVT CM recapitulate disease in vitro by using an innovative 
approach regarding determination of quantitative arrhythmic endpoints. 
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5.3 Electrophysiology Methods 
For more detailed methods for electrophysiology drug trials, please refer to section 2.3 
of Chapter 2. 
Whole single cell recordings in the current-clamp mode, using the rupture membrane 
modality, was used to study both spontaneous and evoked action potentials. Each trial 
started with one Gap-free mode protocol and then three current clamp protocols, with 
subsequent exposure to drugs. RMP was clamped at -80mV in the three current clamp 
protocols.  
Spontaneous data was obtained from the initial Gap-free mode protocol and 
isoprenaline was perfused 1 minute after the Tyrode‟s only perfusion. 
Protocol sequence for drug trial perfusion: 
1 – Gap Free mode – Tyrode‟s,  
2 – Current clamp – Tyrode‟s only,  
3 – Current clamp – Tyrode‟s and isoprenaline (1µM),  
4 – Current clamp - Tyrode‟s and isoprenaline + drug (10µM flecainide, 1µM 
propranolol, 10µM propafenone or 10 µM dantrolene). 
Quantitative endpoints were DADs, defined as any inter AP event with amplitude 
≥3mV. Events were analysed within the full length of the trace (the first 50 evoked or 
spontaneous APs). Evoked APs were obtained from quiescent and spontaneous beating 
cells. 
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5.4 Electrophysiology Results 
5.4.1 Global quantitative analysis of electrophysiology arrhythmic endpoints 
DADs are the primary arrhythmic event in CPVT. In order to test if hiPSC CPVT CM 
recapitulated the disease phenotype in vitro, a quantitative study was undertaken.The 
quantitative study of arrhythmic endpoints for CPVT, namely DADs, involves the 
measurement of these events for frequency (events per minute), amplitude (mV) and 
duration (milliseconds). Although DADs were selected as endpoints for 
arrhythmogenesis in this project, TA (triggered activity) is also an important 
arrhythmogenic event that can occur after a DAD. However, since these were very 
rarely present in these experiments, they weren‟t included in the quantitative analysis. 
This data set includes hiPSC CM from all the drug rescue experiments. Data from 
spontaneous and evoked AP paced at 0.5Hz and 1Hz are included. 
No statistical significance was found in the data sets presented for spontaneous, evoked 
AP at 0.5Hz and evoked AP at 1Hz for DAD frequency, duration and amplitude. 
Disease recapitulation could not be established using DADs as arrhythmic endpoint 
with the patch clamp technique for the current hiPSC CPVT CM model. 
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5.4.1.1 Spontaneous activity 
 
Figure 5.1 – Example traces of spontaneous AP - hiPSC BT1 CM (A) and hiPSC 
CPVT CM (B) in Tyrode’s. Recording obtained in Gap free mode. Irregular rhythm and 
DADs (black arrows) are present in mutant cells trace. Circa 40% hiPSC BT1 CM 
traces presented a DAD absent trace such as seen in figure 6.1A. 90% hiPSC CPVT CM 
traces presented DADs as seen in figure 5.1B. hiPSC CPVT CM (n=21) and hiPSC 
Control BT1 CM (n=10).  
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Figure 5.2 - Spontaneous beating hiPSC CM arrhythmic parameters - DADs 
frequency  - events per minute (A), average DAD duration (C) and average DAD 
amplitude (E) with respective mean percentage change (B, D, F) for hiPSC CPVT CM 
(n=21) and hiPSC Control BT1 CM (n=10). None of the differences reported in figure 
6.2 were found to be statistically significant.  
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5.4.1.2 Evoked activity 
5.4.1.2.1 Induced AP 0.5Hz 
 
Figure 5.3 – Global arrhythmic endpoints for evoked AP 0.5Hz - DADs frequency  - 
events per minute (A), average DAD duration (C) and average DAD amplitude (E) with 
respective mean percentage change (B, D, F). hiPSC CPVT CM (n=58) and control 
hiPSC BT1 CM (n=27) , from evoked AP at 0.5Hz in Tyrode’s and isoprenaline (1µM) 
perfusion. None of the differences reported in figure 5.3 were found to be statistically 
significant.  
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5.4.1.2.2 Induced AP 1Hz 
 
Figure 5.4 - Global arrhythmic endpoints for evoked AP 1Hz - DADs frequency - 
events per minute (A), average DAD duration (C) and average DAD amplitude (E) with 
respective mean percentage change (B, D, F). hiPSC CPVT CM (n=10) and control 
hiPSC BT1 CM (n=8) , from evoked AP at 1Hz in Tyrode’s and isoprenaline (1µM) 
perfusion. None of the differences reported in figure 5.4 were found to be statistically 
significant.  
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5.4.2 AP pharmacological rescue  
The main hypothesis for this project is that hiPSC CPVT CM are able to recapitulate the 
disease phenotype in vitro. To prove if this hypothesis is true, a ß-adrenergic challenge 
with a sequential anti-arrhythmic drug rescue in the presence of the ß-adrenergic agent 
was made. It was postulated that hiPSC CPVT CM would present an increase in pro-
arrhythmic events (DADs) in the presence of a ß-agonist agent.  When perfused with the 
selected anti-arrhythmic drug in the presence of isoprenaline (ß-agonist) it was expected 
that any arrhythmic events would be abolished or reduced in frequency, duration and/or 
amplitude. Other AP parameters were also analysed in order to evaluate any potential 
drug effects in AP shape (AP peak, amplitude, APD50 and APD90). 
For the pharmacological rescue experiments all cells were paced at 0.5Hz and AP 
evoked with RMP clamped at -80mV. The chosen anti-arrhythmic drugs were flecainide 
10µM (Itzhaki et al.,2012), propafenone 10µM (Caspi et al.,2009), propranolol 1µM 
(Matsa et al.,2011 and dantrolene 10µM (Jung et al.,2012). 
Drugs such as flecainide and propafenone are already used in ventricular tachycardia 
management, despite some controversy, especially regarding the first drug. Flecainide 
use has been suggested in refractory cases as a joint therapy with verapamil and 
propranolol (Watanabe et al.,2009). Flecainide is also reported to have an anti-
arrhythmic effect in hiPSC CPCT CM (Itzhaki et al.,2012). It was therefore important to 
assess if the same effect was observed when used to rescue pro-arrhythmic events in 
hiPSC CPVT CM for the mutation studied in the current project.  
 
Propranolol is a ß-adrenergic blocker and since a catecholaminergic stimulus can trigger 
arrhythmia in CPVT, this is a drug of first line of treatment for clinical management of 
this channelopathy.  
 
Dantrolene is a muscle relaxant that acts on RyR1 and is used in the treatment of 
malignant hyperthermia. Dantrolene has been suggested as a possible agent to treat 
CPVT1 based on results obtained from a hiPSC cardiac model of disease (Jung et 
al.,2012).  
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5.4.2.1 Quantitative analysis of arrhythmic endpoints 
 
Arrhythmic endpoints from CPVT and BT1 CM stimulated at 0.5Hz are presented in 
this section as well as AP parameters during the perfusion sequence. Presented 
parameters are AP peak, amplitude, APD50 and APD90. Changes in these parameters 
may reflect drug effect or toxicity so a more detailed study is presented. 
 The perfusion sequence of three solutions for each cell was: Tyrode‟s only followed by 
isoprenaline in Tyrode‟s, followed by antiarrhythmic drug in the presence of 
isoprenaline in Tyrode‟s. A wash out period of 60 seconds in Tyrode‟s was made in 
between stimulation protocols and different perfused solutions. Arrhythmic endpoints 
were DAD frequency, DAD duration and DAD amplitude. 
 
Due to lack of consistent statistical significance for data sets in all experiments using 
different arrhythmic drugs, AP parameter changes and DAD quantification study could 
not demonstrate pharmacological rescue of hiPSC CPVT CM. No significant changes 
were also seen in BT1 CM. 
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Figure 5.5 – Stimulated AP traces 0.5Hz from control BT1 CM -  example traces of 
evoked activity at 0.5Hz of hiPSC BT1 CM, perfused with Tyrode’s (green arrow) with 
sequential isoprenaline (yellow arrow) and anti-arrhythmic drug in the presence of 
isoprenaline (red arrow). 
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Figure 5.6 – Stimulated AP 0.5Hz traces from CPVT CM –example traces of evoked 
activity at 0.5Hz of hiPSC CPVT CM, perfused with Tyrode’s (green arrow) with 
sequential isoprenaline (yellow arrow) and anti-arrhythmic drug in the presence of 
isoprenaline (red arrow). Average APD in Tyrode’s is longer in CPVT CM when 
compared with BT1 CM (figure 5.5). This observation is in accordance with cumulative 
data. Average amplitude is also similar between both cell types in Tyrode’s. 
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5.4.2.1.1 Flecainide 
 
Figure 5.7 – Flecainide perfusion - AP peak and amplitude evoked AP 0.5Hz  - AP 
peak (A) and amplitude (D) with respective mean percentage change for isoprenaline 
(1µM) perfusion (B, E) and flecainide in the presence of isoprenaline (C, F). hiPSC BT1 
CM (n=11) and hiPSC CPVT CM (n=20). Statistical significance in figure 5.7A and 
5.7D was only seen in CPVT CM between Tyrode’s and flecainide in the presence of 
isoprenaline. No statistical significance was found between other data columns. 
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Figure 5.8 – Flecainide perfusion – APD50 and APD90 evoked AP 0.5Hz - APD50 
(A) and APD90 (D) with respective mean percentage change for isoprenaline (1µM) 
perfusion (B, E) and flecainide in the presence of isoprenaline (C, F). hiPSC BT1 CM 
(n=11) and hiPSC CPVT CM (n=20). Statistical significance in figure 5.8A for BT1 CM 
was only seen between Tyrode’s and flecainide in the presence of isoprenaline columns 
as well in figure 5.8D for CPVT CM. In figure 5.8A CPVT CM statistical significance 
was found between Tyrode’s and sequential isoprenaline perfusion. 
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Figure 5.9 – Flecainide perfusion – DAD frequency, evoked AP 0.5Hz  - DAD 
frequency in events per minute (A), mean percentage change for isoprenaline (1µM) 
perfusion (B), and mean percentage change for flecainide in the presence of 
isoprenaline (C). hiPSC BT1 CM (n=11) and hiPSC CPVT CM (n=20). None of the 
differences reported in figure 5.9 were found to be statistically significant. 
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Figure 5.10 – Flecainide perfusion – DAD duration and amplitude, evoked AP 0.5Hz 
- DAD duration (A) and DAD amplitude (D) with respective mean percentage change 
for isoprenaline (1µM) perfusion (B, E) and mean percentage change for flecainide in 
the presence of isoprenaline (C, F,). hiPSC BT1 CM (n=11) and hiPSC CPVT CM 
(n=20). None of the differences reported in figure 5.10 were found to be statistically 
significant 
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5.4.2.1.2 Propafenone 
 
Figure 5.11 – Propafenone perfusion - AP peak and amplitude evoked AP 0.5Hz  - AP 
peak (A) and amplitude (D) with respective mean percentage change for isoprenaline 
(1µM) perfusion (B, E) and propafenone in the presence of isoprenaline (C, F). hiPSC 
BT1 CM (n=8) and hiPSC CPVT CM (n=10). Statistical significant decrease is present   
for CPVT CM (figure 5.11A and 5.11D, between Tyrode’s and propafenone in the 
presence of isoprenaline. No significant effect was seen with isoprenaline perfusion 
alone. 
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Figure 5.12 – Propafenone perfusion – APD50 and APD90 evoked AP 0.5Hz - 
APD50 (A) and APD90 (D) with respective mean percentage change for isoprenaline 
(1µM) perfusion (B, E) and propafenone in the presence of isoprenaline (C, F). hiPSC 
BT1 CM (n=8) and hiPSC CPVT CM (n=10). Statistical significant decrease found only 
for BT1 CM (figure 5.12A and 5.12D) between Tyrode’s and propafenone in the 
presence of isoprenaline. No effect was seen for isoprenaline perfusion alone. 
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Figure 5.13 – Propafenone perfusion – DAD frequency, evoked AP 0.5Hz  - DAD 
frequency in events per minute (A), mean percentage change for isoprenaline (1µM) 
perfusion (B), and mean percentage change for propafenone in the presence of 
isoprenaline (C). hiPSC BT1 CM (n=8) and hiPSC CPVT CM (n=10). None of the 
differences reported in figure 5.13 were found to be statistically significant. 
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Figure 5.14 – Propafenone perfusion – DAD duration and amplitude, evoked AP 
0.5Hz  - DAD duration (A) and DAD amplitude (D) with respective mean percentage 
change for isoprenaline (1µM) perfusion (B, E) and mean percentage change for 
propafenone in the presence of isoprenaline (C, F). hiPSC BT1 CM (n=8) and hiPSC 
CPVT CM (n=10). None of the differences reported in figure 5.14 were found to be 
statistically significant. 
152 
 
5.4.2.1.3 Propranolol 
 
Figure 5.15 – Propranolol perfusion - AP peak and amplitude evoked AP 0.5Hz  - AP 
peak (A) and amplitude (D) with respective mean percentage change for isoprenaline 
(1µM) perfusion (B, E) and propranolol in the presence of isoprenaline (C, F). hiPSC 
BT1 CM (n=5) and hiPSC CPVT CM (n=16). Statistically significant decrease is 
present   for CPVT CM (figure 5.15A and 5.15D), between Tyrode’s and propranolol in 
the presence of isoprenaline. No statistically significant effect was seen with 
isoprenaline perfusion alone. 
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Figure 5.16 – Propranolol perfusion – APD50 and APD90 evoked AP 0.5Hz  - APD50 
(A) and APD90 (D) with respective mean percentage change for isoprenaline (1µM) 
perfusion (B, E) and propranolol in the presence of isoprenaline (C, F). hiPSC BT1 CM 
(n=5) and hiPSC CPVT CM (n=16). Statistical significant decrease is present for CPVT 
CM (figure 5.16A and 5.16D), between Tyrode’s and propranolol in the presence of 
isoprenaline. No statistically significant effect was seen with isoprenaline perfusion 
alone. 
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Figure 5.17 – Propranolol perfusion – DAD frequency, evoked AP 0.5Hz  - DAD 
frequency in events per minute (A), mean percentage change for isoprenaline (1µM) 
perfusion (B), and mean percentage change for propranolol in the presence of 
isoprenaline (C). hiPSC BT1 CM (n=5) and hiPSC CPVT CM (n=16). None of the 
differences reported in figure 5.17 were found to be statistically significant. 
 
155 
 
hiPSC CM
DAD Duration
BT1 CPVT
0
100
200
300
400
Tyrode's
Isoprenaline
Propranolol
*
T
im
e
 (
m
s
)
hiPSC CM
DAD Amplitude
BT1 CPVT
0
2
4
6
Tyrode's
Isoprenaline
Propranolol
V
o
lt
a
g
e
 (
m
V
)
hiPSC CM Propranolol Trial
Isoprenaline effect
 DAD Duration
BT1 CPVT
0
50
100
150
%
 M
e
a
n
 C
h
a
n
g
e
hiPSC CM Propranolol Trial
Isoprenaline effect
DAD Amplitude
BT1 CPVT-60
-40
-20
0
20
%
 M
e
a
n
 C
h
a
n
g
e
hiPSC CM Propranolol Trial
Propranolol effect
 DAD Duration
BT1 CPVT
-150
-100
-50
0
*
%
 M
e
a
n
 C
h
a
n
g
e
hiPSC CM Propranolol Trial
Propranolol effect
DAD Amplitude
BT1 CPVT
-80
-60
-40
-20
0
%
 M
e
a
n
 C
h
a
n
g
e
A D
B
E
C F
 
 
Figure 5.18 – Propranolol perfusion – DAD duration and amplitude, evoked AP 
0.5Hz  - DAD duration (A) and DAD amplitude (D) with respective mean percentage 
change for isoprenaline (1µM) perfusion (B, E) and mean percentage change for 
propranolol in the presence of isoprenaline (C, F,). hiPSC BT1 CM (n=5) and hiPSC 
CPVT CM (n=16). A statistical significant 70% decrease is present in DAD duration 
when propranolol in the presence of isoprenaline is perfused after isoprenaline 
stimulation alone (figure 5.18A, 5.18C). 
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5.4.2.1.4 Dantrolene 
 
Figure 5.19 – Dantrolene perfusion - AP peak and amplitude evoked AP 0.5Hz  - AP 
peak (A) and amplitude (D) with respective mean percentage change for isoprenaline 
(1µM) perfusion (B, E) and dantrolene in the presence of isoprenaline (C, F). hiPSC 
BT1 CM (n=9) and hiPSC CPVT CM (n=10). Statistically significant decrease found 
only for BT1 CM (figure 5.19A and 5.19D) between Tyrode’s and dantrolene in the 
presence of isoprenaline. No effect was seen for isoprenaline perfusion alone. 
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Figure 5.20 – Dantrolene perfusion – APD50 and APD90 evoked AP 0.5Hz  - APD50 
(A) and APD90 (D) with respective mean percentage change for isoprenaline (1µM) 
perfusion (B, E) and dantrolene in the presence of isoprenaline (C, F). hiPSC BT1 CM 
(n=9) and hiPSC CPVT CM (n=10). Statistically significant decrease found for BT1 
CM and CPVT CM between Tyrode’s and dantrolene in the presence of isoprenaline 
(figure 5.20A). Figure 5.20D also presents a statistically significant decrease found for 
BT1 CM between Tyrode’s and dantrolene in the presence of isoprenaline. No effect 
was seen for isoprenaline perfusion alone. 
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Figure 5.21 – Dantrolene perfusion – DAD frequency, evoked AP 0.5Hz  - DAD 
frequency in events per minute (A), mean percentage change for isoprenaline (1µM) 
perfusion (B), and mean percentage change for dantrolene in the presence of 
isoprenaline (C). hiPSC BT1 CM (n=9) and hiPSC CPVT CM (n=10). None of the 
differences reported in figure 5.21 were found to be statistically significant. 
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Figure 5.22 – Dantrolene perfusion – DAD duration and amplitude, evoked AP 0.5Hz  
- DAD duration (A) and DAD amplitude (D) with respective mean percentage change 
for isoprenaline (1µM) perfusion (B, E) and mean percentage change for dantrolene in 
the presence of isoprenaline (C, F,). hiPSC BT1 CM (n=9) and hiPSC CPVT CM 
(n=10). None of the differences reported in figure 5.22 were found to be statistically 
significant. 
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5.4.2.2 Qualitative analysis of arrhythmic endpoints 
In this project, it was determined that, in order to study and eventually validate an in 
vitro model of a CPVT1, the selected endpoints (DADs) should be counted and 
measured while perfused with different pharmacological agents. However, this 
approach was largely absent in the published literature where a more or less qualitative 
evaluation was more frequently reported. A qualitative study analysis of obtained data is 
here presented.  
DADs are the most typical arrhythmic endpoint in CPVT. However, the presence of 
EADs has also been documented in CPVT hiPSC CM (Kujala et al., 2012). EADs are 
not the most frequent hallmark for this disease but for comparative purposes with 
published data, these endpoints are also included in this qualitative analysis.  Both 
spontaneous and evoked traces at 0.5Hz were analysed. In the case of spontaneous 
activity experiments no anti-arrhythmic drugs were perfused.The criteria used for the 
qualitative analysis was the presence of one event of each type per full trace. DADs and 
EADs were considered as any event with an amplitude ≥ 3mV, either between APs 
(DADs) or before reaching full repolarization (EADs). Each trace could therefore have 
a maximum of one DAD and one EAD (possibly both simultaneously) for this analysis. 
A normal trace did not present a single DAD or EAD. 
No statistical significance was found in the presented qualitative endpoint 
arrhythmogenic study for mutant and control CM with spontaneous and evoked activity 
(0.5Hz and 1Hz).  
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5.4.2.2.1 Spontaneous activity 
In this data set, normal traces were considered absent from any DAD or EAD (with 
amplitude ≥3 mV). Each arrhythmic trace may have a maximum of one DAD and one 
EAD simultaneously. 
 
 
Figure 5.23 – Qualitative analysis of spontaneous hiPSC CM arrhythmic endpoints - 
data from spontaneous activity traces for both hiPSC CPVT CM (A, n=21) and control 
hiPSC BT1 CM (B, n=10). None of the differences reported in figure 5.23 were found to 
be statistically significant. 
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5.4.2.2.2 Evoked activity 
For evoked activity experiments, analysed traces were the same as those analysed for 
quantitative data. Data were obtained with sequential perfusion protocol using Tyrode‟s 
only, isoprenaline and anti-arrhythmic drug in the presence of isoprenaline. 
 
 
 
Figure 5.24 – Flecainide - Qualitative analysis of arrhythmic endpoints from evoked 
activity traces -  Evoked activity 0.5Hz, hiPSC BT-1 CM (A, n=20) and hiPSC CPVT 
CM (B, n=11) using flecainide (10µM) as anti- arrhythmic drug. None of the 
differences reported in figure 5.24 were found to be statistically significant. 
 
0
10
20
30
40
50
60
70
80
90
100
Tyrode's Isoprenaline Iso+Flecainide
%
 
Arrhythmic events hiPSC Control BT1 CM 
Flecainide trial 0.5Hz 
DAD
EAD
Normal
A 
0
10
20
30
40
50
60
70
80
90
100
Tyrode's Isoprenaline Iso+Flecainide
 %
 
Arrhythmic events hiPSC CPVT CM 
Flecainide trial 0.5Hz 
DAD
EAD
Normal
B 
163 
 
 
 
 
 
 
Figure 5.25 – Propafenone - Qualitative analysis of arrhythmic endpoints from 
evoked activity traces -  Evoked activity 0.5Hz, hiPSC BT-1 CM (A, n=8) and hiPSC 
CPVT CM (B, n=10) using propafenone (10µM) as anti-arrhythmic drug. None of the 
differences reported in figure 5.25 were found to be statistically significant. 
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Figure 5.26 – Dantrolene - Qualitative analysis of arrhythmic endpoints from evoked 
activity traces -  Evoked activity 0.5Hz, hiPSC BT-1 CM (A, n=9) and hiPSC CPVT CM 
(B, n=10) using dantrolene (10µM) as anti-arrhythmic drug. None of the differences 
reported in figure 5.26 were found to be s statistically significant. 
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Figure 5.27 – Propranolol - Qualitative analysis of arrhythmic endpoints from evoked 
activity traces -  Evoked activity 0.5Hz, hiPSC BT-1 CM (A, n=5) and hiPSC CPVT CM 
(B, n=21) using propranolol (1µM) as anti-arrhythmic drug. None of the differences 
reported in figure 5.27 were found to be statistically significant. 
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5.5 Discussion - Electrophysiology 
A trial of a more rigorous electrophysiological quantitative analysis is reported for the 
first time regarding the use of hiPSC CPVT CM as an in vitro model of disease. No 
reports of this nature were found in the current literature, and hence this is also an 
innovative approach for in vitro CPVT disease modelling. A qualitative comparative 
analysis was also presented so that a comparison could be made with literature reports. 
If these cells are able to have any real potential to model disease and eventually be used 
for CPVT novel drug discovery and personalised treatment, quantification of arrhythmic 
endpoints seems to be essential to validate their predictive translational clinical value. 
Although lower than the physiological range for the human adult heart rate (60 to 
100bpm), 0.5Hz frequency was chosen for most of the experiments. Higher frequencies 
would not only bias the endpoint baseline, reducing the ability to measure any change, 
but would also shorten AP duration. This could eventually mask possible endogenous 
pro-arrhythmic behaviour, in the form of DADs and eventually EADs. Studied cells, 
would also last longer while being patched at 0.5Hz than at higher frequencies 
presenting stronger, more lasting patch clamp seals. However for comparison purposes, 
data obtained from 1Hz stimulation is also presented in this study. 
5.5.1 Quantitative arrhythmic endpoint analysis 
The expected response from a good in vitro model of CPVT should involve an increase 
in DAD frequency and amplitude when stimulated with a ß-agonist. In this study 
isoprenaline was used. This drug should also predispose to TA if a higher DAD 
threshold would be reached. DAD duration was expected to decrease with isoprenaline 
response as well an APD50 shortening.  
5.5.1.1 Spontaneous activity 
Spontaneous activity AP analysis tends to present more subjectivity than evoked 
activity APs. It is very difficult to start measurements systematically in the same point 
of origin and these cells are more prone to irregular rhythm when spontaneously beating 
than when APs are induced and therefore better controlled. One of the main factors that 
predisposes to increased native frequency of hiPSC CM is temperature. For this reason 
most recordings were made at 25ºC in order to reduce potential depolarizing events and 
to try to isolate the isoprenaline effect. Despite these limitations, several reports   
(Kujala et al., 2012; Itzhaki et al.,2012) studied arrhythmic events mainly in cells with 
spontaneous activity at 37 ºC.  
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In this study, no significant differences were found in DADs frequency, duration or 
amplitude for hiPSC CM with spontaneous activity. Due to the spontaneous nature of 
hiPSC CM, it was considered that evoked APs could give more certainty that observed 
events were not due to spontaneous beating. 
5.5.1.2 Evoked activity 
Data obtained from evoked activity at 0.5Hz and 1Hz showed no statistically significant 
differences. Measurement of DADs from evoked activity is less prone to bias than data 
obtained from hiPSC CM with spontaneous activity. Obtaining more data from a higher 
number of cells could help in determining if increasing pacing frequency could worsen 
the CPVT phenotype by increasing DAD and TA frequency. More mature cells may 
eventually display a more accurate CPVT phenotype. Using the procedures described 
here and based on present data, it was not possible to establish a correlation between 
CPVT severity and pacing rate. 
5.5.1.2.1 Pharmacological rescue 
The use of flecainide in the presence of isoprenaline did not demonstrate any significant 
effect on measured parameters of DADs. A significant AP peak and AP amplitude 
decrease in CPVT CM (Figure 6.7A and D respectively) can be explained by the I(Na) 
blocking properties of flecainide. Decreased APD50 with isoprenaline (Figure 6.8) was 
also expected, as a shortening of this parameter is typical for a ß-agonist effect. In 
contrast to what Itzhaki et al., (2012) demonstrated, flecainide efficacy in reducing 
arrhythmic endpoints, could not be observed in the current project. It is nonetheless 
surprising that these authors found significant results in a small number of analysed 
cells (n=6), since in the data reported in the present project, 20 hiPSC CPVT CM were 
analysed. 
Similar to what was observed in the flecainide experiments, propafenone perfusion, 
significantly decreased AP peak and AP amplitude in CPVT CM. This can be explained 
with a similar mechanism of action to flecainide, by blocking I(Na) (Figure 6.11A and D 
respectively). A significant shortening of APD50 and APD90 in BT1 CM was also 
observed, possibly as a result of isoprenaline or propafenone effect. Since no response 
to isoprenaline alone was observed and no propafenone alone experiments were made, it 
is difficult to determine any clear drug effect over APD50.   
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The anti-arrhythmic agent propranolol caused a significant reduction in DAD duration 
in the presence of isoprenaline (Figure 6.18A,C). However, this seems to be an isolated 
finding since in no other experiment was this response repeated. From a disease 
recapitulation perspective it could have some importance if isoprenaline alone had 
previously caused a significant response. 
Dantrolene efficacy in reducing pro-arrhythmic events has already been demonstrated in 
hiPSC CPVT CM (Jung et al.,2012). In the present study no significant effect was seen 
in the arrhythmic selected endpoints for this study, but no effect was seen with 
isoprenaline perfusion as well.  
It was expected that isoprenaline would cause a significant increase in arrhythmic 
events. Since this response was absent, a correlation could not be established for the 
sequential pharmacological rescue with the chosen drugs.  
In summary, using quantitative arrhythmic endpoints as DAD frequency, amplitude or 
duration, it was not possible to recapitulate CPVT in vitro.  
5.5.2 Qualitative endpoint analysis 
By analysing the same data sets using a qualitative approach, no statistical significant 
changes were found. Therefore these data could not be compared with other published 
results that report DAD and EAD percentage of events.  
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5.6 Validation by Ca
2+
 Imaging  
In order to validate hiPSC CPVT CM as an in vitro model of disease, Ca
2+ 
handling in 
these cells needed to be studied. Different Ca
2+
 fluorescence imaging experiments were 
performed and both qualitative and quantitative arrhythmogenic endpoints were defined 
to evaluate the effects of increased pacing (simulating intense exercise) and ß – agonist 
stimulation.  The published literature contains only two reports using defined qualitative 
arrhythmic endpoints. These reports used stimulated activity in hiPSC CPVT CM to 
determine the percentage of pro-arrhythmogenic Ca
2+
 cycling abnormalities (Kujala et 
al.,2012; Jung et al.,2012). In both reports three types of pro-arrhythmic Ca
2+
 transient 
traces were defined as endpoints. Both hiPSC CPVT CM and control hiPSC CM were 
then challenged with ß-agonist perfusion and increased pacing.  
For the current project three types of qualitative arrhythmic traces were defined, based 
on Ca
2+
 transient amplitude and rhythmicity: AR1 – transients with irregular amplitude 
and regular rhythm; AR2 – transients with regular amplitude and irregular rhythm and 
AR3 – transients with irregular amplitude and irregular rhythm. This last type of Ca2+ 
transient represents a more severe phenotype of Ca
2+
 cycling abnormality (figure 
5.28C). A normal trace was considered to have regular amplitude and regular rhythm.  
It was determined that a quantitative approach would also be necessary to evaluate the 
in vitro disease recapitulation potential of these cells. Selected Ca
2+
 imaging parameters 
were peak regularity, ITN (Inter Transient Noise), amplitude, standardised area, rate and 
rate of decay. Perfusion with anti-arrhythmic drugs in the presence of isoprenaline 
should rescue pro-arrhythmic behaviour, as reflected in these parameters. Decreases in 
ITN and peak regularity are good indicators of antiarrhythmic response. However, 
effects on amplitude, rate and rate decay are also important parameters to study in order 
to observe the actions of a drug on basic CM behaviour. These last three parameters are 
related to inotropy, chronotropy and lusitropy of the heart. 
The main hypothesis tested in these experiments was that abnormal Ca
2+
 handling 
behaviour is more frequent and severe in CPVT CM compared with BT1 CM. It was 
also hypothesised that isoprenaline perfusion or increased pacing would produce a more 
severe arrhythmic phenotype. Perfusion with anti-arrhythmic drugs in the presence of 
isoprenaline should improve this phenotype by restoring endpoints close to baseline 
levels. 
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No reports were found in the literature that used quantitative pro-arrhythmic parameters 
from global Ca
2+ 
transients. The current study hence presents an innovative approach to 
determine if hiPSC CPVT CM have the ability to recapitulate disease in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28 – Example traces of arrhythmic sub-types used in Ca2+ imaging   
qualitative assessment study. (A) Arrhythmic sub-type AR1 with “calcium alternans”; 
(B) Arrythmic sub-type AR2, (C) Arrhythmic sub-type AR3. 
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5.7 Ca
2+
 Imaging Methods 
For more detailed information about Ca
2+
 Imaging Methods, please refer to section 2.4 
of Chapter 2. 
For the drug perfusion trial experiments, FLUO-4 AM® (fluo-4 acetoxymethyl) from 
Invitrogen was used as a Ca
2+ 
sensitive fluorescent indicator (5µM). Local and global 
hiPSC CM Ca
2+
 signals, were recorded using laser scanning confocal microscopy, (SP5; 
Leica Microsystems). 
Disaggregated single cells, in glass bottom Mattek dishes, were incubated for 20 
minutes at room temperature in modified Tyrode‟s and FLUO-4 AM® (5µM). Ca2+ 
dependent signals were visualized with a 63x oil immersion objective, using argon laser 
excitation at 488nm. Experiments were conducted at 37 ºC and images recorded every 
100ms at a 512x512 pixel resolution.  
All recordings (90 seconds each) were made following a triple sequential protocol for 
each field of view. First perfusion on Tyrode‟s only, second perfusion withTyrode‟s and 
isoprenaline (1µM), and third with Tyrode‟s with a drug in the presence of isoprenaline 
(1µM). Drugs used were propranolol (1µM), flecainide (10µM) and dantrolene (10µM). 
A 60 seconds washout was performed with Tyrode‟s in between each protocol. 
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5.8 Ca
2+
 Imaging Results 
Validation of hiPSC CPVT CM as an in vitro model of disease requires that the Ca
2+ 
handling and arrhythmogenic profile these cells be determined. Both qualitative and 
quantitative arrhythmogenic endpoints were defined to evaluate the effects of ß– agonist 
stimulation (strong emotion and exercise).   
It is the first time that a more detailed Ca
2+ 
handling arrhythmogenic profile is 
investigated using hiPSC CPVT CM as a potential model of disease.  
For the chosen quantitative Ca
2+ 
handling arrhythmogenic endpoints, no consistent 
statistically response was found for the majority of the experiments. 
Qualitative analysis of the chosen arrhythmic endpoints also did not show statistical 
significance. 
From the presented Ca
2+ 
handling arrhythmogenic profile data it was conclude that 
disease recapitulation is not consistent and therefore relevant for the CPVT CM model 
used in this project. 
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5.8.1 Quantitative analysis of arrhythmic endpoints 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.29 – Sequential example traces of Ca2+imaging drug perfusion trial - Ca2+ 
imaging of spontaneous beating hiPSC CPVT CM, in Tyrode’s (A) isoprenaline 1µM 
(B) and propranolol 1µM in the presence of isoprenaline 1µM  (C). Sequential traces 
from the same cell. Similar sequence of traces was obtained for dantrolene and 
flecainide. 
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5.8.1.1 Flecainide 
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Figure 5.30 – Amplitude and standardised area of Ca2+ transients upon flecainide 
perfusion  - Mean percentage change presented for isoprenaline perfusion in amplitude 
and standardised area (B and E respectively) and flecainide in the presence of 
isoprenaline (C, F respectively). hiPSC CPVT CM (n=16) and control hiPSC BT1 CM 
(n=36). None of the differences reported in figure 5.30 were found to be statistically 
significant. 
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Figure 5.31 – Peak regularity and ITN of Ca2+ transients upon flecainide perfusion - 
Mean percentage change presented for isoprenaline perfusion in peak regularity and 
ITN (B and E respectively) and flecainide in the presence of isoprenaline (C, F 
respectively). hiPSC CPVT CM (n=16) and control hiPSC BT1 CM (n=36). A 
significant 50% decrease in peak regularity was observed in CPVT CM upon 
isoprenaline perfusion (figure 5.31A, B). Flecainide in the presence of isoprenaline, 
presented a very significant increase of 300% in peak regularity (figure 5.31C) for 
CPVT CM. None of the differences reported in figure 5.31A were found to be 
statistically significant for BT1 CM. 
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Figure 5.32 – Rate (Hz) and Rate decay of Ca2+ transients upon flecainide perfusion - 
Mean percentage change presented for isoprenaline perfusion in rate (Hz) and rate 
decay (B and E respectively) and flecainide in the presence of isoprenaline (C, F 
respectively). hiPSC CPVT CM (n=16) and control hiPSC BT1 CM (n=36). Rate decay 
presented a significant decrease in BT1 CM upon flecainide perfusion in the presence of 
isoprenaline after isoprenaline alone (figure 5.32D, F). CPVT CM rate decay also 
presented a significant decrease when perfused with flecainide in the presence of 
isoprenaline, compared with the Tyrode’s rate decay value (figure 5.32D). None of the 
differences reported for rate (Hz) (figure 5.32A) were found to be statistically 
significant for both cell types. 
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5.8.1.2 Dantrolene 
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Figure 5.33 – Amplitude and standardised area of Ca2+ transients upon dantrolene 
perfusion  - Mean percentage change presented for isoprenaline perfusion in amplitude 
and standardised area (B and E respectively) and dantrolene in the presence of 
isoprenaline (C, F respectively). hiPSC CPVT CM (n=14) and control hiPSC BT1 CM 
(n=14). Amplitude in CPVT CM significantly decreased in the presence of isoprenaline 
compared with Tyrode’s (figure 5.33A, B). A significant decrease was also observed in 
CPVT CM when perfused with dantrolene in the presence of isoprenaline when 
compared with the Tyrode’s baseline values (figure 5.33A). A 20% decrease in 
standardised area was found to be significant for both BT1 CM and CPVT CM when 
perfused with dantrolene in the presence of isoprenaline and compared with the 
baseline Tyrode’s values (figure 5.33D). 
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Figure 5.34 – Peak regularity and ITN of Ca2+ transients upon dantrolene perfusion - 
Mean percentage change presented for isoprenaline perfusion in peak regularity and 
ITN (B and E respectively) and dantrolene in the presence of isoprenaline (C, F 
respectively). hiPSC CPVT CM (n=14) and control hiPSC BT1 CM (n=14). When 
perfused with isoprenaline alone, ITN showed a significant 20% decrease in CPVT CM 
when compared with Tyrode’s (Figure 5.34 D, E).  Perfusion of dantrolene in the 
presence of isoprenaline also produced a significant ITN decrease if compared with the 
baseline Tyrode’s value (figure 5.34 D). 
 
179 
 
 
Figure 5.35 – Rate (Hz) and Rate decay of Ca2+ transients upon dantrolene perfusion 
- Mean percentage change presented for isoprenaline perfusion in rate (Hz) and rate 
decay (B and E respectively) and dantrolene in the presence of isoprenaline (C, F 
respectively). hiPSC CPVT CM (n=14) and control hiPSC BT1 CM (n=14). A 
significant increase was seen in beating rate (Hz) in both control and mutant CM upon 
isoprenaline perfusion (figure 5.35A, B). Similarly, a rate increase was found to be 
significant when BT1 CM and CPVT CM were perfused with dantrolene in the presence 
of isoprenaline and compared with Tyrode’s (figure 5.35A). In figure 5.35D and 5.35F 
a significant 10% decrease in rate decay was present in BT1 CM upon perfusion with 
dantrolene in the presence of isoprenaline. 
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5.8.1.3 Propranolol 
 
Figure 5.36 – Amplitude and standardised area of Ca2+ transients upon propranolol 
perfusion  - Mean percentage change presented for isoprenaline perfusion in amplitude 
and standardised area (B and E respectively) and propranolol in the presence of 
isoprenaline (C, F respectively). hiPSC CPVT CM (n=12) and control hiPSC BT1 CM 
(n=29). Average Ca
2+
 transient amplitude, significantly decreased by 50% in CPVT CM 
when perfused with isoprenaline (figure 5.36A,B). A significant decrease was also 
observed in amplitude when perfused with propranolol in the presence of isoprenaline 
when compared with Tyrode’s alone (figure 5.36A). Standardised area value also 
presented a significant decrease in CPVT CM when perfused with isoprenaline (figure 
5.36D, E). In the presence of propranolol and isoprenaline a significant decrease was 
also present when compared with Tyrode’s alone (figure 5.36D). 
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Figure 5.37 – Peak regularity and ITN of Ca2+ transients upon propranolol perfusion 
- Mean percentage change presented for isoprenaline perfusion in peak regularity and 
ITN (B and E respectively) and propranolol in the presence of isoprenaline (C, F 
respectively). hiPSC CPVT CM (n=12) and control hiPSC BT1 CM (n=29). A 
significant increase of approximately 50% was observed in the peak regularity 
parameter for CPVT CM when perfused with propranolol in the presence of 
isoprenaline, compared with isoprenaline perfused alone (figure 5.37 A, C). 
Isoprenaline perfusion produced a significant 43% decrease in ITN in CPVT CM 
compared with baseline Tyrode’s data (figure 5.37D, E).  
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Figure 5.38 – Rate (Hz) and Rate decay of Ca2+ transients upon propranolol 
perfusion - Mean percentage change presented for isoprenaline perfusion in rate (Hz) 
and rate decay (B and E respectively) and propranolol in the presence of isoprenaline 
(C, F respectively). hiPSC CPVT CM (n=12) and control hiPSC BT1 CM (n=29). A 
significant 30% increase in beating rate (Hz) was observed in CPVT when perfused 
with isoprenaline (figure 5.38A, B). Rate decay value significantly decreased 50% in 
CPVT CM with isoprenaline perfusion (figure 5.38D,E), demonstrating a positive 
lusitropic effect. A significant decrease was also observed with propranolol in the 
presence of isoprenaline when compared with Tyrode’s (figure 5.38D). 
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5.8.2 Qualitative analysis of arrhythmic endpoints 
In this set of experiments, a qualitative study of arrhythmic endpoints is presented for 
hPSC CM with spontaneous activity. Traces used for this study were the same obtained 
for the quantitative drug perfusion trial presented in the previous section. A normal trace 
was defined as presenting normal rhythm and normal amplitude. AR1 – trace with 
irregular amplitude and regular rhythm, AR2 – trace with regular amplitude and 
irregular rhythm, AR3 – trace with irregular amplitude and irregular rhythm. 
5.8.2.1 Spontaneous activity 
5.8.2.1.1 Flecainide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.39 – Flecainide perfusion qualitative study - Ca2+ imaging arrhythmic 
endpoints, on spontaneous beating hiPSC BT1 CM (n=36) and hiPSC CPVT CM 
(n=16). None of the differences reported in figure 5.39 were found to be statistically 
significant. 
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5.8.2.1.2 Dantrolene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.40 – Dantrolene perfusion qualitative study - Ca2+ imaging arrhythmic 
endpoints, on spontaneous beating hiPSC BT1 CM (n=14) and hiPSC CPVT CM 
(n=14). None of the differences reported in figure 5.40 were found to be statistically 
significant. 
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5.8.2.1.3 Propranolol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.41 – Propranolol perfusion qualitative study - Ca2+ imaging arrhythmic 
endpoints, on spontaneous beating hiPSC BT1 CM (n=29) and hiPSC CPVT CM 
(n=12). None of the differences reported in figure 5.41 were found to be statistically 
significant. 
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5.8.2.2 Stimulated activity – Frequency study 
The objective of doing an increased stimulated frequency study was to determine if the 
arrhythmic phenotype of CPVT CM would increase with frequency increase. It was 
expected for the number of normal traces to decrease with frequency increase. This 
could be a suggestion of disease recapitulation, simulating what violent exercise does in  
CPVT. Isoprenaline perfusion was expected to worsen the phenotype in each stimulated 
frequency. 
5.8.2.2.1 – 0.5Hz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.42 – Stimulation 0.5Hz qualitative study - arrhythmic endpoints from Ca2+ 
imaging data in Tyrode’s and isoprenaline perfusion (1µM). hiPSC BT1 CM (n=18) 
and hiPSC CPVT CM (n=48). None of the differences reported in figure 5.42 were 
found to be statistically significant. 
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5.8.2.2.2 – 1Hz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.43 – Stimulation 1Hz qualitative study - arrhythmic endpoints from Ca2+ 
imaging data in Tyrode’s and isoprenaline perfusion (1µM). hiPSC BT1 CM (n=18) 
and hiPSC CPVT CM (n=40). None of the differences reported in figure 5.43 were 
found to be statistically significant. 
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5.8.2.2.3 – 1.5Hz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.44 – Stimulation 1.5Hz qualitative study - arrhythmic endpoints from Ca2+ 
imaging data in Tyrode’s and isoprenaline perfusion (1µM). hiPSC BT1 CM (n=18) 
and hiPSC CPVT CM (n=32). None of the differences reported in figure 5.44 were 
found to be statistically significant. 
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5.8.2.2.4 – 2Hz 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.45 – Stimulation 2Hz qualitative study - arrhythmic endpoints from Ca2+ 
imaging data in Tyrode’s and isoprenaline perfusion (1µM). hiPSC BT1 CM (n=16) 
and hiPSC CPVT CM (n=28). None of the differences reported in figure 5.45 were 
found to be statistical significant. 
 
 
 
 
190 
 
5.9 Discussion for Ca
2+
 imaging 
5.9.1 Quantitative analysis 
From Ca
2+
 imaging experiments presented in this chapter it was not possible to establish 
that the chosen endpoints recapitulate disease. Firstly, because no statistical significance 
was found for the majority of the data sets in both mutant and control cells. But when 
statistically significant differences are confirmed, expected response to isoprenaline 
perfusion, fails to recapitulate CPVT in most cases. A response to isoprenaline 
perfusion is pivotal to validate a CPVT model of in vitro disease. If this response does 
not clearly increase the average of arrhythmic endpoints drug rescue is not valid and 
hence results not trustworthy for any translational extrapolation. 
5.9.2 Qualitative analysis 
5.9.2.1 Drug trial 
No statistical significance was found for the qualitative analysis of arrhythmic endpoints 
in the current report.  
5.9.2.2 Frequency stimulation study 
This study was designed to determine if an increase in pacing frequency would increase 
arrhythmogenic behaviour. It also aimed to determine if isoprenaline perfusion would 
increase different sub-types of arrhythmic behaviour in synergy with an increase in 
pacing rate. No statistical significance was found for qualitative analysis of arrhythmic 
endpoints in any of the frequency stimulation trials. 
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6.10 Conclusion 
From the data reported in this chapter it is clear that hiPSC CPVT CM with the 
Ser2246Leu mutation did not recapitulate the disease in vitro. An electrophysiology 
study of DADs frequency, duration and amplitude did not present statistical significance 
and even failed to show a clear trend towards CPVT phenotype recapitulation. In Ca
2+
 
imaging experiments, some parameters, in a limited number of trials, seem to 
recapitulate CPVT features, but statistical significance was not found in the majority of 
parameters. An increase in population sample of both CPVT CM and control CM could 
make a difference in statistical significance determination. More mature hiPSC CM may 
also display a more “adult-like” phenotype and eventually recapitulate disease more 
consistently. Despite this a high degree of variability in the behaviour of hiPSC CM 
between batches for the same protocols is obvious. 
More studies using different mutations could assist in clarifying if hiPSC CPVT CM are 
able to recapitulate disease and if different mutations present a different severity of 
phenotype.  
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Chapter 6 
Discussion 
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6.1 CPVT1 hiPSC in vitro models of disease  
Inherited channelopathies such as CPVT are a major clinical challenge to modern 
medicine. The accurate diagnosis of this disease involves specific procedures that may 
include a stress test, with carries with it associated risks, and genetic testing. But one of 
the biggest problems may arise with treating this channelopathy as a number of patients 
may be refractory to medical treatment. In this case an ICD implantation is required, 
which will result in a great loss of quality of life for the affected patient. This becomes 
even more dramatic as the majority of CPVT patients are children (Liu et al.,2008). 
 
Innovative hiPSC technology has allowed the creation of individual specific pluripotent 
cells that can be differentiated in CM. By maintaining a patient genotype, during the 
reprograming process, a specific individual cardiac model can be created. The 
possibility of replicating disease in vitro is incredible, presenting great potential in 
determining CPVT phenotype severity and in eventually optimising personalised 
treatment options. The potential that hiPSC CPVT CM may have, has already been 
presented as a reality by several authors (Fatima et al.,2011; Itzhaki et al.,2012; Kujala 
et al.,2012; Jung et al.,2012 and Di Pasquale et al; 2013). 
 
However these publications seem to lack an objective measure of CPVT characteristic 
arrhythmic endpoints. Without a rigorous assessment of arrhythmic endpoints it appears 
premature to claim CPVT disease recapitulation using hiPSC CM. Another problem 
found in most publications is the absence of optimal control hiPSC CM that can be used 
to compare with mutant cells. Individual and batch heterogeneity is an accepted 
problem of hPSC CM, from hESC CM to hiPSC CM and different control lines have 
been used in different publications.  
 
The ideal control hiPSC CM would be a hiPSC CPVT CM with a non functional 
expressed mutation. This could be achieved artificially with siRNA as demonstrated 
with success in a different channelopathy (Matsa et al.,2014). 
 
In the current project it was not possible to use these ideal control hiPSC CPVT CM. 
Instead a “healthy” subject hiPSC derived CM cell line was used as control. The best 
protocol to recapitulate CPVT in vitro involves a ß-agonist perfusion to elicit cardiac 
arrhythmogenesis. In these experiments isoprenaline was chosen for this purpose. 
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Sequential perfusion with a target drug in the presence of isoprenaline may determine if 
disease phenotype can be rescued or reduced. 
 
A characterisation of any cardiac in vitro model of disease is required before hiPSC 
derived CM can be used as a potential translational clinical instrument. 
 
In the current project, a hiPSC CM characterisation was made in order to study if these 
cells present cardiac physiological features. Positive inotropy, lusitropy and chronotry 
should be consistently present before determining that these cells recapitulate disease in 
vitro. If the studied cells failed to demonstrate that they behave like adult CM, then drug 
rescue experiments will have limited value.  
 
Another unresolved problem that hiPSC CPVT CM present is that the majority of these 
cells are spontaneously active. CPVT is mainly a ventricular disease so spontaneous 
activity is not desirable for an ideal model. For this reason, in the current project both 
spontaneous and stimulated experiments were used to compare results. Arrhythmic 
endpoints are more standardised and less biased by using evoked or stimulated activity. 
 
The final validation of the hiPSC CPVT CM used in this study was the sequential 
perfusion of cells with Tyrode‟s, isoprenaline and an antiarrhythmic drug in the 
presence of isoprenaline. The objective of this sequence was to recreate a physiological 
response that was similar to what happens in a human CPVT heart. Another arrhythmic 
factor is pacing rate. To account for this, experiments were performed at different 
pacing rates, both with patch clamp and Ca
2+
 imaging. 
 
Recapitulation of CPVT in vitro using hiPSC derived CM is a complex process that 
involves multiple factors. And while an ideal method may not be possible, a more 
rigorous attempt to produce such a model is reported in the current project.  
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6.2 Functional characterisation of hiPSC CPVT CM 
 
The following hypotheses were formulated in an attempt to establish if hiPSC CPVT 
CM are representative of adult cardiac cells. 
 
1 – hiPSC CPVT CM and hiPSC control CM BT-1 express basic CM markers 
(Troponin C) and Ca
2+
 handling proteins (RyR2, CASQ2, PLB, SERCA2A). 
 
From WB experiments (Chapter 4) it was not possible to confirm expression of basic 
cardiac Ca
2+
 handling proteins (RyR2, CASQ, PLB and SERCA2A). Troponin C was 
found to be present in control BT1 CM with ICC but could not be found in CPVT CM. 
Other authors have confirmed expression of CASQ and PLB (Jung et al.,2012) and 
RyR2 (Di Pasquale et al.,2013) in CPVT CM. These reports mention the use of more 
mature cells, from 1 to 3 months post differentiation.  This factor may be very relevant 
to the negative expression found for the CM marker proteins in this project. A more 
prolonged maturation study could clarify if hiPSC CPVT CM used in this project do not 
express a CM typical protein profile or if just more time is needed for them to do so. 
2 - hiPSC CPVT CM and hiPSC Control CM BT-1 possess a typical CM AP and that 
the three CM sub-types are present in a cell population. 
In this report, typical cardiac AP were obtained both from BT1 CM and CPVT CM. 
Typical AP traces were obtained from both spontaneous (figure 4.6) and evoked AP 
(figure 4.8). The three different sub-types of AP were present in both cell types for 
evoked activity (figure 4.17). Differences in sub-type percentages are seen in the 
literature, and these can change from batch to batch, as do the criteria used to classify 
them. Di Pasquale et al., 2013 and Zhu et al., 2010 classified hPSC CM in two subtypes, 
nodal (i.e. cells from the AV node) and working like (i.e. atrial and ventricular 
chamber). The fact that hPSC can produce the three main cardiac AP sub-types suggests 
that these cells have the potential to behave like CM.  
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3- hiPSC CPVT CM and hiPSC control CM BT-1 present basic CM physiological and 
pharmacological response; namely the ß- adrenergic response (to isoprenaline and 
propranolol) demonstrated by the expected inotropic, lusitropic and chronotropic 
properties. 
 
A good cardiac model is expected to present positive inotropy, lusitropy and 
chronotropy. In this project no consistent response was seen across different 
experiments for ß-adrenergic stimulation. Lack of statistical significance for observed 
positive differences in most isoprenaline perfusion experiments and significant negative 
responses in some cases make it impossible to confirm the expected responses to 
isoprenaline and propranolol. These findings demonstrate a high degree of variability in 
individual cells and cell batches.  
 
4 - hiPSC CPVT CM and hiPSC Control CM (BT-1) present a basic cardiomyocyte 
Ca
2+
 handling pharmacological response, namely to caffeine, ryanodine and nifedipine. 
 
Both hiPSC CPVT and BT1 CM responded as expected to nifedipine perfusion, with a 
decrease of Ca
2+
 transient average amplitude or standardised area. This suggests that 
both cell types have functional LTCC (figure 4.36). Caffeine perfusion experiments 
suggest a functional RyR2 with 20% BT1 CM and 60% CPVT CM response to this 
drug (figure 4.38). Ryanodine was only perfused in a low number of CPVT cells so it 
was not possible to determine the effect of this drug effect on RyR2 expressed in these 
cells. Overall, it was not possible to establish that the CPVT CM and BT1 CM used in 
this project have a fully functional CICR protein profile. 
 
6.3 Validation of hiPSC CPVT CM as in vitro model of disease 
 
An increase in arrhythmic endpoints upon isoprenaline perfusion was expected from 
both a quantitative and a qualitative analysis. To validate these hiPSC CPVT CM as a 
good in vitro model of disease these arrhythmogenic endpoints should decrease or 
return to baseline when perfused with an antiarrhythmic drug. Although several authors 
have presented data that they interpret as demonstrating disease recapitulation, no 
systematic methodology has been reported to determine quantitative response of DADs 
(using patch clamp) or other objective parameters for Ca
2+
 imaging (ITN, peak 
regularity, rate decay) in these cells. 
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In order to validate the cells used in this project, the following hypotheses were 
formulated: 
 
1 – hiPSC CPVT CM will present a higher qualitative and quantitative arrhythmic 
response (with higher AP DADs incidence as a hallmark) than hiPSC control CM BT-1 
when stimulated by increased pacing or ß-agonist stimulation. 
 
Using the patch clamp technique to measure DAD frequency, duration and amplitude, 
no statistically significant changes were observed for these parameters as the result of 
isoprenaline perfusion in both control and mutant cells. The same observation was made 
in qualitative data analysis. Although this systematic approach was carefully designed 
to evaluate DADs with an innovative and previously unreported methodology, disease 
recapitulation could not be confirmed. No consistent and significant increase in 
arrhythmic endpoints was observed upon ß-agonist stimulation. 
 
2 – hiPSC CPVT CM will have both a qualitative and quantitative higher incidence of 
abnormal calcium transients (indicating enhanced arrhythmic behaviour) than hiPSC 
control BT-1 CM when stimulated by increased pacing or ß-agonist stimulation. 
 
In agreement with data collected using the patch clamp technique, Ca
2+
 imaging 
revealed that ß-agonist stimulation did not caused a statistically significant increase in 
arrhythmogenic endpoints in CPVT CM. Qualitative analysis demonstrated a trend that 
could be interpreted as an indication of disease recapitulation, but no statistically 
significant differences were observed. 
 
A quantitative reduction in ITN peak regularity was expected with isoprenaline 
perfusion, but across different experiments, this response was not statistically 
significant and therefore the hypothesis was rejected. 
 
3 - hiPSC CPVT CM arrhythmic behaviour (namely DADs frequency, amplitude and 
duration) can be rescued or improved when treated with anti-arrhythmic drugs in the 
presence of isoprenaline. 
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4 – hiPSC CPVT CM arrhythmic behaviour (abnormal Ca2+ transients and respective 
parameters) can be rescued or improved when treated with anti-arrhythmic drugs in the 
presence of isoprenaline. 
 
Hypotheses 3 and 4 were also rejected, since they can only be tested following an 
increase in arrhythmogenic endpoints upon ß-agonist stimulation. As this initial 
response was not confirmed, pharmacological rescue of an arrhythmic phenotype could 
not be considered relevant or significant. 
 
6.4 Conclusion remarks 
 
Disease modelling using patient specific CPVT hiPSC derived CM is still a relatively 
new research area that has emerged in the past four years. The need to develop human 
CPVT cardiac models to study mechanisms of disease and for new drug discovery has 
generated some advances concerning the disease modelling potential of these cells. 
However, a systematic and quantitative approach, that is necessary to determine how 
accurate a model of patient specific disease these cells are, is absent from the literature. 
By using an innovative more accurate quantitative approach the present report 
demonstrates that these cells do not always recapitulate CPVT in vitro.  
 
There are nonetheless some factors that can be relevant to this conclusion. The 
immature nature of these hiPSC derived CM may contribute to a lack of consistent 
response of disease modelling. Different AP sub-types may also contribute to a more 
heterogeneous response and different mutations may also present different specific 
phenotypes.  
 
Despite these factors, it is clear from the work presented in this thesis, that, contrary to 
several reports in the literature (Fatima et al.,2011; Jung et al,2012; Itzhaki et al.,2012, 
Kujala et al.,2012), disease recapitulation is not always easily attainable using CPVT 
hiPSC derived CM. The potential of hiPSC CPVT CM as an in vitro model of disease 
therefore requires further investigations using more quantitative methods, as used here, 
to measure arrhythmic endpoints.  
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6.5 Future work 
 
In order to better understand the hiPSC CPVT CM potential as an in vitro model of 
disease future work is necessary. Some of the adaptations that could be done to the 
methodology reported in this thesis could be: 
- Use of more mature hiPSC CM with 3-4 months post differentiation. 
- Control hiPSC CM derived from CPVT CM with corrected mutation (possibly with 
siRNA). 
- Dose- response curve for isoprenaline perfusion. 
- Selective analysis of ventricular-like CM with flow cytometry. 
- Comparison analysis of quiescent ventricular-like CM with spontaneous 
ventricular-like CM. 
- Comparison of single cell results with results from monolayers or small clumps of 
cells. 
- Use of a different mutation and cell line of hiPSC CPVT CM in order to compare 
results. 
By incorporating these changes into the study of hiPSC CPVT CM, new and more 
accurate insights in to the cells real potential for in vitro disease modelling will be 
obtained.  
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Appendix I 
In this section, the hiPSC CPVT characterisation data is presented. Procedures were, 
performed at University of Nottingham, by Prof. Chris Denning‟s group at the Wolfson 
Centre for Stem Cells. The control cell line BT1 CM was also characterised by the same 
group using the same methods (data not shown).  
The adult fibroblasts reprogrammed into hiPSC for this project were obtained from a 
patient that had undergone cardiac surgery for implantation of an ICD. This 5 year old 
patient presented a RyR2 genotyped mutation, c.6737C>T (Ser2246Leu) and the 
resultant ryanodine receptor malfunction is known to cause a classical bidirectional 
ventricular tachycardia, leading to arrhythmia. The patient presented clinical symptoms 
and because no response was obtained to antiarrhythmic medical treatment an ICD was 
placed to prevent arrhythmia and potentially syncope and death. 
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RyR2 mutation detection - c.6737C>T (Ser2246Leu) 
Normal  
6721 - GAT GTG GCT GCA GCT TCG GTG ATG GAT AAT AAT GAA CTA GCA TTA GCT CTG 
CGT GAG CCG - 6780  
 
2241 - D V A A A S V M D N N E L A L A L R E P - 2260  
 
Mutant  
6721 – GAT GTG GCT GCA GCT TTG GTG ATG GAT AAT AAT GAA CTA GCA TTA GCT CTG 
CGT GAG CCG - 6780  
 
2241 - D V A A A L V M D N N E L A L A L R E P – 2260 
 
 
  : Patient mutation  
 
Figure 1a - Current study CPVT1 patient single point mutation at the RyR2  - 
aminoacid sequence from normal and mutant RyR2 (A). Location of the mutation in the 
RyR2 predicted structure and domains (B). Adapted from (Bers,2004) Journal of 
Molecular and Cellular Cardiology. 
 
 
 
 
 
 
A 
B 
226 
 
CPVT1 patient fibroblast culture and reprogramming 
 
Dermal fibroblasts were isolated from a skin biopsy obtained from a CPVT1 clinically 
and genetically diagnosed patient, after informed consent was given by the patient. Skin 
samples were cleaned from adipose and epidermal tissue and were reduced to 1mm 
pieces. They were then digested with 2.5% trypsin (Invitrogen) for 15min, and 1mg/ml 
Collegenase IV (Invitrogen) for 90 minutes, both at 37
o
C. Digested cells were plated in 
Chang‟s-D medium (Metachem) supplemented with 2mM L-glutamine (Invitrogen) and 
100mM HEPES (SIGMA). Cells were then grown for 2-3 weeks until fibroblast 
populations emerged. Fibroblasts were grown in DMEM medium (Invitrogen), 
supplemented with 10% FBS, 0.1mM non-essential amino acids (Invitrogen) and 2mM 
L-glutamine. Fibroblast culture for 10-15 passages was completed before exposure to 
reprogramming factors. Generation of hiPSCs clones was obtained by lentiviral delivery 
of human OCT4, SOX2, NANOG, and LIN28 (Matsa et al.,2011) into patient 
fibroblasts between passage 15 and 20. Fibroblast cells were seeded in tissue culture-
treated 6 well plates (NUNC) at a density of 100,000 cells/well and left to adhere to the 
plastic for 4h. Lentiviral particles encoding human OCT4, SOX2, LIN28 and NANOG 
were produced using the HEK293 cell line. Viral supernatants were precipitated via 
incubation in 60mM CaCl2 at 37 °C for 30-40 minutes and then purified by conjugation 
to streptavidin paramagnetic beads (Promega), for 3-5h at room temperature on a rolling 
platform. Viral particles were finally re-suspended in DMEM with 10% FBS, and were 
used to transduce fibroblasts.  
 
A medium change with fibroblast culture medium was performed 24h post transduction 
(PTD), and 48h PTD the cells were transferred to 90mm dishes where they were 
cultured onto mitomycin C inactivated MEFs (3.6x10
6
 cells/plate) in hiPSC culture 
medium (DMEM-F12 supplemented with 15% KSR, 100µM β-mercaptoethanol, 
10ng/ml bFGF (Sigma-Aldrich), 2mM GlutaMAX™-1 (Invitrogen), and 0.1mM non-
essential amino acids). The medium was changed daily with hiPSC culture medium for 
1 week, and with MEF conditioned medium supplemented with 10ng/ml bFGF. 
 At 18-23 days PTD, reprogrammed hiPSCs were isolated by TRA-1-81 based positive 
selection over a magnetic column (Miltenyi Biotec), as described previously (Matsa et 
al.,2011). hiPSCs were then transferred to feeder-free conditions on Matrigel-coated 
flasks and cultured in MEF conditioned medium supplemented with 10ng/ml bFGF.  
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Mutation identification 
To confirm the presence of the CPVT mutation in patients specific fibroblasts and 
derived CPVT hiPSCs, genomic DNA was extracted from frozen cell pellets (QIAGEN 
DNeasy Blood and Tissue kit). Polymerase chain reaction (PCR) was performed using 
25 mL reaction mixture, which comprised Hotstar Taq polymerase (0.125 mL; 
QIAGEN), 5 mM forward and reverse primers (Invitrogen), 10× buffer (2.5 mL; 
QIAGEN), 2.5 mM dNTPs (2.5 mL; Invitrogen) and 1 mL of genomic DNA diluted to 
100 ng/mL. The PCR conditions were 958C for 15 min, then 35 cycles (958C, 1 min; 
558C, 30 s; 728C, 1 min) and a final extension step at 728C for 5 min. Polymerase 
chain reaction products were electrophoresed on a 1.5% agarose gel, purified (QIAGEN 
QIAquick Gel Extraction kit), and sequenced using the reverse primer. 
 
 
Pluripotency markers 
Pluripotency and differentiation markers were detected by ICC and flow cytometry. 
 
Primary 
antibody 
Supplier Dilution 
Secondary 
antibody 
Supplier Dilution 
OCT4 Santa Cruz; SC-5279 1:200 
goat anti-mouse 
AlexaFluor® 633 
Invitrogen; 
A21052 
1:400 
SSEA4 Millipore; MAB4304 1:50 
SSEA1 Millipore; MAB117P 1:50 
TRA-1-81 Millipore; MAB4381 1:50 
P4HB Abcam; ab44971 1:50 
c-MYC Abcam; ab32 1:250 
α-actinin SIGMA; A7811 1:800 
β-III-tubulin COVANCE; MMS-435P 1:1000 
AFP Sigma; A8452 1:1000 
LIN28 Abcam; ab462020 1:1500 
goat anti-rabbit 
AlexaFluor® 633 
Invitrogen; 
A21071 
1:400 
REX1 Abcam; ab50828 1:50 
1:200 
Troponin-I Spectral Diagnostics; PA-1010 1:1000 
SOX2 R&D Systems; AF2018 1:200 
rabbit anti-goat 
AlexaFluor® 568 
Invitrogen; 
A11079 
1:400 NANOG R&D Systems; AF1997 1:50 
DNMT3B Santa Cruz; SC-10236 1:250 
KLF4 R&D Systems; AF3640 1:100 1:200 
 
Table 1a - Antibodies list used for CPVT hiPSC immunofluorescence staining and 
flow cytometry - used for pluripotency characterisation at Nottingham University – 
Wolfson Centre for Stem Cells.  
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ICC  
 
For CPVT hiPSC immunofluorescence experiments, cells were grown to confluence in 
8-chamber glass slides (NUNC) and then fixed in 4% PFA. Cells were permeabilised 
with 0.1% Triton-X-100 (Sigma-Aldrich), and blocked with 8% goat or rabbit serum 
(Sigma-Aldrich) in PBS, as appropriate. Primary antibody incubations were performed 
overnight at 4°C and secondary antibodies at room temperature for 1h (antibody 
dilutions shown in table 3.1). Cells were imaged using a Nikon Eclipse 90i fluorescence 
microscope and images were analysed using Volovity software (Improvision).  
 
Flow cytometry 
For flow cytometry analysis, CPVT hiPSC were harvested and fixed in 4% 
paraformaldehyde (PFA, Sigma-Aldrich), then re-suspended in 2% FBS in PBS. Cells 
were incubated in the dark with PE-conjugated antibodies, or relevant isotype controls, 
for 20min at room temperature, washed in 2% FBS and analysed in a flow cytometer 
(FC500, BD Biociences). 
 
Growth kinetics 
Population doublings (PDs) at each passage were calculated using the formula [log10 
(total cell counts/cells seeded)/ log10 (2)], where the cell number seeded was 1.2x10
6
 
cells/t25 flask. Proliferation rates were calculated by total hours in test culture/ 
cumulative PDs.  
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Results 
CPVT hiPSC line was genotyped for mutation RyR2 6737 C>T (figure 1a, 2a) and 
presented a normal karyotype (data not shown). CPVT hiPSC displayed population 
doubling rates similar to hESCs (figure 6a).  
 
Flow cytometry (figure 3a) and ICC showed that hiPSCs had reactivated marker SSEA1 
and the pluripotency markers TRA-1-81 and SSEA4 (figure 4a). NANOG, SOX2, 
OCT4, cMYC were also activated (figure 5a) as well LIN28, DNMT3B, REX1 and 
KLF4, (data not shown).  
 
Regulatory regions within the OCT4 and NANOG promoters acquired a 
hypomethylated state in hiPSCs, relative to the originating fibroblasts and hiPSC 
differentiated progeny (data not shown). EB differentiation from hiPSCs showed 
contribution to the three embryonic germ layers; endoderm, ectoderm, and mesoderm 
via expression of the markers b-III-tubulin, a-fetoprotein, and cardiac a-actinin (data not 
shown).  
These experiments confirmed that hiPSC lines were pluripotent and ready to be used for 
differentiation protocols.  
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CPVT1 mutation confirmation 
      Serine  
Control 
                                                              Leucine 
 
Patient Fibroblast Line 
Figure 2a - Confirmation of patient genotype -  RyR2 6737 C>T . Chromatograms 
from control BT1 hiPSC cells and CPVT fibroblasts. Single point mutation in RyR2 
identified in patient fibroblast line (mutant cells). 
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Flow cytometry 
 
 
Figure 3a - Flow cytometry for differentiation marker and pluripotency markers 
confirmation  - SSEA1 and SSEA4 and TRA-1-81. 
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ICC 
 
 
Figure 4a - ICC panel for differentiation and pluripotency markers  - SSEA1 
(differentiation marker) SSEA4 and TRA-1-81 (pluripotency markers) – 
immunostaining for CPVT hiPSC cell line. 
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Figure 5a - ICC panel for pluripotency inducing reprogramming factors - NANOG 
and SOX2 (A) and OCT4 and c-MYC (B) – immunostaining for CPVT hiPSC cell line. 
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Growth kinetics 
 
Figure 6a - Growth kinetics of CPVT1 hiPSC line and HUES7 – (hESC) cell line used 
as control. 
 
 
